UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER 1-11846

AptarGroup, Inc.


Delaware						36-3853103
(State of Incorporation)						(I.R.S. Employer Identification No.)

265 EXCHANGE DRIVE, SUITE 301, CRYSTAL LAKE, IL 60014

815-477-0424

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $.01 par value	ATR	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☑

Accelerated filer

☐

Non-accelerated
filer

☐

Smaller reporting
company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

The number of shares outstanding of common stock, as of October ~~21, 2022,~~20, 2023, was ~~65,284,008~~65,781,269 shares.

Table of Contents

AptarGroup, Inc.

Form 10-Q

Quarter Ended September 30, ~~2022~~2023

INDEX


Part I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)

	Condensed Consolidated Statements of Income – Three and Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022	1

	Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022	2

	Condensed Consolidated Balance Sheets – September 30, ~~2022~~2023 and December 31, ~~2021~~2022	3

	Condensed Consolidated Statements of Changes in Equity – Three and Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022	5

	Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022	7

	Notes to Condensed Consolidated Financial Statements	9

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3231

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	4947

Item 4.	Controls and Procedures	4947

Part II.	OTHER INFORMATION

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	5048

Item 5.	Other Information	48

Item 6.	Exhibits	5149

	Signature	5250

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)


In thousands, except per share amounts	In thousands, except per share amounts									In thousands, except per share amounts

		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022

Net Sales	Net Sales	$	836,860	$	825,442	$	2,526,335	$	2,413,228	Net Sales	$	892,997	$	836,860	$	2,648,970	$	2,526,335
Operating Expenses:	Operating Expenses:									Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)	Cost of sales (exclusive of depreciation and amortization shown below)	546,376		537,085		1,638,114		1,548,840		Cost of sales (exclusive of depreciation and amortization shown below)	566,691		546,376		1,697,824		1,638,114
Selling, research & development and administrative	Selling, research & development and administrative	135,428		135,931		416,351		411,192		Selling, research & development and administrative	138,137		135,428		427,488		416,351
Depreciation and amortization	Depreciation and amortization	57,601		59,280		174,818		174,508		Depreciation and amortization	62,686		57,601		184,212		174,818
Restructuring initiatives	Restructuring initiatives	2,270		10,223		2,989		18,771		Restructuring initiatives	6,161		2,270		19,628		2,989
Total Operating Expenses	Total Operating Expenses	741,675		742,519		2,232,272		2,153,311		Total Operating Expenses	773,675		741,675		2,329,152		2,232,272
Operating Income	Operating Income	95,185		82,923		294,063		259,917		Operating Income	119,322		95,185		319,818		294,063

Other (Expense) Income:	Other (Expense) Income:									Other (Expense) Income:
Interest expense	Interest expense	(9,756)		(8,011)		(30,668)		(22,601)		Interest expense	(9,984)		(9,756)		(29,900)		(30,668)
Interest income	Interest income	752		401		2,029		1,406		Interest income	946		752		2,266		2,029
Net investment gain (loss)		649		(9,021)		(1,084)		6,177
Net investment (loss) gain										Net investment (loss) gain	(1,240)		649		1,839		(1,084)
Equity in results of affiliates	Equity in results of affiliates	178		(71)		(184)		(505)		Equity in results of affiliates	1,002		178		1,514		(184)
Miscellaneous, net		(2,093)		13		(3,144)		(2,978)
Miscellaneous income (expense), net										Miscellaneous income (expense), net	3		(2,093)		(1,341)		(3,144)
Total Other Expense	Total Other Expense	(10,270)		(16,689)		(33,051)		(18,501)		Total Other Expense	(9,273)		(10,270)		(25,622)		(33,051)

Income before Income Taxes	Income before Income Taxes	84,915		66,234		261,012		241,416		Income before Income Taxes	110,049		84,915		294,196		261,012

Provision for Income Taxes	Provision for Income Taxes	30,738		19,340		80,851		55,309		Provision for Income Taxes	25,751		30,738		72,265		80,851

Net Income	Net Income	$	54,177	$	46,894	$	180,161	$	186,107	Net Income	$	84,298	$	54,177	$	221,931	$	180,161

Net Loss Attributable to Noncontrolling Interests		$	67	$	366	$	131	$	381
Net (Gain) Loss Attributable to Noncontrolling Interests										Net (Gain) Loss Attributable to Noncontrolling Interests	$	(2)	$	67	$	201	$	131

Net Income Attributable to AptarGroup, Inc.	Net Income Attributable to AptarGroup, Inc.	$	54,244	$	47,260	$	180,292	$	186,488	Net Income Attributable to AptarGroup, Inc.	$	84,296	$	54,244	$	222,132	$	180,292

Net Income Attributable to AptarGroup, Inc. per Common Share:	Net Income Attributable to AptarGroup, Inc. per Common Share:									Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic	Basic	$	0.83	$	0.72	$	2.75	$	2.84	Basic	$	1.28	$	0.83	$	3.39	$	2.75
Diluted	Diluted	$	0.81	$	0.70	$	2.70	$	2.75	Diluted	$	1.26	$	0.81	$	3.32	$	2.70

Average Number of Shares Outstanding:	Average Number of Shares Outstanding:									Average Number of Shares Outstanding:
Basic	Basic	65,322		65,900		65,446		65,652		Basic	65,707		65,322		65,550		65,446
Diluted	Diluted	66,581		67,801		66,825		67,799		Diluted	67,035		66,581		66,865		66,825

Dividends per Common Share	Dividends per Common Share	$	0.38	$	0.38	$	1.14	$	1.12	Dividends per Common Share	$	0.41	$	0.38	$	1.17	$	1.14

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)


In thousands	In thousands									In thousands

		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022

Net Income	Net Income	$	54,177	$	46,894	$	180,161	$	186,107	Net Income	$	84,298	$	54,177	$	221,931	$	180,161
Other Comprehensive Income (Loss):	Other Comprehensive Income (Loss):									Other Comprehensive Income (Loss):
Foreign currency translation adjustments	Foreign currency translation adjustments	(92,164)		(30,410)		(184,051)		(57,783)		Foreign currency translation adjustments	(52,514)		(92,164)		(28,639)		(184,051)
Changes in derivative gains, net of tax		3,542		230		3,663		1,039
Changes in derivative gains (losses), net of tax										Changes in derivative gains (losses), net of tax	2,707		3,542		(2,424)		3,663
Defined benefit pension plan, net of tax	Defined benefit pension plan, net of tax									Defined benefit pension plan, net of tax
Actuarial gain (loss), net of tax		31		87		(719)		529
Actuarial (loss) gain, net of tax										Actuarial (loss) gain, net of tax	(5)		31		63		(719)

Amortization of prior service cost included in net income, net of tax	Amortization of prior service cost included in net income, net of tax	25		25		78		90		Amortization of prior service cost included in net income, net of tax	33		25		98		78
Amortization of net loss included in net income, net of tax	Amortization of net loss included in net income, net of tax	1,551		2,333		4,703		7,041		Amortization of net loss included in net income, net of tax	161		1,551		483		4,703
Total defined benefit pension plan, net of tax	Total defined benefit pension plan, net of tax	1,607		2,445		4,062		7,660		Total defined benefit pension plan, net of tax	189		1,607		644		4,062
Total other comprehensive loss	Total other comprehensive loss	(87,015)		(27,735)		(176,326)		(49,084)		Total other comprehensive loss	(49,618)		(87,015)		(30,419)		(176,326)
Comprehensive (Loss) Income		(32,838)		19,159		3,835		137,023
Comprehensive Income Attributable to Noncontrolling Interests		910		832		1,750		847
Comprehensive (Loss) Income Attributable to AptarGroup, Inc.		$	(31,928)	$	19,991	$	5,585	$	137,870
Comprehensive Income (Loss)										Comprehensive Income (Loss)	34,680		(32,838)		191,512		3,835
Comprehensive Loss Attributable to Noncontrolling Interests										Comprehensive Loss Attributable to Noncontrolling Interests	88		910		319		1,750
Comprehensive Income (Loss) Attributable to AptarGroup, Inc.										Comprehensive Income (Loss) Attributable to AptarGroup, Inc.	$	34,768	$	(31,928)	$	191,831	$	5,585

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


In thousands	In thousands					In thousands

		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
Assets	Assets					Assets
Cash and equivalents	Cash and equivalents	$	124,812	$	122,925	Cash and equivalents	$	151,573	$	141,732
Short-term investments		—		740
Total Cash and equivalents and Short-term investments		124,812		123,665
Accounts and notes receivable, less current expected credit loss ("CECL") of $9,899 in 2022 and $7,374 in 2021		690,818		671,350

Accounts and notes receivable, less current expected credit loss ("CECL") of $12,209 in 2023 and $9,519 in 2022						Accounts and notes receivable, less current expected credit loss ("CECL") of $12,209 in 2023 and $9,519 in 2022	717,484		676,987
Inventories	Inventories	462,752		441,464		Inventories	490,872		486,806
Prepaid and other	Prepaid and other	121,352		121,729		Prepaid and other	142,829		124,766
Total Current Assets	Total Current Assets	1,399,734		1,358,208		Total Current Assets	1,502,758		1,430,291
Land	Land	28,373		31,436		Land	29,421		30,197
Buildings and improvements	Buildings and improvements	630,968		631,897		Buildings and improvements	718,242		693,542
Machinery and equipment	Machinery and equipment	2,713,619		2,862,142		Machinery and equipment	3,022,026		2,925,517
Property, Plant and Equipment, Gross	Property, Plant and Equipment, Gross	3,372,960		3,525,475		Property, Plant and Equipment, Gross	3,769,689		3,649,256
Less: Accumulated depreciation	Less: Accumulated depreciation	(2,147,160)		(2,249,598)		Less: Accumulated depreciation	(2,381,041)		(2,305,592)
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net	1,225,800		1,275,877		Property, Plant and Equipment, Net	1,388,648		1,343,664
Investments in equity securities	Investments in equity securities	51,491		59,485		Investments in equity securities	48,022		52,308
Goodwill	Goodwill	910,041		974,157		Goodwill	943,037		945,632
Intangible assets, net	Intangible assets, net	317,144		362,343		Intangible assets, net	287,231		315,744
Operating lease right-of-use assets	Operating lease right-of-use assets	57,098		62,454		Operating lease right-of-use assets	53,510		58,675
Miscellaneous	Miscellaneous	65,164		48,840		Miscellaneous	75,018		57,144
Total Other Assets	Total Other Assets	1,400,938		1,507,279		Total Other Assets	1,406,818		1,429,503
Total Assets	Total Assets	$	4,026,472	$	4,141,364	Total Assets	$	4,298,224	$	4,203,458

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


In thousands, except share and per share amounts	In thousands, except share and per share amounts					In thousands, except share and per share amounts

		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
Liabilities and Stockholders’ Equity	Liabilities and Stockholders’ Equity					Liabilities and Stockholders’ Equity
Current Liabilities:	Current Liabilities:					Current Liabilities:
Notes payable, revolving credit facility and overdrafts	Notes payable, revolving credit facility and overdrafts	$	53,209	$	147,276	Notes payable, revolving credit facility and overdrafts	$	124,503	$	3,810
Current maturities of long-term obligations, net of unamortized debt issuance costs	Current maturities of long-term obligations, net of unamortized debt issuance costs	111,034		142,351		Current maturities of long-term obligations, net of unamortized debt issuance costs	366,378		118,981
Accounts payable, accrued and other liabilities	Accounts payable, accrued and other liabilities	732,409		692,865		Accounts payable, accrued and other liabilities	740,759		794,385
Total Current Liabilities	Total Current Liabilities	896,652		982,492		Total Current Liabilities	1,231,640		917,176
Long-Term Obligations, net of unamortized debt issuance costs	Long-Term Obligations, net of unamortized debt issuance costs	1,028,048		907,024		Long-Term Obligations, net of unamortized debt issuance costs	680,065		1,052,597
Deferred income taxes	Deferred income taxes	19,545		27,547		Deferred income taxes	17,448		20,563
Retirement and deferred compensation plans	Retirement and deferred compensation plans	105,947		116,809		Retirement and deferred compensation plans	57,433		48,977
Operating lease liabilities	Operating lease liabilities	42,125		48,010		Operating lease liabilities	39,697		42,948
Deferred and other non-current liabilities	Deferred and other non-current liabilities	46,030		74,882		Deferred and other non-current liabilities	58,252		52,993
Commitments and contingencies	Commitments and contingencies	—		—		Commitments and contingencies	—		—
Total Deferred Liabilities and Other	Total Deferred Liabilities and Other	213,647		267,248		Total Deferred Liabilities and Other	172,830		165,481
AptarGroup, Inc. stockholders’ equity	AptarGroup, Inc. stockholders’ equity					AptarGroup, Inc. stockholders’ equity
Common stock, $.01 par value, 199 million shares authorized, 70.7 million and 70.4 million shares issued as of September 30, 2022 and December 31, 2021, respectively		707		704
Common stock, $.01 par value, 199 million shares authorized, 71.5 million and 70.9 million shares issued as of September 30, 2023 and December 31, 2022, respectively						Common stock, $.01 par value, 199 million shares authorized, 71.5 million and 70.9 million shares issued as of September 30, 2023 and December 31, 2022, respectively	715		709
Capital in excess of par value	Capital in excess of par value	954,477		916,534		Capital in excess of par value	1,028,663		968,618
Retained earnings	Retained earnings	1,895,049		1,789,413		Retained earnings	2,074,434		1,929,240
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(490,748)		(316,041)		Accumulated other comprehensive loss	(371,440)		(341,366)
Less: Treasury stock at cost, 5.4 million and 4.9 million shares as of September 30, 2022 and December 31, 2021, respectively		(484,803)		(421,203)
Less: Treasury stock at cost, 5.7 million and 5.6 million shares as of September 30, 2023 and December 31, 2022, respectively						Less: Treasury stock at cost, 5.7 million and 5.6 million shares as of September 30, 2023 and December 31, 2022, respectively	(532,633)		(503,266)
Total AptarGroup, Inc. Stockholders’ Equity	Total AptarGroup, Inc. Stockholders’ Equity	1,874,682		1,969,407		Total AptarGroup, Inc. Stockholders’ Equity	2,199,739		2,053,935
Noncontrolling interests in subsidiaries	Noncontrolling interests in subsidiaries	13,443		15,193		Noncontrolling interests in subsidiaries	13,950		14,269
Total Stockholders’ Equity	Total Stockholders’ Equity	1,888,125		1,984,600		Total Stockholders’ Equity	2,213,689		2,068,204
Total Liabilities and Stockholders’ Equity	Total Liabilities and Stockholders’ Equity	$	4,026,472	$	4,141,364	Total Liabilities and Stockholders’ Equity	$	4,298,224	$	4,203,458

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)


In thousands	In thousands																								In thousands

Three Months Ended	Three Months Ended	AptarGroup, Inc. Stockholders’ Equity																							Three Months Ended	AptarGroup, Inc. Stockholders’ Equity
September 30, 2022 and 2021		Retained Earnings			Accumulated Other Comprehensive (Loss) Income			Common Stock Par Value			Treasury Stock				Capital in Excess of Par Value				Non- Controlling Interest			Total Equity
September 30, 2023 and 2022													September 30, 2023 and 2022	Retained Earnings							Accumulated Other Comprehensive (Loss) Income						Common Stock Par Value			Treasury Stock			Capital in Excess of Par Value						Non- Controlling Interest					Total Equity
				Retained Earnings						Accumulated Other Comprehensive (Loss) Income			Common Stock Par Value					Treasury Stock				Capital in Excess of Par Value						Non- Controlling Interest								Total Equity
Balance - June 30, 2021
Balance - June 30, 2022																									Balance - June 30, 2022	$	1,865,634			$	(404,576)		$	706						$	(467,550)				$	939,897				$	14,353				$	1,948,464
Net income (loss)	Net income (loss)	47,260					—				—						—								—				(366)			46,894			Net income (loss)		54,244					—					—					—					—	(67)	54,177

Acquisitions of non-controlling interest		—			—			—			—				—				38,543					38,543

Foreign currency translation adjustments	Foreign currency translation adjustments	—			(29,944)			—			—				—				(466)			(30,410)			Foreign currency translation adjustments	—			(91,321)			—						—					—					(843)					(92,164)
Changes in unrecognized pension gains and related amortization, net of tax	Changes in unrecognized pension gains and related amortization, net of tax	—			2,445			—			—				—				—			2,445			Changes in unrecognized pension gains and related amortization, net of tax	—			1,607			—						—					—					—					1,607
Changes in derivative gains, net of tax	Changes in derivative gains, net of tax	—			230			—			—				—				—			230			Changes in derivative gains, net of tax	—			3,542			—						—					—					—					3,542
Stock awards and option exercises	Stock awards and option exercises	—			—			1			884				4,219				—			5,104			Stock awards and option exercises	—			—			1						1,988					14,580					—					16,569
Cash dividends declared on common stock	Cash dividends declared on common stock	(25,078)			—			—			—				—				—			(25,078)			Cash dividends declared on common stock	(24,829)			—			—						—					—					—					(24,829)
Treasury stock purchased	Treasury stock purchased	—			—			—			(28,398)				—				—			(28,398)			Treasury stock purchased	—			—			—						(19,241)					—					—					(19,241)
Balance - September 30, 2021		$	1,756,820		$	(330,327)		$	703		$	(371,896)			$	902,601			$	38,092		$	1,995,993
Balance - September 30, 2022																									Balance - September 30, 2022	$	1,895,049		$	(490,748)		$	707					$	(484,803)				$	954,477				$	13,443				$	1,888,125

Balance - June 30, 2022		$	1,865,634		$	(404,576)		$	706		$	(467,550)			$	939,897			$	14,353		$	1,948,464
Balance - June 30, 2023																									Balance - June 30, 2023	$	2,017,065		$	(321,913)		$	713					$	(526,484)				$	1,005,007				$	14,038				$	2,188,426
Net income (loss)	Net income (loss)	54,244			—			—			—				—				(67)			54,177			Net income (loss)	84,296			—			—						—					—					2					84,298

Foreign currency translation adjustments	Foreign currency translation adjustments	—			(91,321)			—			—				—				(843)			(92,164)			Foreign currency translation adjustments	(1)			(52,423)			—						—					—					(90)					(52,514)
Changes in unrecognized pension gains and related amortization, net of tax	Changes in unrecognized pension gains and related amortization, net of tax	—			1,607			—			—				—				—			1,607			Changes in unrecognized pension gains and related amortization, net of tax	—			189			—						—					—					—					189
Changes in derivative gains, net of tax	Changes in derivative gains, net of tax	—			3,542			—			—				—				—			3,542			Changes in derivative gains, net of tax	—			2,707			—						—					—					—					2,707
Stock awards and option exercises	Stock awards and option exercises	—			—			1			1,988				14,580				—			16,569			Stock awards and option exercises	—			—			2						2,114					23,656					—					25,772
Cash dividends declared on common stock	Cash dividends declared on common stock	(24,829)			—			—			—				—				—			(24,829)			Cash dividends declared on common stock	(26,926)			—			—						—					—					—					(26,926)
Treasury stock purchased	Treasury stock purchased	—			—��			—			(19,241)				—				—			(19,241)			Treasury stock purchased	—			—			—						(8,263)					—					—					(8,263)
Balance - September 30, 2022		$	1,895,049		$	(490,748)		$	707		$	(484,803)			$	954,477			$	13,443		$	1,888,125
Balance - September 30, 2023																									Balance - September 30, 2023	$	2,074,434		$	(371,440)		$	715					$	(532,633)				$	1,028,663				$	13,950				$	2,213,689

Table of Contents


In thousands	In thousands																					In thousands

Nine Months Ended	Nine Months Ended	AptarGroup, Inc. Stockholders’ Equity																				Nine Months Ended		AptarGroup, Inc. Stockholders’ Equity
September 30, 2022 and 2021		Retained Earnings				Accumulated Other Comprehensive (Loss) Income		Common Stock Par Value				Treasury Stock		Capital in Excess of Par Value				Non- Controlling Interest		Total Equity

Balance - December 31, 2020				$	1,643,825					$	(281,709)					$	695					$	(361,583)				$	849,161			$	396				$	1,850,785
Net income (loss)		186,488				—		—				—		—				(381)		186,107

Acquisitions of non-controlling interest		—				—		—				—		—				38,543		38,543
Foreign currency translation adjustments		—				(57,317)		—				—		—				(466)		(57,783)
Changes in unrecognized pension gains and related amortization, net of tax		—				7,660		—				—		—				—		7,660
Changes in derivative gains, net of tax		—				1,039		—				—		—				—		1,039
Stock awards and option exercises		—				—		8				18,085		53,440				—		71,533
Cash dividends declared on common stock		(73,493)				—		—				—		—				—		(73,493)
Treasury stock purchased		—				—		—				(28,398)		—				—		(28,398)
Balance - September 30, 2021		$	1,756,820			$	(330,327)	$	703			$	(371,896)	$	902,601			$	38,092	$	1,995,993
September 30, 2023 and 2022																						September 30, 2023 and 2022		Retained Earnings					Accumulated Other Comprehensive (Loss) Income				Common Stock Par Value					Treasury Stock				Capital in Excess of Par Value				Non- Controlling Interest				Total Equity

Balance - December 31, 2021	Balance - December 31, 2021	$	1,789,413			$	(316,041)	$	704			$	(421,203)	$	916,534			$	15,193	$	1,984,600	Balance - December 31, 2021				$	1,789,413								$	(316,041)				$	704			$	(421,203)			$	916,534			$	15,193	$	1,984,600
Net income (loss)	Net income (loss)	180,292				—		—				—		—				(131)		180,161		Net income (loss)		180,292					—				—					—				—				(131)				180,161

Foreign currency translation adjustments	Foreign currency translation adjustments	—				(182,432)		—				—		—				(1,619)		(184,051)		Foreign currency translation adjustments		—					(182,432)				—					—				—				(1,619)				(184,051)
Changes in unrecognized pension gains and related amortization, net of tax		—				4,062		—				—		—				—		4,062
Changes in derivative gains, net of tax		—				3,663		—				—		—				—		3,663
Changes in unrecognized pension gains (losses) and related amortization, net of tax																						Changes in unrecognized pension gains (losses) and related amortization, net of tax		—					4,062				—					—				—				—				4,062
Changes in derivative gains (losses), net of tax																						Changes in derivative gains (losses), net of tax		—					3,663				—					—				—				—				3,663
Stock awards and option exercises	Stock awards and option exercises	—				—		3				8,729		37,943				—		46,675		Stock awards and option exercises		—					—				3					8,729				37,943				—				46,675
Cash dividends declared on common stock	Cash dividends declared on common stock	(74,656)				—		—				—		—				—		(74,656)		Cash dividends declared on common stock		(74,656)					—				—					—				—				—				(74,656)
Treasury stock purchased	Treasury stock purchased	—				—		—				(72,329)		—				—		(72,329)		Treasury stock purchased		—					—				—					(72,329)				—				—				(72,329)
Balance - September 30, 2022	Balance - September 30, 2022	$	1,895,049			$	(490,748)	$	707			$	(484,803)	$	954,477			$	13,443	$	1,888,125	Balance - September 30, 2022		$	1,895,049				$	(490,748)			$	707				$	(484,803)			$	954,477			$	13,443			$	1,888,125

Balance - December 31, 2022																						Balance - December 31, 2022		$	1,929,240				$	(341,366)			$	709				$	(503,266)			$	968,618			$	14,269			$	2,068,204
Net income (loss)																						Net income (loss)		222,132					—				—					—				—				(201)				221,931

Foreign currency translation adjustments																						Foreign currency translation adjustments		(227)					(28,294)				—					—				—				(118)				(28,639)
Changes in unrecognized pension gains (losses) and related amortization, net of tax																						Changes in unrecognized pension gains (losses) and related amortization, net of tax		—					644				—					—				—				—				644
Changes in derivative gains (losses), net of tax																						Changes in derivative gains (losses), net of tax		—					(2,424)				—					—				—				—				(2,424)
Stock awards and option exercises																						Stock awards and option exercises		—					—				6					7,935				60,045				—				67,986
Cash dividends declared on common stock																						Cash dividends declared on common stock		(76,711)					—				—					—				—				—				(76,711)
Treasury stock purchased																						Treasury stock purchased		—					—				—					(37,302)				—				—				(37,302)
Balance - September 30, 2023																						Balance - September 30, 2023		$	2,074,434				$	(371,440)			$	715				$	(532,633)			$	1,028,663			$	13,950			$	2,213,689

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

In thousands, brackets denote cash outflows
Nine Months Ended September 30, 2022 2021
Cash Flows from Operating Activities:
Net income $ 180,161 $ 186,107
Adjustments to reconcile net income to net cash provided by operations:
Depreciation 142,046 144,637
Amortization 32,772 29,871
Stock-based compensation 31,941 29,720
Provision for CECL 3,344 1,016
Loss (gain) on disposition of fixed assets 315 (225)
Net loss (gain) on remeasurement of equity securities 1,084 (6,177)
Deferred income taxes (9,506) (10,926)
Defined benefit plan expense 18,367 21,930
Equity in results of affiliates 184 505
Change in fair value of contingent consideration (2,265) 3,110
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables (76,921) (109,194)
Inventories (62,139) (71,482)
Prepaid and other current assets (9,903) (13,105)
Accounts payable, accrued and other liabilities 62,053 63,724
Income taxes payable 15,470 (1,656)
Retirement and deferred compensation plan liabilities (15,432) (6,400)
Other changes, net (5,222) (2,082)
Net Cash Provided by Operations 306,349 259,373
Cash Flows from Investing Activities:
Capital expenditures (226,131) (216,689)
Proceeds from government grants 17,058 —
Proceeds from sale of property, plant and equipment 778 4,916
Maturity of short-term investment 740 —
Purchase of short-term investments — (76)
Acquisition of business, net of cash acquired and release of escrow (4,100) (124,998)
Acquisition of intangible assets, net (5,189) —
Investment in equity securities — (5,871)
Proceeds from sale of investment in equity securities 1,599 —
Notes receivable, net (7,155) (713)
Net Cash Used by Investing Activities (222,400) (343,431)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts 35,058 10,059
Repayments of notes payable and overdrafts (33,417) (11,702)
Repayments and proceeds of short term revolving credit facility, net (93,468) 6,766
Proceeds from long-term obligations 406,550 11,660
Repayments of long-term obligations (262,245) (66,026)
Debt issuance costs (4,009) (1,718)
Dividends paid (74,656) (73,493)
Proceeds from stock option exercises 18,411 53,979
Purchase of treasury stock (72,329) (28,398)
Net Cash Used by Financing Activities (80,105) (98,873)
Effect of Exchange Rate Changes on Cash (957) (7,482)
Net Increase (Decrease) in Cash and Equivalents and Restricted Cash 2,887 (190,413)
Cash and Equivalents and Restricted Cash at Beginning of Period 122,925 304,970
Cash and Equivalents and Restricted Cash at End of Period $ 125,812 $ 114,557


In thousands, brackets denote cash outflows

Nine Months Ended September 30,	2023		2022

Cash Flows from Operating Activities:
Net income	$	221,931	$	180,161
Adjustments to reconcile net income to net cash provided by operations:
Depreciation	150,718		142,046
Amortization	33,494		32,772
Stock-based compensation	36,084		31,941
Provision for CECL	3,449		3,344
(Gain) loss on disposition of fixed assets	(3,753)		315
Net (gain) loss on remeasurement of equity securities	(1,839)		1,084
Deferred income taxes	(16,978)		(9,506)
Defined benefit plan expense	10,659		18,367
Equity in results of affiliates	(1,514)		184
Change in fair value of contingent consideration	—		(2,265)
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables	(43,061)		(76,921)
Inventories	(5,188)		(62,139)
Prepaid and other current assets	(19,236)		(9,903)
Accounts payable, accrued and other liabilities	3,860		62,053
Income taxes payable	(8,732)		15,470
Retirement and deferred compensation plan liabilities	1,323		(15,432)
Other changes, net	(5,615)		(5,222)
Net Cash Provided by Operations	355,602		306,349
Cash Flows from Investing Activities:
Capital expenditures	(231,199)		(226,131)
Proceeds from government grants	—		17,058
Proceeds from sale of property, plant and equipment	6,037		778
Maturity of short-term investment	—		740

Acquisition of businesses, net of cash acquired and release of escrow	(16,570)		(4,100)
Acquisition of intangible assets, net	(3,648)		(5,189)

Proceeds from sale of investment in equity securities	5,604		1,599
Notes receivable, net	439		(7,155)
Net Cash Used by Investing Activities	(239,337)		(222,400)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts	24,392		35,058
Repayments of notes payable and overdrafts	(27,863)		(33,417)
Proceeds and (repayments) of short term revolving credit facility, net	123,514		(93,468)
Proceeds from long-term obligations	257		406,550
Repayments of long-term obligations	(117,289)		(262,245)
Debt issuance costs	—		(4,009)
Payment of contingent consideration obligation	(22,750)		—
Dividends paid	(76,711)		(74,656)
Proceeds from stock option exercises	39,742		18,411
Purchase of treasury stock	(37,302)		(72,329)
Net Cash Used by Financing Activities	(94,010)		(80,105)
Effect of Exchange Rate Changes on Cash	(12,914)		(957)
Net Increase in Cash and Equivalents and Restricted Cash	9,341		2,887
Cash and Equivalents and Restricted Cash at Beginning of Period	142,732		122,925
Cash and Equivalents and Restricted Cash at End of Period	$	152,073	$	125,812

Table of Contents

Restricted cash included in the line item prepaid and other on the Condensed Consolidated Balance Sheets as shown below represents amounts held in escrow related to the Metaphase acquisition.


Nine Months Ended September 30,	Nine Months Ended September 30,	2022		2021		Nine Months Ended September 30,	2023		2022

Cash and equivalents	Cash and equivalents	$	124,812	$	114,557	Cash and equivalents	$	151,573	$	124,812
Restricted cash included in prepaid and other	Restricted cash included in prepaid and other	1,000		—		Restricted cash included in prepaid and other	500		1,000
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	$	125,812	$	114,557	Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	$	152,073	$	125,812

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

Table of Contents

AptarGroup, Inc.

Notes to Condensed Consolidated Financial Statements

(Dollars in Thousands, Except per Share Amounts, or as Otherwise Indicated)

(Unaudited)

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation.

In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.

Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar and remeasured our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method. During the third quarter of 2021, we utilized the Blue Chip Swap and recognized a gain of $1.4 million. Our Argentinian operations contributed less than 1.5% of consolidated net assets and revenues as of and for the nine months ended September 30, 2022.

The COVID-19 pandemic resulted in disruptions to the global economy and supply chains. As the rates of transmission have slowed in many regions during 2022, we have seen several of our impacted applications return to more normal volume levels. We have seen improvement in sales of our products to our prescription, beauty, hair care and sun care customers as people return to more active lifestyles. However, we have also seen more normal volumes in some of the applications which benefited from the pandemic, such as our personal cleansing and surface cleaner products, food applications, active material science solutions and injectables components. While some countries continue to experience disruptions due to efforts to eliminate the virus, we do not believe these impacts will be material to our business based on the current environment.

As of September 30, 2022, the war in Ukraine has not had a significant direct impact on our business, though the near-term visibility for this situation is expected to remain fluid and uncertain for the next several quarters. However, we have experienced some indirect impacts on our business, including higher energy and other input costs as well as certain supply chain disruptions.

ADOPTION OF RECENT ACCOUNTING STANDARDS

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification.

In ~~November 2021,~~September 2022, the FASB issued ASU ~~2021-10, Government Assistance~~2022-04, Liabilities-Supplier Finance Programs (Topic ~~832): Disclosures by Business Entities about Government Assistance. This update~~405), which enhances the transparency of supplier finance programs and requires ~~annual~~certain disclosures ~~about transactions with~~for a ~~government that~~buyer in a supplier finance program. The requirements are ~~accounted~~effective for ~~by applying a grant or contribution accounting model by analogy~~fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the ~~nature of the transaction, the financial statement line items affected by the transaction and any significant terms and conditions associated with the transactions.~~amendment on roll forward information, which is effective for fiscal years beginning after December 13, 2023. Early adoption is permitted. We adopted this guidance in the fourth quarter of ~~2021 using the prospective approach.~~

~~Table of Contents~~

2022.

In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and ~~can~~could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. ~~During 2021, we amended~~We adopted this guidance in the ~~revolving credit facility to provide mechanics relating to a transition~~second quarter of 2023 and have transitioned away from LIBOR (in the case of USD) and the designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans madeto SOFR in ~~the applicable currency. We are evaluating any further impact this standard may have on~~ our ~~Condensed Consolidated Financial Statements and anticipate no further significant impacts.~~revolving credit facility.

Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.

INCOME TAXES

We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made.

The tax rate for the three months ended September 30, 2022 reflects an out-of-period charge of $7.2 million for taxes due to a legal entity reorganization to enhance the Company's dividend and cash management capabilities. The tax charge contributed 8.5% to the impact on the effective tax rate for the three months ended September 30, 2022. The tax charge should have been recognized in the three months ended March 31, 2022. The impacts of the error on the three months ended March 31, 2022 and the three months ended September 30, 2022 are not considered material to either period.

We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely ~~reinvested. As~~reinvested with the following exceptions: all earnings in Germany, the pre-2023 earnings in Suzhou, China and the pre-2020 earnings in Italy, Switzerland and Colombia. The change in the Suzhou, China assertion was made in the current quarter. Under current U.S. tax laws, all of ~~September 30, 2022, under currently enacted laws, we do not have a balance of foreign~~our non-U.S. earnings ~~that will be~~are subject to U.S. taxation ~~upon repatriation.~~on a current or deferred basis. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals.

Table of Contents

We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition.

We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and ~~governmental~~government bodies. We believe that we have adequately provided a tax reserve for any adjustments that may result from tax examinations or uncertain tax positions. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.

ASSETS HELD FOR SALE

Assets to be disposed of by sale are reported at the lower of their carrying amount or fair value less costs to sell, and are not depreciated while they are held for sale. During the second quarter of 2023, we recorded $0.7 million as assets held for sale within prepaid and other on our Condensed Consolidated Balance Sheets related to three buildings located in France. During the third quarter of 2023, two of the three buildings were sold and we recognized a $0.8 million gain on sale.

SUPPLY CHAIN FINANCE PROGRAM

We facilitate a supply chain finance program ("SCF") across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions.

All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Condensed Consolidated Balance Sheets, and associated payments are included in operating activities within our Condensed Consolidated Statements of Cash Flows. As of September 30, 2023, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities were approximately $37.3 million.

We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered a third party alternative for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.

NOTE 2 – REVENUE

Segment financial information for the prior periods has been recast to conform to the current presentation. Refer to Note 16 - Segment Information. Revenue by segment and geography based on shipped from locations for the three and nine months ended September 30, 2023 and 2022 ~~and 2021 is~~was as follows:

For the Three Months Ended September 30, 2022
Segment Europe Domestic Latin
America Asia Total
Pharma $ 212,751 $ 105,542 $ 6,309 $ 18,795 $ 343,397
Beauty + Home 189,963 98,216 44,573 27,071 359,823
Food + Beverage 34,119 76,052 12,399 11,070 133,640
Total $ 436,833 $ 279,810 $ 63,281 $ 56,936 $ 836,860


	For the Three Months Ended September 30, 2023
Segment	Europe		Domestic		Latin America		Asia		Total
Aptar Pharma	$	252,174	$	106,804	$	11,118	$	19,092	$	389,188
Aptar Beauty	203,599		58,181		39,963		22,237		323,980
Aptar Closures	53,431		89,795		21,956		14,647		179,829
Total	$	509,204	$	254,780	$	73,037	$	55,976	$	892,997


	For the Three Months Ended September 30, 2022
Segment	Europe		Domestic		Latin America		Asia		Total
Aptar Pharma	$	212,751	$	105,542	$	6,309	$	18,795	$	343,397
Aptar Beauty	169,936		75,070		35,195		22,845		303,046
Aptar Closures	54,146		99,198		21,777		15,296		190,417
Total	$	436,833	$	279,810	$	63,281	$	56,936	$	836,860

Table of Contents

For the Three Months Ended September 30, 2021
Segment Europe Domestic Latin
America Asia Total
Pharma $ 202,893 $ 89,620 $ 5,318 $ 15,394 $ 313,225
Beauty + Home 193,772 109,103 40,441 30,772 374,088
Food + Beverage 36,824 81,514 11,991 7,800 138,129
Total $ 433,489 $ 280,237 $ 57,750 $ 53,966 $ 825,442


	For the Nine Months Ended September 30, 2023
Segment	Europe		Domestic		Latin America		Asia		Total
Aptar Pharma	$	733,749	$	309,946	$	30,699	$	61,540	$	1,135,934
Aptar Beauty	629,168		175,942		113,282		61,564		979,956
Aptar Closures	167,836		261,903		63,128		40,213		533,080
Total	$	1,530,753	$	747,791	$	207,109	$	163,317	$	2,648,970

For the Nine Months Ended September 30, 2022
Segment Europe Domestic Latin
America Asia Total
Pharma $ 632,876 $ 320,297 $ 20,503 $ 52,414 $ 1,026,090
Beauty + Home 601,322 296,386 122,275 79,385 1,099,368
Food + Beverage 102,731 231,934 37,389 28,823 400,877
Total $ 1,336,929 $ 848,617 $ 180,167 $ 160,622 $ 2,526,335

For the Nine Months Ended September 30, 2021
Segment Europe Domestic Latin
America Asia Total
Pharma $ 623,060 $ 272,442 $ 15,982 $ 40,916 $ 952,400
Beauty + Home 575,383 311,589 113,665 80,643 1,081,280
Food + Beverage 97,728 220,551 33,129 28,140 379,548
Total $ 1,296,171 $ 804,582 $ 162,776 $ 149,699 $ 2,413,228


	For the Nine Months Ended September 30, 2022
Segment	Europe		Domestic		Latin America		Asia		Total
Aptar Pharma	$	632,876	$	320,297	$	20,503	$	52,414	$	1,026,090
Aptar Beauty	540,629		224,269		97,337		67,558		929,793
Aptar Closures	163,424		304,051		62,327		40,650		570,452
Total	$	1,336,929	$	848,617	$	180,167	$	160,622	$	2,526,335

We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the invoicing for the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance.

The opening and closing balances of our contract asset and contract liabilities ~~are~~were as follows:


		Balance as of December 31, 2021		Balance as of September 30, 2022		Increase/ (Decrease)			Balance as of December 31, 2022		Balance as of September 30, 2023		Increase/ (Decrease)
Contract asset (current)	Contract asset (current)	$	16,878	$	12,495	$	(4,383)	Contract asset (current)	$	16,736	$	19,768	$	3,032

Contract liability (current)	Contract liability (current)	86,340		89,573		3,233		Contract liability (current)	80,241		73,282		(6,959)
Contract liability (long-term)	Contract liability (long-term)	21,905		24,225		2,320		Contract liability (long-term)	25,361		32,818		7,457

The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the invoicing. The total amount of revenue recognized during the current year against contract liabilities is ~~$96.1~~$106.0 million, including ~~$52.8~~$59.4 million relating to contract liabilities at the beginning of the year. Current contract assets ~~and long-term contract assets~~ are included within the ~~Prepaid~~prepaid and Other and Miscellaneous assets, respectively, while current contract liabilities and long-term contract liabilities are included within ~~Accounts~~accounts payable, accrued and other liabilities and deferred and other non-current liabilities, respectively, within our Condensed Consolidated Balance Sheets.

Determining the Transaction Price

In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identify reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which we will be entitled.

~~Table of Contents~~

Product Sales

We primarily manufacture and sell drug ~~delivery,~~and consumer product dosing, dispensing and ~~active material science solutions.~~protection technologies. The amount of consideration is typically fixed for customers. At the time of delivery, the customer is invoiced at the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer.

Table of Contents

To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. For a majority of product sales, control of the goods transfers to the customer at the time of shipment of the goods. Once the goods are shipped, we are precluded from redirecting the shipment to another customer. Therefore, our performance obligation is satisfied at the time of shipment. For sales in which control transfers upon delivery, shipping and/or handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs and revenue is recorded upon final delivery to the customer location. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale.

There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress towards completion using the output method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks. We believe this measurement provides a faithful depiction of the transfer of goods as the costs incurred reflect the value of the products produced.

As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties.

Tooling Sales

We also build or contract for molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress towards completion using the input method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any ~~material~~ significant payment terms as payment is typically either received during the mold-build process or shortly after completion.

In certain instances, we offer extended warranties on our tools above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. We do not have any material extended warranties as of September 30, ~~2022~~2023 or December 31, ~~2021.~~2022.

Service Sales

We also provide services to our ~~pharmaceutical~~ customers. As with product sales, we recognize revenue based on completion of each performance obligation of the service contract. Milestone deliverables and upfront payments are tied to specific performance obligations and recognized upon satisfaction of the individual performance obligation.

Contract Costs

We do not incur significant costs to obtain or fulfill revenue contracts.

Credit Risk

We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review.

We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.

Table of Contents

Current uncertainty in credit and market conditions due to the COVID-19 pandemic, the war in Ukraine, rising interest rates and inflation may slow our collection efforts if customers experience significant difficulty accessing credit and paying their obligations. Imposed sanctions delay payment, which may lead to higher than normal accounts receivable and increased CECL charges.

NOTE 3 - INVENTORIES

Inventories, by component net of reserves, consisted of:


		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
Raw materials	Raw materials	$	150,931	$	140,818	Raw materials	$	145,742	$	159,041
Work in process	Work in process	138,890		137,654		Work in process	173,453		153,592
Finished goods	Finished goods	172,931		162,992		Finished goods	171,677		174,173
Total	Total	$	462,752	$	441,464	Total	$	490,872	$	486,806

NOTE 4 – GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for the nine months ended September 30, 2023 by reporting segment ~~since December 31, 2021 are~~were as follows:

Pharma Beauty +
Home Food +
Beverage Total
Balance as of December 31, 2021 $ 520,197 $ 325,719 $ 128,241 $ 974,157
Acquisition 3,029 — — 3,029
Foreign currency exchange effects (51,844) (14,462) (839) (67,145)
Balance as of September 30, 2022 $ 471,382 $ 311,257 $ 127,402 $ 910,041



	Aptar Pharma		Aptar Beauty		Aptar Closures		Total
Balance as of December 31, 2022	$	498,742	$	319,011	$	127,879	$	945,632
Reclassification due to segment change	—		(39,472)		39,472		—
Acquisitions	—		3,655		114		3,769
Foreign currency exchange effects	(5,191)		(1,025)		(148)		(6,364)
Balance as of September 30, 2023	$	493,551	$	282,169	$	167,317	$	943,037

The table below shows a summary of intangible assets as of September 30, ~~2022~~2023 and December 31, ~~2021.~~2022.


			September 30, 2022						December 31, 2021								September 30, 2023						December 31, 2022
Weighted Average Amortization Period (Years)	Weighted Average Amortization Period (Years)		Gross Carrying Amount		Accumulated Amortization		Net Value		Gross Carrying Amount		Accumulated Amortization		Net Value		Weighted Average Amortization Period (Years)		Gross Carrying Amount		Accumulated Amortization		Net Value		Gross Carrying Amount		Accumulated Amortization		Net Value
Amortized intangible assets:	Amortized intangible assets:														Amortized intangible assets:
Patents	Patents	9.0	$	7,498	$	(1,678)	$	5,820	$	2,767	$	(1,528)	$	1,239	Patents	9.8	$	7,181	$	(1,617)	$	5,564	$	8,044	$	(1,968)	$	6,076
Acquired technology	Acquired technology	11.4	128,193		(50,619)		77,574		140,936		(45,613)		95,323		Acquired technology	11.4	136,860		(65,378)		71,482		135,191		(56,628)		78,563
Customer relationships	Customer relationships	13.4	298,658		(90,059)		208,599		311,964		(77,512)		234,452		Customer relationships	13.5	304,726		(116,570)		188,156		305,994		(99,130)		206,864
Trademarks and trade names	Trademarks and trade names	7.1	42,531		(25,729)		16,802		44,893		(22,886)		22,007		Trademarks and trade names	7.5	44,140		(32,555)		11,585		43,998		(28,190)		15,808
License agreements and other	License agreements and other	38.0	14,755		(6,406)		8,349		16,179		(6,857)		9,322		License agreements and other	31.4	16,910		(6,466)		10,444		15,425		(6,992)		8,433
Total intangible assets	Total intangible assets	13.1	$	491,635	$	(174,491)	$	317,144	$	516,739	$	(154,396)	$	362,343	Total intangible assets	13.3	$	509,817	$	(222,586)	$	287,231	$	508,652	$	(192,908)	$	315,744

Aggregate amortization expense for the intangible assets above for the quarters ended September 30, 2023 and 2022 was $11,400 and ~~2021 was~~ $10,678, ~~and $10,249,~~ respectively. Aggregate amortization expense for the intangible assets above for the nine months ended September 30, 2023 and 2022 was $33,494 and ~~2021 was~~ $32,772, ~~and $29,871,~~ respectively.

~~Table~~As of ~~Contents~~

~~Future~~September 30, 2023, future estimated amortization expense for the years ending December 31 is as follows:


2022		$	10,685	(remaining estimated amortization for 2022)
2023	2023	42,362			2023	$	11,473	(remaining estimated amortization for 2023)
2024	2024	39,151			2024	41,267
2025	2025	37,702			2025	39,565
2026	2026	35,611			2026	37,287
2027					2027	26,026
Thereafter	Thereafter	151,633			Thereafter	131,613

Table of Contents

Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of September 30, ~~2022.~~2023.

NOTE 5 – INCOME TAXES

The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated ~~full year-taxes,~~full-year taxes, adjusted for the impact of discrete quarterly items.

The effective tax rate for the three months ended September 30, ~~2022~~2023 and ~~2021,~~2022, respectively, was ~~36.2%~~23.4% and ~~29.2%~~36.2%. The effective tax rate for the nine months ended September 30, ~~2022~~2023 and ~~2021,~~2022, respectively, was ~~31.0%~~24.6% and ~~22.9%~~31.0%. The effective tax rate for the three months ended September 30, 2023 reflects additional tax benefits from employee stock-based compensation and a benefit related to a change in the U.S. tax regulations issued during the quarter related to foreign tax credits. The effective tax rate for the three months ended September 30, 2022 reflects an out-of-period charge of $7.2 million for taxes related to a legal entity reorganization to enhance ~~the Company's~~our dividend and cash management capabilities. The tax charge ~~contributed~~had an 8.5% ~~to the~~ impact on the effective tax rate for the three months ended September 30, 2022. The ~~tax charge should have been recognized in the three months ended March 31, 2022. The~~ lower reported effective tax rate for the nine months ended September 30, ~~2021~~2023 reflects additional tax benefits from employee stock-based ~~compensation. The impacts~~compensation, the refining of certain U.S. tax filing positions and a change in the ~~error on~~U.S. tax regulations pertaining to foreign tax credits. As mentioned above, the ~~three months ended March 31, 2022 and~~tax rate for the ~~three~~nine months ended September 30, 2022, ~~are not considered material to either period.~~reflects an out-of-period charge for $7.2 million and had a 2.8% impact on the effective tax rate.

NOTE 6 – DEBT

Notes Payable, Revolving Credit Facility and Overdrafts

At September 30, ~~2022~~2023 and December 31, ~~2021,~~2022, our notes payable, revolving credit facility and overdrafts consisted of the following:

September 30,
2022 December 31,
2021
Revolving credit facility 1.68% $ 49,005 $ 144,383
Overdrafts 1.46% to 15.37% 4,204 2,893
$ 53,209 $ 147,276


	September 30, 2023		December 31, 2022

Revolving credit facility 4.73% to 6.18%	$	123,790	$	—
Overdrafts 4.64% to 4.71%	713		3,810
	$	124,503	$	3,810

On June 30, 2021, we entered into an amended and restated multi-currency revolving credit facility (the "revolving credit facility") with a syndicate of banks to replace the then-existing facility maturing July 2022 (the "prior credit facility") and to amend and restate the unsecured term loan facility extended to our wholly-owned UK subsidiary under the prior credit facility (as amended, the "amended term facility"). The revolving credit facility matures in June 2026, subject to a maximum of two one-year extensions in certain circumstances, and provides for unsecured financing of up to $600 million available in the U.S. and to our wholly-owned UK subsidiary. The amended term facility matured in July 2022 and was repaid in full. The revolving credit facility can be drawn in various currencies including USD, EUR, GBP, and CHF to the equivalent of $600 million, which may be increased by up to $300 million subject to the satisfaction of certain conditions. As of September 30, 2023, $44.5 million and €75.0 million ($79.3 million) was utilized under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. As of December 31, 2022, no balance was utilized under the revolving credit facility in the U.S. and ~~€50.0 million (approximately $49.0 million)~~no balance was utilized by our wholly-owned UK subsidiary. As of December 31, 2021, $133 million was utilized under the revolving credit facility in the U.S., €10 million (approximately $11.4 million given the exchange rates at the end of 2021) was utilized by our wholly-owned UK subsidiary and $56 million remained outstanding under the amended term facility.

~~Table of Contents~~

In October 2020, we entered into an unsecured money market borrowing arrangement to provide short term financing of up to $30 million that is available in the U.S. No borrowing on this facility is permitted over a quarter end date. As such, no balance was utilized under this arrangement as of September 30, ~~2022~~2023 or December 31, ~~2021.~~2022.

Long-Term Obligations

On July 19, 2023, we repaid in full the €100 million 0.98% Senior Notes that were due July 2023.

Table of Contents

On March 7, 2022, we issued $400 million aggregate principal amount of 3.60% Senior Notes due March 2032 in an underwritten public offering. The form and terms of the notes were established pursuant to an Indenture, dated as of March 7, 2022, as amended and supplemented by a First Supplemental Indenture, dated as of March 7, 2022, each between the Company and U.S. Bank Trust Company, National Association, as trustee. Interest is payable semi-annually in arrears. The notes are unsecured obligations and rank equally in right of payment with all of our other existing and future senior, unsecured indebtedness.

We redeemed all $75.0 million of our 3.25% senior unsecured notes during the second quarter of 2022 at a price equal to the principal amount plus accrued interest and a $0.4 million make-whole payment.

~~We redeemed all $125.0 million of our 3.49% senior unsecured notes during the third quarter of 2022 at a price equal to the principal amount plus accrued interest.~~

At September 30, ~~2022~~2023 and December 31, ~~2021,~~2022, our long-term obligations consisted of the following:


		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
Notes payable 0.00% – 14.42%, due in monthly and annual installments through 2028		$	24,032	$	22,785
Senior unsecured notes 3.2%, due in 2022		—		75,000
Senior unsecured debts 2.19% USD floating swapped to 1.36% EUR fixed, due in 2022		—		56,000
Senior unsecured notes 3.5%, due in 2023		—		125,000
Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2031						Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2031	$	15,005	$	29,167
Senior unsecured notes 1.0%, due in 2023	Senior unsecured notes 1.0%, due in 2023	98,010		113,830		Senior unsecured notes 1.0%, due in 2023	—		106,995
Senior unsecured notes 3.4%, due in 2024	Senior unsecured notes 3.4%, due in 2024	50,000		50,000		Senior unsecured notes 3.4%, due in 2024	50,000		50,000
Senior unsecured notes 3.5%, due in 2024	Senior unsecured notes 3.5%, due in 2024	100,000		100,000		Senior unsecured notes 3.5%, due in 2024	100,000		100,000
Senior unsecured notes 1.2%, due in 2024	Senior unsecured notes 1.2%, due in 2024	196,020		227,660		Senior unsecured notes 1.2%, due in 2024	211,440		213,990
Senior unsecured notes 3.6%, due in 2025	Senior unsecured notes 3.6%, due in 2025	125,000		125,000		Senior unsecured notes 3.6%, due in 2025	125,000		125,000
Senior unsecured notes 3.6%, due in 2026	Senior unsecured notes 3.6%, due in 2026	125,000		125,000		Senior unsecured notes 3.6%, due in 2026	125,000		125,000
Senior unsecured notes 3.6%, due in 2032, net of discount of $1.0 million		399,024		—
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.9 million						Senior unsecured notes 3.6%, due in 2032, net of discount of $0.9 million	399,128		399,050
Finance Lease Liabilities	Finance Lease Liabilities	26,741		30,185		Finance Lease Liabilities	24,867		26,934
Unamortized debt issuance costs	Unamortized debt issuance costs	(4,745)		(1,085)		Unamortized debt issuance costs	(3,997)		(4,558)
		$	1,139,082	$	1,049,375		$	1,046,443	$	1,171,578
Current maturities of long-term obligations	Current maturities of long-term obligations	(111,034)		(142,351)		Current maturities of long-term obligations	(366,378)		(118,981)
Total long-term obligations	Total long-term obligations	$	1,028,048	$	907,024	Total long-term obligations	$	680,065	$	1,052,597

The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are ~~disclosed~~discussed in Note 7, due annually from the current balance sheet date for the next five years and thereafter are:


Year One	$	~~107,873~~363,408
Year Two	~~104,859~~6,368
Year Three	~~251,033~~256,200
Year Four	~~254,048~~315
Year Five	~~175~~72
Thereafter	~~399,098~~399,210

~~Table of Contents~~

Covenants

Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:

Requirement

Level at September 30, ~~2022~~2023

Consolidated Leverage Ratio (1)

Maximum of 3.50 to 1.00

~~1.76~~1.61 to 1.00

Consolidated Interest Coverage Ratio (1)

Minimum of 3.00 to 1.00

~~16.02~~16.19 to 1.00

(1)Definitions of ratios are included as part of the revolving credit facility agreement and the private placement agreements.

NOTE 7 – LEASES

We lease certain warehouse, plant and office facilities, as well as certain equipment, under non-cancelable operating and finance leases expiring at various dates through the year ~~2034.~~2037. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term.

Amortization expense related to finance leases is included in depreciation expense, while rent expense related to operating leases is included within cost of sales and selling, research & development and administrative ~~expenses (“SG&A”).~~expenses.

Table of Contents

The components of lease expense for the three and nine months ended September 30, ~~2022~~2023 and ~~2021~~2022 were as follows:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Operating lease cost	Operating lease cost	$	4,870	$	5,423	$	15,605	$	17,256	Operating lease cost	$	5,150	$	4,870	$	15,841	$	15,605

Finance lease cost:	Finance lease cost:									Finance lease cost:
Amortization of right-of-use assets	Amortization of right-of-use assets	$	1,050	$	1,107	$	3,307	$	3,182	Amortization of right-of-use assets	$	908	$	1,050	$	2,686	$	3,307
Interest on lease liabilities	Interest on lease liabilities	307		343		947		1,030		Interest on lease liabilities	289		307		883		947
Total finance lease cost	Total finance lease cost	$	1,357	$	1,450	$	4,254	$	4,212	Total finance lease cost	$	1,197	$	1,357	$	3,569	$	4,254

Short-term lease and variable lease costs	Short-term lease and variable lease costs	$	4,226	$	3,353	$	11,437	$	8,925	Short-term lease and variable lease costs	$	5,774	$	4,226	$	15,883	$	11,437

Supplemental cash flow information related to leases was as follows:


Nine Months Ended September 30,	Nine Months Ended September 30,	2022		2021		Nine Months Ended September 30,	2023		2022
Cash paid for amounts included in the measurement of lease liabilities:	Cash paid for amounts included in the measurement of lease liabilities:					Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	Operating cash flows from operating leases	$	15,001	$	17,310	Operating cash flows from operating leases	$	15,993	$	15,001
Operating cash flows from finance leases	Operating cash flows from finance leases	941		1,052		Operating cash flows from finance leases	883		941
Financing cash flows from finance leases	Financing cash flows from finance leases	2,749		3,392		Financing cash flows from finance leases	2,377		2,749

Right-of-use assets obtained in exchange for lease obligations:	Right-of-use assets obtained in exchange for lease obligations:					Right-of-use assets obtained in exchange for lease obligations:
Operating leases	Operating leases	$	13,146	$	6,890	Operating leases	$	7,764	$	13,146
Finance leases	Finance leases	919		5,707		Finance leases	401		919

NOTE 8 – RETIREMENT AND DEFERRED COMPENSATION PLANS

Effective January 1, 2021, our domestic noncontributory retirement plans were closed to new employees and employees who were rehired after December 31, 2020. These employees are instead eligible for additional contribution to their defined contribution 401(k) employee savings plan. All domestic employees with hire/rehire dates prior to January 1, 2021 are still eligible for the domestic pension plans and continue to accrue plan benefits after this date.

Components of Net Periodic Benefit Cost:


	Domestic Plans				Foreign Plans
Three Months Ended September 30,	2023		2022		2023		2022
Service cost	$	2,409	$	3,948	$	1,487	$	1,775
Interest cost	2,158		1,742		915		330
Expected return on plan assets	(3,094)		(3,228)		(589)		(653)
Amortization of net loss	—		1,668		230		403
Amortization of prior service cost	—		—		45		35
Net periodic benefit cost	$	1,473	$	4,130	$	2,088	$	1,890


	Domestic Plans				Foreign Plans
Nine Months Ended September 30,	2023		2022		2023		2022
Service cost	$	7,228	$	11,838	$	4,444	$	5,621
Interest cost	6,473		5,227		2,735		1,045
Expected return on plan assets	(9,283)		(9,684)		(1,758)		(2,069)
Amortization of net loss	—		5,003		687		1,280
Amortization of prior service cost	—		—		133		106
Net periodic benefit cost	$	4,418	$	12,384	$	6,241	$	5,983

Table of Contents

~~Components of Net Periodic Benefit Cost:~~

Domestic Plans Foreign Plans
Three Months Ended September 30, 2022 2021 2022 2021
Service cost $ 3,948 $ 4,074 $ 1,775 $ 2,037
Interest cost 1,742 1,601 330 203
Expected return on plan assets (3,228) (3,060) (653) (675)
Amortization of net loss 1,668 2,498 403 568
Amortization of prior service cost — — 35 34
Net periodic benefit cost $ 4,130 $ 5,113 $ 1,890 $ 2,167

Domestic Plans Foreign Plans
Nine Months Ended September 30, 2022 2021 2022 2021
Service cost $ 11,838 $ 12,242 $ 5,621 $ 6,186
Interest cost 5,227 4,816 1,045 629
Expected return on plan assets (9,684) (9,197) (2,069) (2,119)
Amortization of net loss 5,003 7,502 1,280 1,748
Amortization of prior service cost — — 106 123
Net periodic benefit cost $ 12,384 $ 15,363 $ 5,983 $ 6,567

The components of net periodic benefit cost, other than the service cost component, are included in the line ~~Miscellaneous,~~miscellaneous income (expense), net in the Condensed Consolidated Statements of Income.

Employer Contributions

We currently have no minimum funding requirements for our domestic and foreign plans. ~~We contributed $15.0 million~~There were no contributions to our domestic defined benefit plans during the nine months ended September 30, ~~2022~~2023 and we do not expect ~~additional~~ significant payments during ~~2022.~~the rest of 2023. We contributed ~~$1.3~~$1.0 million to our foreign defined benefit plans during the nine months ended September 30, ~~2022~~2023 and do not expect additional significant contributions during ~~2022.~~the rest of 2023.

NOTE 9 – ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME

Changes in Accumulated Other Comprehensive (Loss) Income by Component:


		Foreign Currency		Defined Benefit Pension Plans		Derivatives		Total			Foreign Currency		Defined Benefit Pension Plans		Derivatives		Total
Balance - December 31, 2020		$	(178,025)	$	(102,322)	$	(1,362)	$	(281,709)
Balance - December 31, 2021										Balance - December 31, 2021	$	(249,500)	$	(66,486)	$	(55)	$	(316,041)
Other comprehensive (loss) income before reclassifications	Other comprehensive (loss) income before reclassifications	(57,317)		529		7,346		(49,442)		Other comprehensive (loss) income before reclassifications	(182,432)		(719)		3,617		(179,534)
Amounts reclassified from accumulated other comprehensive income (loss)	Amounts reclassified from accumulated other comprehensive income (loss)	—		7,131		(6,307)		824		Amounts reclassified from accumulated other comprehensive income (loss)	—		4,781		46		4,827
Net current-period other comprehensive (loss) income	Net current-period other comprehensive (loss) income	(57,317)		7,660		1,039		(48,618)		Net current-period other comprehensive (loss) income	(182,432)		4,062		3,663		(174,707)
Balance - September 30, 2021		$	(235,342)	$	(94,662)	$	(323)	$	(330,327)
Balance - September 30, 2022										Balance - September 30, 2022	$	(431,932)	$	(62,424)	$	3,608	$	(490,748)

Balance - December 31, 2021		$	(249,500)	$	(66,486)	$	(55)	$	(316,041)
Other comprehensive (loss) income before reclassifications		(182,432)		(719)		3,617		(179,534)
Balance - December 31, 2022										Balance - December 31, 2022	$	(328,740)	$	(5,951)	$	(6,675)	$	(341,366)
Other comprehensive income (loss) before reclassifications										Other comprehensive income (loss) before reclassifications	(28,294)		63		(2,424)		(30,655)
Amounts reclassified from accumulated other comprehensive income	Amounts reclassified from accumulated other comprehensive income	—		4,781		46		4,827		Amounts reclassified from accumulated other comprehensive income	—		581		—		581
Net current-period other comprehensive (loss) income		(182,432)		4,062		3,663		(174,707)
Balance - September 30, 2022		$	(431,932)	$	(62,424)	$	3,608	$	(490,748)
Net current-period other comprehensive income (loss)										Net current-period other comprehensive income (loss)	(28,294)		644		(2,424)		(30,074)
Balance - September 30, 2023										Balance - September 30, 2023	$	(357,034)	$	(5,307)	$	(9,099)	$	(371,440)

Reclassifications Out of Accumulated Other Comprehensive (Loss) Income:


Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income				Affected Line in the Statement Where Net Income is Presented
Three Months Ended September 30,	2023		2022

Defined Benefit Pension Plans
Amortization of net loss	$	230	$	2,071	(1)
Amortization of prior service cost	45		35		(1)
	275		2,106		Total before tax
	(81)		(530)		Tax impact
	$	194	$	1,576	Net of tax
Derivatives
Changes in cross currency swap: interest component	$	—	$	(33)	Interest Expense
Changes in cross currency swap: foreign exchange component	—		4,843		Miscellaneous, net
	$	—	$	4,810	Net of tax
Total reclassifications for the period	$	194	$	6,386

Table of Contents

~~Reclassifications Out of Accumulated Other Comprehensive (Loss) Income:~~

Details about Accumulated Other
Comprehensive Income Components Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement
Where Net Income is Presented
Three Months Ended September 30, 2022 2021
Defined Benefit Pension Plans
Amortization of net loss $ 2,071 $ 3,066 (1)
Amortization of prior service cost 35 34 (1)
2,106 3,100 Total before tax
(530) (742) Tax impact
$ 1,576 $ 2,358 Net of tax
Derivatives
Changes in cross currency swap: interest component $ (33) $ 2 Interest Expense
Changes in cross currency swap: foreign exchange component 4,843 (3,052) Miscellaneous, net
$ 4,810 $ (3,050) Net of tax
Total reclassifications for the period $ 6,386 $ (692)


Details about Accumulated Other Comprehensive Income Components	Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income				Affected Line in the Statement Where Net Income is Presented	Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income				Affected Line in the Statement Where Net Income is Presented
Nine Months Ended September 30,	Nine Months Ended September 30,	2022		2021			Nine Months Ended September 30,	2023		2022

Defined Benefit Pension Plans	Defined Benefit Pension Plans						Defined Benefit Pension Plans
Amortization of net loss	Amortization of net loss	$	6,283	$	9,250	(1)	Amortization of net loss	$	687	$	6,283	(1)
Amortization of prior service cost	Amortization of prior service cost	106		123		(1)	Amortization of prior service cost	133		106		(1)
		6,389		9,373		Total before tax		820		6,389		Total before tax
		(1,608)		(2,242)		Tax impact		(239)		(1,608)		Tax impact
		$	4,781	$	7,131	Net of tax		$	581	$	4,781	Net of tax
Derivatives	Derivatives						Derivatives
Changes in cross currency swap: interest component	Changes in cross currency swap: interest component	$	(171)	$	(16)	Interest Expense	Changes in cross currency swap: interest component	$	—	$	(171)	Interest Expense
Changes in cross currency swap: foreign exchange component	Changes in cross currency swap: foreign exchange component	217		(6,291)		Miscellaneous, net	Changes in cross currency swap: foreign exchange component	—		217		Miscellaneous, net
		$	46	$	(6,307)	Net of tax		$	—	$	46	Net of tax
Total reclassifications for the period	Total reclassifications for the period	$	4,827	$	824		Total reclassifications for the period	$	581	$	4,827

(1)These accumulated other comprehensive ~~(loss)~~ income components are included in the computation of net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

NOTE 10 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional currency denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks.

~~Table of Contents~~

For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Condensed Consolidated Balance Sheets (See Note 11 - Fair Value).

Cash Flow Hedge

For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Condensed Consolidated Statements of Cash Flows.

Net Investment Hedge

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A weakening U.S. dollar has an additive effect. In ~~2017,~~some cases, we maintain debt in these subsidiaries to offset the net asset exposure. Conversely, a strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our ~~wholly-owned UK subsidiary borrowed $280 million in term loan borrowings under~~financial condition and results of operations. In the event we plan on a full or partial liquidation of any of our ~~prior credit facility. In order~~foreign subsidiaries where our net investment is likely to ~~mitigate~~be monetized, we will consider hedging the currency ~~risk~~exposure associated with such a transaction.

Table of U.S. dollar debt on a euro functional currency entity and to mitigate the risk of variability in interest rates, we entered into a EUR/USD floating-to-fixed cross currency swap on July 20, 2017 in the notional amount of $280 million to effectively hedge the foreign exchange and interest rate exposure on the $280 million term loan. This EUR/USD swap agreement fixed our U.S. dollar floating-rate debt to 1.36% euro fixed-rate debt. The swap agreement expired on July 20, 2022.Contents

~~Net Investment Hedge~~

On July 6, 2022, we entered into a seven year USD/EUR fixed-to-fixed cross currency interest rate swap to effectively hedge the interest rate exposure relating to $203 million of the $400 million 3.60% Senior Notes due March 2032, which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged ~~USD~~ $203 million of fixed-rate 3.60% U.S. dollar debt to €200 million of fixed-rate 2.5224% euro debt. We pay semi-annual fixed rate interest payments on the euro notional amount of €2.5 million and receive semi-annual fixed rate interest payments on the USD notional amount of $3.7 million. This swap has been designated as a net investment hedge to effectively hedge the foreign exchange risk associated with €200 million of our euro denominated net assets. We elected the spot method for recording the net investment hedge. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense in the Condensed Consolidated Statements of Income. Gains and losses resulting from the fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive ~~loss~~(loss) income as the swaps are effective in hedging the designated risk. As of September 30, ~~2022,~~2023, the fair value of the cross currency swap was a ~~$4.8~~$12.0 million ~~asset.~~liability. The swap agreement will mature on September 15, 2029.

~~Hedge of Net Investments in Foreign Operations~~

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we maintain debt in these subsidiaries to offset the net asset exposure. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction.

Other

As of September 30, ~~2022,~~2023, we have recorded the fair value of foreign currency forward exchange contracts of ~~$0.2~~$0.4 million in ~~Prepaid~~prepaid and other and ~~$0.9~~$0.3 million in ~~Accounts~~accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets. All forward exchange contracts outstanding as of September 30, ~~2022~~2023 had an aggregate notional contract amount of ~~$56.9~~$51.1 million.

~~Table of Contents~~

Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of September 30, ~~2022~~2023 and December 31, ~~2021~~2022


			September 30, 2022				December 31, 2021						September 30, 2023				December 31, 2022
		Balance Sheet Location	Derivatives Designated as Hedging Instruments		Derivatives not Designated as Hedging Instruments		Derivatives Designated as Hedging Instruments		Derivatives not Designated as Hedging Instruments			Balance Sheet Location	Derivatives Designated as Hedging Instruments		Derivatives not Designated as Hedging Instruments		Derivatives Designated as Hedging Instruments		Derivatives not Designated as Hedging Instruments
Derivative Assets	Derivative Assets										Derivative Assets
Foreign Exchange Contracts	Foreign Exchange Contracts	Prepaid and other	$	—	$	176	$	—	$	331	Foreign Exchange Contracts	Prepaid and other	$	—	$	377	$	—	$	1,107
Cross Currency Swap Agreement (1)		Prepaid and other	4,778		—		511		—

			$	4,778	$	176	$	511	$	331			$	—	$	377	$	—	$	1,107

Derivative Liabilities	Derivative Liabilities										Derivative Liabilities
Foreign Exchange Contracts	Foreign Exchange Contracts	Accounts payable, accrued and other liabilities	$	—	$	914	$	—	$	221	Foreign Exchange Contracts	Accounts payable, accrued and other liabilities	$	—	$	305	$	—	$	269
Cross Currency Swap Contract (1)											Cross Currency Swap Contract (1)	Accounts payable, accrued and other liabilities	12,049		—		8,840		—
													$	12,049	$	305	$	8,840	$	269
			$	—	$	914	$	—	$	221

__________________________

(1)This cross currency swap agreement is composed of both an interest component and a foreign exchange component.

The Effect of Derivatives Designated as Hedging Instruments on Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended September 30, ~~2022~~2023 and ~~2021~~2022


Derivatives Designated as Hedging Instruments	Derivatives Designated as Hedging Instruments	Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative				Location of (Loss) Gain Recognized in Income on Derivatives	Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative				Total Amount of Affected Income Statement Line Item		Derivatives Designated as Hedging Instruments	Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative				Location of (Loss) Gain Recognized in Income on Derivatives	Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative				Total Amount of Affected Income Statement Line Item
		2022		2021			2022		2021					2023		2022			2023		2022
Cross currency swap agreement:	Cross currency swap agreement:												Cross currency swap agreement:
Interest component	Interest component	$	(30)	$	228	Interest expense	$	33	$	(2)	$	(9,756)	Interest component	$	—	$	(30)	Interest expense	$	—	$	33	$	(9,984)
Foreign exchange component	Foreign exchange component	(1,238)		3,052		Miscellaneous, net	(4,843)		3,052		(2,093)		Foreign exchange component	2,707		(1,238)		Miscellaneous, net	—		(4,843)		3
		$	(1,268)	$	3,280		$	(4,810)	$	3,050				$	2,707	$	(1,268)		$	—	$	(4,810)

Table of Contents

The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022


Derivatives Designated as Hedging Instruments	Derivatives Designated as Hedging Instruments	Amount of Gain Recognized in Other Comprehensive Income on Derivative				Location of Gain Recognized in Income on Derivatives	Amount of Gain Reclassified from Accumulated Other Comprehensive Income on Derivative				Total Amount of Affected Income Statement Line Item		Derivatives Designated as Hedging Instruments	Amount of Gain Recognized in Other Comprehensive Income on Derivative				Location of Gain Recognized in Income on Derivatives	Amount of Gain Reclassified from Accumulated Other Comprehensive Income on Derivative				Total Amount of Affected Income Statement Line Item
		2022		2021			2022		2021					2023		2022			2023		2022
Cross currency swap agreement:	Cross currency swap agreement:												Cross currency swap agreement:
Interest component	Interest component	$	229	$	1,055	Interest expense	$	171	$	16	$	(30,668)	Interest component	$	—	$	229	Interest expense	$	—	$	171	$	(29,900)
Foreign exchange component	Foreign exchange component	3,388		6,291		Miscellaneous, net	(217)		6,291		(3,144)		Foreign exchange component	(2,424)		3,388		Miscellaneous, net	—		(217)		(1,341)
		$	3,617	$	7,346		$	(46)	$	6,307				$	(2,424)	$	3,617		$	—	$	(46)

~~Table of Contents~~

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended September 30, ~~2022~~2023 and ~~2021~~2022


Derivatives Not Designated as Hedging Instruments	Derivatives Not Designated as Hedging Instruments	Location of (Loss) Gain Recognized in Income on Derivatives	Amount of (Loss) Gain Recognized in Income on Derivatives				Derivatives Not Designated as Hedging Instruments	Location of (Loss) Gain Recognized in Income on Derivatives	Amount of (Loss) Gain Recognized in Income on Derivatives
			2022		2021				2023		2022
Foreign Exchange Contracts	Foreign Exchange Contracts	Other (Expense) Income: Miscellaneous, net	$	(853)	$	1,518	Foreign Exchange Contracts	Other (Expense) Income: Miscellaneous, net	$	44	$	(853)
			$	(853)	$	1,518			$	44	$	(853)

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022


Derivatives Not Designated as Hedging Instruments	Location of Loss Recognized in Income on Derivatives	Amount of Loss Recognized in Income on Derivatives
		2023		2022
Foreign Exchange Contracts	Other (Expense) Income: Miscellaneous, net	$	(756)	$	(962)
		$	(756)	$	(962)

Derivatives Not Designated
as Hedging Instruments Location of Loss Recognized
in Income on Derivatives Amount of Loss
Recognized in Income
on Derivatives
2022 2021
Foreign Exchange Contracts Other (Expense) Income:
Miscellaneous, net $ (962) $ (171)
$ (962) $ (171)

Table of Contents


				Gross Amounts Offset in the Statement of Financial Position		Net Amounts Presented in the Statement of Financial Position				Gross Amounts not Offset in the Statement of Financial Position													Gross Amounts Offset in the Statement of Financial Position		Net Amounts Presented in the Statement of Financial Position		Gross Amounts not Offset in the Statement of Financial Position
		Gross Amount						Financial Instruments			Cash Collateral Received		Net Amount			Gross Amount								Financial Instruments			Cash Collateral Received		Net Amount

September 30, 2022
September 30, 2023																	September 30, 2023
Derivative Assets	Derivative Assets	$	4,954		—			$	4,954		—		—				$	4,954		Derivative Assets	$	377			—		$	377	—	—		$	377
Total Assets	Total Assets	$	4,954	—		$	4,954			—		—		$	4,954		Total Assets		$	377			—		$	377	—		—	$	377

Derivative Liabilities	Derivative Liabilities	$	914	—		$	914			—		—		$	914		Derivative Liabilities		$	12,354			—		$	12,354	—		—	$	12,354
Total Liabilities	Total Liabilities	$	914	—		$	914			—		—		$	914		Total Liabilities		$	12,354			—		$	12,354	—		—	$	12,354

December 31, 2021
December 31, 2022																	December 31, 2022
Derivative Assets	Derivative Assets	$	842	—		$	842			—		—		$	842		Derivative Assets		$	1,107			—		$	1,107	—		—	$	1,107
Total Assets	Total Assets	$	842	—		$	842			—		—		$	842		Total Assets		$	1,107			—		$	1,107	—		—	$	1,107

Derivative Liabilities	Derivative Liabilities	$	221	—		$	221			—		—		$	221		Derivative Liabilities		$	9,109			—		$	9,109	—		—	$	9,109
Total Liabilities	Total Liabilities	$	221	—		$	221			—		—		$	221		Total Liabilities		$	9,109			—		$	9,109	—		—	$	9,109

NOTE 11 – FAIR VALUE

Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:

•Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.

•Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

•Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.

As of September 30, 2023, the fair values of our financial assets and liabilities were categorized as follows:


	Total		Level 1		Level 2		Level 3
Assets
Investment in equity securities (1)	$	1,532	$	1,532	$	—	$	—
Foreign exchange contracts (2)	377		—		377		—

Convertible notes	5,650		—		—		5,650
Total assets at fair value	$	7,559	$	1,532	$	377	$	5,650
Liabilities
Foreign exchange contracts (2)	$	305	$	—	$	305	$	—
Cross currency swap contract (2)	12,049		—		12,049		—

Total liabilities at fair value	$	12,354	$	—	$	12,354	$	—

Table of Contents

As of ~~September 30,~~December 31, 2022, the fair values of our financial assets and liabilities were categorized as follows:

Total Level 1 Level 2 Level 3
Assets
Investment in equity securities (1)
$ 6,323 $ 6,323 $ — $ —
Foreign exchange contracts (2)
176 — 176 —
Cross currency swap agreement (2)
4,778 — 4,778 —
Convertible notes 6,000 — — 6,000
Total assets at fair value $ 17,277 $ 6,323 $ 4,954 $ 6,000
Liabilities
Foreign exchange contracts (2)
$ 914 $ — $ 914 $ —
Contingent consideration obligation 31,643 — — 31,643
Total liabilities at fair value $ 32,557 $ — $ 914 $ 31,643

~~As of December 31, 2021, the fair values of our financial assets and liabilities were categorized as follows:~~


		Total		Level 1		Level 2		Level 3			Total		Level 1		Level 2		Level 3
Assets	Assets									Assets
Investment in equity securities (1)	Investment in equity securities (1)	$	9,006	$	9,006	$	—	$	—	Investment in equity securities (1)	$	5,297	$	5,297	$	—	$	—
Foreign exchange contracts (2)	Foreign exchange contracts (2)	331		—		331		—		Foreign exchange contracts (2)	1,107		—		1,107		—
Cross currency swap agreement (2)		511		—		511		—

Convertible note										Convertible note	5,650		—		—		5,650
Total assets at fair value	Total assets at fair value	$	9,848	$	9,006	$	842	$	—	Total assets at fair value	$	12,054	$	5,297	$	1,107	$	5,650
Liabilities	Liabilities									Liabilities
Foreign exchange contracts (2)	Foreign exchange contracts (2)	$	221	$	—	$	221	$	—	Foreign exchange contracts (2)	$	269	$	—	$	269	$	—

Cross currency swap contract (2)										Cross currency swap contract (2)	8,840		—		8,840		—
Contingent consideration obligation	Contingent consideration obligation	33,908		—		—		33,908		Contingent consideration obligation	25,310		—		—		25,310
Total liabilities at fair value	Total liabilities at fair value	$	34,129	$	—	$	221	$	33,908	Total liabilities at fair value	$	34,419	$	—	$	9,109	$	25,310

(1)Investment in PureCycle Technologies ("PCT" or "PureCycle"). See Note 18 -– Investment in Equity Securities for discussion of this investment.

(2)Market approach valuation technique based on observable market transactions of spot and forward rates.

The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the ~~instruments.~~instrument. We consider our long-term debt obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was ~~$0.9 billion~~$517.3 million as of September 30, ~~2022~~2023 and ~~$0.9 billion~~$868.7 million as of December 31, ~~2021.~~2022.

During the first quarter of 2022, we invested $5.0 million in a convertible note in Enable Injections, Inc. This investment is recorded at fair value and is a Level 3 fair value measurement.

During the second quarter of 2022, we invested $1.0 million in a convertible note in Siklus Refill Pte. Ltd. ("Siklus"). During the fourth quarter of 2022, Siklus repaid $0.4 million of its convertible note. This investment is recorded at fair value and is a Level 3 fair value measurement.

As discussed in Note 12 -– Fair Value of our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, we ~~have a~~had contingent consideration ~~obligation~~obligations to the selling equity holders of:

–Fusion Packaging, Inc. ("Fusion") in connection with the acquisition of 100% of the equity interests of Fusion (the "Fusion Acquisition") based on 2022 cumulative performance targets, and

–Noble International Holdings, Inc., Genia Medical, Inc. and JBCB Holdings, LLC (collectively referred to as "Noble") in connection with the acquisition of 100% of the equity interests of Noble (the "Noble Acquisition") based on 2024 cumulative performance targets.

~~Table of Contents~~

We consider these obligations a Level 3 ~~liabilities~~liability and ~~have~~ estimated the aggregate fair value for these contingent consideration arrangements as follows:

September 30, 2022 December 31, 2021
Fusion Acquisition $ 26,681 $ 27,166
Noble Acquisition 4,962 6,742
$ 31,643 $ 33,908


	September 30, 2023		December 31, 2022
Fusion Acquisition	$	—	$	25,310
Noble Acquisition	—		—

	$	—	$	25,310

Table of Contents

Changes in the fair value of these obligations are recorded within selling, research & development and administrative expenses in our Condensed Consolidated Statements of Income. Significant changes to the inputs, as noted above, can result in a significantly higher or lower fair value measurement. In April 2023, we repaid the outstanding contingent consideration obligation to the selling equity holders of Fusion. Approximately $22.8 million is recorded as a financing activity in our Condensed Consolidated Statements of Cash Flows representing the portion of the outstanding contingent consideration that was associated with the acquisition fair value of the liability. The remaining $2.5 million is recorded within cash flow from operations. The following table provides a summary of changes in our Level 3 fair value measurements:


Balance, December 31, ~~2021~~2022	$	~~33,908~~25,310

~~Decrease~~Increase in fair value recorded in earnings	~~(2,265)~~—
Payments	(25,310)
Balance, September 30, ~~2022~~2023	$	~~31,643~~—

NOTE 12 -– COMMITMENTS AND CONTINGENCIES

In the normal course of business, we are subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, ~~our~~ results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur ~~and~~that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows.

Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of September 30, ~~2022~~2023 and December 31, ~~2021.~~2022.

A fire caused damage to our facility in Annecy, France in June 2016. We were insured for the damages caused by the fire, including business interruption insurance. During the second quarter of 2022, we filed a lawsuit against the insurance company to recover a part of our claim. No gain contingencies have been recognized as our ability to realize those gains remains uncertain.

In March 2017, the Supreme Court of Brazil issued a decision that a certain state value added tax should not be included in the calculation of federal gross receipts taxes. We submitted our claim and on September 30, 2021, we received a formal decision statement from the Federal Regional Court of Brazil that the favorable court decisions are final. As a result, in September 2021, we recorded recoveries of $2.7 million in cost of sales. We do not expect to receive any further amounts in future periods.

We are periodically subject to loss contingencies resulting from custom duties assessments. We accrue for anticipated costs when an assessment has indicated that a loss is probable and can be reasonably estimated. We have received claims worth approximately $13 million in principal and $5 million to $6 million for interest and penalties. We are currently defending our position with respect to these claims in the respected administrative procedures. Due to uncertainty in the amount of the assessment and the timing of our appeal, no liability is recorded as of September 30, ~~2022.~~2023.

We will continue to evaluate these liabilities periodically based on available information, including the progress of remedial investigations, the status of discussions with regulatory authorities regarding the methods and extent of remediation and the apportionment of costs and penalties among potentially responsible parties.

NOTE 13 – STOCK REPURCHASE PROGRAM

On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

During the three and nine months ended September 30, 2023, we repurchased approximately 66 thousand shares for $8.3 million and 318 thousand shares for $37.3 million, respectively. During the three and nine months ended September 30, 2022, we repurchased approximately 181 thousand shares for $19.2 million and 669 thousand shares for $72.3 million, respectively. ~~During the three and nine months ended September 30, 2021, we repurchased approximately 220 thousand shares for $28.4 million.~~ As of September 30, ~~2022,~~2023, there was ~~$128.1~~$70.9 million of authorized share repurchases remaining under the existing authorization.

~~Table of Contents~~

NOTE 14 – STOCK-BASED COMPENSATION

We issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company’s 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. ~~Performance-based~~

Table of Contents

For awards granted in the first quarter of 2023 and thereafter, our performance-based RSUs ~~have one of two vesting conditions: (1)~~will vest solely based on our ~~internal financial~~return on invested capital ("ROIC"). Award share payouts depend on the extent to which the ROIC performance ~~metrics and (2) based on our~~goal has been achieved, but the final payout is adjusted by a total shareholder return ~~(“TSR”~~("TSR") ~~relative to total shareholder returns of an industrial peer group.~~ modifier.

At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest ~~over one year.~~on or around the first anniversary of the date of grant.

The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement.


Nine Months Ended September 30,	Nine Months Ended September 30,	2022			2021			Nine Months Ended September 30,	2023			(1)	2022
Fair value per stock award	Fair value per stock award	$	141.95		$	171.63		Fair value per stock award	$	116.17			$	141.95
Grant date stock price	Grant date stock price	$	114.52		$	141.59		Grant date stock price	$	111.38			$	114.52
Assumptions:	Assumptions:							Assumptions:
Aptar's stock price expected volatility	Aptar's stock price expected volatility	20.20		%	21.40		%	Aptar's stock price expected volatility	20.00		%		20.20		%
Expected average volatility of peer companies	Expected average volatility of peer companies	41.70		%	50.00		%	Expected average volatility of peer companies	39.70		%		41.70		%
Correlation assumption	Correlation assumption	41.20		%	58.10		%	Correlation assumption	33.30		%		41.20		%
Risk-free interest rate	Risk-free interest rate	2.04		%	0.32		%	Risk-free interest rate	3.83		%		2.04		%
Dividend yield assumption	Dividend yield assumption	1.33		%	1.02		%	Dividend yield assumption	1.36		%		1.33		%

(1)The 2023 award inputs and assumptions are related to PSU-ROIC awards with a TSR modifier.

A summary of RSU activity as of September 30, ~~2022~~2023 and changes during the nine month period then ended is presented below:


		Time-Based RSUs			Performance-Based RSUs				Time-Based RSUs			Performance-Based RSUs
		Units	Weighted Average Grant-Date Fair Value		Units	Weighted Average Grant-Date Fair Value			Units	Weighted Average Grant-Date Fair Value		Units	Weighted Average Grant-Date Fair Value
Nonvested at January 1, 2022		485,479	$	108.73	650,553	$	111.04
Nonvested at January 1, 2023								Nonvested at January 1, 2023	426,361	$	111.60	610,871	$	118.77
Granted	Granted	200,815	111.85		249,656	123.97		Granted	121,848	110.30		151,415	115.69
Vested	Vested	(149,044)	106.69		(43,388)	134.97		Vested	(181,248)	104.29		(99,878)	89.33
Forfeited	Forfeited	(6,131)	111.59		(75,050)	112.28		Forfeited	(11,488)	108.05		(133,905)	93.61
Nonvested at September 30, 2022		531,119	$	110.39	781,771	$	113.73
Nonvested at September 30, 2023								Nonvested at September 30, 2023	355,473	$	115.08	528,503	$	129.82

Included in the time-based ~~RSUs~~RSU activity for the nine months ended September 30, ~~2022~~2023 are ~~10,589~~10,614 units granted to non-employee directors and ~~10,007~~10,589 units vested related to non-employee directors.


Nine Months Ended September 30,	Nine Months Ended September 30,	2022		2021		Nine Months Ended September 30,	2023		2022
Compensation expense	Compensation expense	$	31,925	$	29,493	Compensation expense	$	32,209	$	31,925
Fair value of units vested	Fair value of units vested	20,663		29,671		Fair value of units vested	27,662		20,663
Intrinsic value of units vested	Intrinsic value of units vested	22,329		39,752		Intrinsic value of units vested	32,319		22,329

The actual tax benefit realized for the tax deduction from RSUs was approximately $5.6 million and $6.2 million in the nine months ended September 30, ~~2022.~~2023 and 2022, respectively. As of September 30, ~~2022,~~2023, there was ~~$57.3~~$53.0 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of ~~2.1~~1.9 years.

Historically we issued stock options to our employees and non-employee directors. We ~~have~~did not ~~issued any~~issue stock options ~~since 2018.~~between 2019 and 2022. Stock options were awarded in the first quarter of 2023 with the exercise price equal to the market price on the date of grant based on the Black-Scholes model and generally vest over three years and expire 10 years after grant. ~~For stock option grants, we used historical data to estimate expected life and volatility.~~

Table of Contents

The Company uses historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the stock awards plans were $19.84 and $24.23 per share for executive officers and all others employees, respectively, during the first nine months of 2023. Aptar executive officers received stock options with an exercise price that was 110% of the closing market price on the date of grant. These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:


Stock Award Plans:
Nine Months Ended September 30,	2023
Dividend Yield	1.41	%
Expected Stock Price Volatility	16.55	%
Risk-free Interest Rate	3.57	%
Expected Life of Option (years)	7

A summary of option activity under our stock plans during the nine months ended September 30, ~~2022~~2023 is presented below:

Stock Awards Plans Director Stock Option Plans
Options Weighted Average
Exercise Price Options Weighted Average
Exercise Price
Outstanding, January 1, 2022 3,072,503 $ 71.99 51,700 $ 63.91
Exercised (284,885) 64.62 — —
Forfeited or expired (400) 51.80 — —
Outstanding at September 30, 2022 2,787,218 $ 72.74 51,700 $ 63.91
Exercisable at September 30, 2022 2,787,218 $ 72.74 51,700 $ 63.91
Weighted-Average Remaining Contractual Term (Years):
Outstanding at September 30, 2022 3.4 1.3
Exercisable at September 30, 2022 3.4 1.3
Aggregate Intrinsic Value:
Outstanding at September 30, 2022 $ 64,654 $ 1,656
Exercisable at September 30, 2022 $ 64,654 $ 1,656
Intrinsic Value of Options Exercised During the Nine Months Ended:
September 30, 2022 $ 13,618 $ —
September 30, 2021 $ 65,139 $ 4,248



	Stock Awards Plans				Director Stock Option Plans
	Options		Weighted Average Exercise Price		Options		Weighted Average Exercise Price
Outstanding, January 1, 2023	2,623,944		$	73.34	51,700		$	63.91
Granted	314,833		116.20		—		—
Exercised	(545,104)		69.30		(32,700)		62.36
Forfeited or expired	(4,130)		83.84		—		—
Outstanding at September 30, 2023	2,389,543		$	79.89	19,000		$	66.59
Exercisable at September 30, 2023	2,075,973		$	74.40	19,000		$	66.59
Weighted-Average Remaining Contractual Term (Years):
Outstanding at September 30, 2023	3.7				0.6
Exercisable at September 30, 2023	2.8				0.6
Aggregate Intrinsic Value:
Outstanding at September 30, 2023	$	108,471			$	1,115
Exercisable at September 30, 2023	$	105,629			$	1,115
Intrinsic Value of Options Exercised During the Nine Months Ended:
September 30, 2023	$	27,392			$	1,978
September 30, 2022	$	13,618			$	—

Nine Months Ended September 30,

2023

~~2021~~

Compensation expense (included in SG&A)

~~185~~ 3,561

Compensation expense (included in Cost of sales)

314

Compensation expense, Total

~~227~~ 3,875

Compensation expense, net of tax

~~174~~ 3,875

~~Grant date fair value of options vested~~

~~2,421~~

The ~~reduction~~increase in stock option expense is due to ~~our move to RSUs~~the newly issued options as discussed above. Cash received from option exercises for the nine months ended September 30, ~~2022~~2023 and ~~2021~~2022 was approximately ~~$18.4~~$39.7 million and ~~$54.0~~$18.4 million, respectively. The actual tax benefit realized for the tax deduction from option exercises was approximately ~~$2.8~~$6.8 million and ~~$15.4~~$2.8 million in the nine months ended September 30, ~~2022~~2023 and ~~2021,~~2022, respectively. As of September 30, ~~2022,~~2023, there ~~is no remaining valuation~~was $3.1 million of total unrecognized compensation cost relating to stock option awards which is expected to be ~~expensed in future periods.~~recognized over a weighted-average period of 2.2 years.

Table of Contents

NOTE 15 – EARNINGS PER SHARE

Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and nine months ended September 30, 2023 and 2022 ~~and 2021 is~~was as follows:

~~Table of Contents~~


		Three Months Ended									Three Months Ended
		September 30, 2022				September 30, 2021					September 30, 2023				September 30, 2022
		Diluted		Basic		Diluted		Basic			Diluted		Basic		Diluted		Basic
Consolidated operations	Consolidated operations									Consolidated operations
Income available to common stockholders	Income available to common stockholders	$	54,244	$	54,244	$	47,260	$	47,260	Income available to common stockholders	$	84,296	$	84,296	$	54,244	$	54,244

Average equivalent shares	Average equivalent shares									Average equivalent shares
Shares of common stock	Shares of common stock	65,322		65,322		65,900		65,900		Shares of common stock	65,707		65,707		65,322		65,322
Effect of dilutive stock-based compensation	Effect of dilutive stock-based compensation									Effect of dilutive stock-based compensation
Stock options	Stock options	884		—		1,464		—		Stock options	874		—		884		—
Restricted stock	Restricted stock	375		—		437		—		Restricted stock	454		—		375		—
Total average equivalent shares	Total average equivalent shares	66,581		65,322		67,801		65,900		Total average equivalent shares	67,035		65,707		66,581		65,322
Net income per share	Net income per share	$	0.81	$	0.83	$	0.70	$	0.72	Net income per share	$	1.26	$	1.28	$	0.81	$	0.83


		Nine Months Ended									Nine Months Ended
		September 30, 2022				September 30, 2021					September 30, 2023				September 30, 2022
		Diluted		Basic		Diluted		Basic			Diluted		Basic		Diluted		Basic
Consolidated operations	Consolidated operations									Consolidated operations
Income available to common stockholders	Income available to common stockholders	$	180,292	$	180,292	$	186,488	$	186,488	Income available to common stockholders	$	222,132	$	222,132	$	180,292	$	180,292

Average equivalent shares	Average equivalent shares									Average equivalent shares
Shares of common stock	Shares of common stock	65,446		65,446		65,652		65,652		Shares of common stock	65,550		65,550		65,446		65,446
Effect of dilutive stock-based compensation	Effect of dilutive stock-based compensation									Effect of dilutive stock-based compensation
Stock options	Stock options	1,034		—		1,688		—		Stock options	886		—		1,034		—
Restricted stock	Restricted stock	345		—		459		—		Restricted stock	429		—		345		—
Total average equivalent shares	Total average equivalent shares	66,825		65,446		67,799		65,652		Total average equivalent shares	66,865		65,550		66,825		65,446
Net income per share	Net income per share	$	2.70	$	2.75	$	2.75	$	2.84	Net income per share	$	3.32	$	3.39	$	2.70	$	2.75

NOTE 16 – SEGMENT INFORMATION

During the year ended December 31, 2022, our organizational structure consisted of three market-focused business segments: Pharma, Beauty+Home and Food+Beverage. Effective January 1, 2023, we realigned two of our segments, allowing us to better serve our customers and positioning us for long-term profitable growth. We ~~are organized into~~continue to have three reporting ~~segments. Operations~~segments; Aptar Pharma and Aptar Beauty are named for the markets they serve with multiple product platforms, while Aptar Closures is named primarily for a single product platform that ~~sell dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health~~serves all available markets.

We combined all of our closures operations into a single segment - Aptar Closures. The Aptar Closures business serves multiple markets, ~~form the Pharma segment. Operations that sell dispensing systems and sealing solutions primarily to the beauty,~~including food, beverage, personal care, ~~and~~ home care, ~~markets form the~~beauty and healthcare. Closures that were developed in Beauty + Home moved to Aptar Closures together with the operations of legacy Food + Beverage. Aptar's food protection business and our elastomeric flow-control technology business continue to report through the Aptar Closures segment. ~~Operations that sell~~

At the same time, we have simplified and focused our Beauty + Home segment to better leverage our complex spray and dispensing ~~systems, sealing~~ solutions for prestige and ~~food service trays~~premium brands in the beauty and personal care markets. For many of our customers, personal care products are considered part of "beauty" and so we renamed this segment, simply, Aptar Beauty. The segment realignment had no impact on our consolidated statements of income, balance sheets, and cash flows. Segment financial information for the prior periods has been recast to conform to the ~~food and beverage markets form the Food + Beverage segment.~~current presentation.

Table of Contents

The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.

~~Table of Contents~~

Financial information regarding our reporting segments is shown below:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Total Sales:	Total Sales:									Total Sales:
Pharma		$	345,079	$	317,358	$	1,037,120	$	961,718
Beauty + Home		365,105		378,158		1,117,070		1,098,176
Food + Beverage		133,869		138,735		401,758		381,356
Aptar Pharma										Aptar Pharma	$	389,423	$	345,079	$	1,136,544	$	1,037,120
Aptar Beauty										Aptar Beauty	330,467		308,353		1,002,209		947,515
Aptar Closures										Aptar Closures	181,562		192,706		539,472		577,940
Total Sales	Total Sales	$	844,053	$	834,251	$	2,555,948	$	2,441,250	Total Sales	$	901,452	$	846,138	$	2,678,225	$	2,562,575
Less: Intersegment Sales:	Less: Intersegment Sales:									Less: Intersegment Sales:
Pharma		$	1,682	$	4,133	$	11,030	$	9,318
Beauty + Home		5,282		4,070		17,702		16,896
Food + Beverage		229		606		881		1,808
Aptar Pharma										Aptar Pharma	$	235	$	1,682	$	610	$	11,030
Aptar Beauty										Aptar Beauty	6,487		5,307		22,253		17,722
Aptar Closures										Aptar Closures	1,733		2,289		6,392		7,488
Total Intersegment Sales	Total Intersegment Sales	$	7,193	$	8,809	$	29,613	$	28,022	Total Intersegment Sales	$	8,455	$	9,278	$	29,255	$	36,240
Net Sales:	Net Sales:									Net Sales:
Pharma		$	343,397	$	313,225	$	1,026,090	$	952,400
Beauty + Home		359,823		374,088		1,099,368		1,081,280
Food + Beverage		133,640		138,129		400,877		379,548
Aptar Pharma										Aptar Pharma	$	389,188	$	343,397	$	1,135,934	$	1,026,090
Aptar Beauty										Aptar Beauty	323,980		303,046		979,956		929,793
Aptar Closures										Aptar Closures	179,829		190,417		533,080		570,452
Net Sales	Net Sales	$	836,860	$	825,442	$	2,526,335	$	2,413,228	Net Sales	$	892,997	$	836,860	$	2,648,970	$	2,526,335
Adjusted EBITDA (1):	Adjusted EBITDA (1):									Adjusted EBITDA (1):
Pharma		$	107,235	$	100,738	$	333,793	$	315,201
Beauty + Home		41,230		43,789		125,607		117,055
Food + Beverage		18,816		22,379		55,756		61,995
Aptar Pharma										Aptar Pharma	$	136,344	$	107,235	$	371,508	$	333,793
Aptar Beauty										Aptar Beauty	41,070		36,563		121,375		112,343
Aptar Closures										Aptar Closures	27,607		23,483		81,387		69,020
Corporate & Other, unallocated	Corporate & Other, unallocated	(13,537)		(12,745)		(45,170)		(40,311)		Corporate & Other, unallocated	(11,659)		(13,537)		(45,996)		(45,170)
Acquisition-related costs (2)	Acquisition-related costs (2)	(231)		(1,793)		(231)		(4,227)		Acquisition-related costs (2)	—		(231)		(255)		(231)
Restructuring Initiatives (3)	Restructuring Initiatives (3)	(2,270)		(10,223)		(2,989)		(18,771)		Restructuring Initiatives (3)	(6,161)		(2,270)		(19,628)		(2,989)
Net unrealized investment gain (loss) (4)		277		(9,021)		(2,297)		6,177
Net unrealized investment (loss) gain (4)										Net unrealized investment (loss) gain (4)	(5,428)		277		(2,349)		(2,297)
Depreciation and amortization	Depreciation and amortization	(57,601)		(59,280)		(174,818)		(174,508)		Depreciation and amortization	(62,686)		(57,601)		(184,212)		(174,818)
Interest Expense	Interest Expense	(9,756)		(8,011)		(30,668)		(22,601)		Interest Expense	(9,984)		(9,756)		(29,900)		(30,668)
Interest Income	Interest Income	752		401		2,029		1,406		Interest Income	946		752		2,266		2,029
Income before Income Taxes	Income before Income Taxes	$	84,915	$	66,234	$	261,012	$	241,416	Income before Income Taxes	$	110,049	$	84,915	$	294,196	$	261,012

(1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.

(2)Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 – Acquisitions for further details).

Table of Contents

(3)Restructuring Initiatives includes expense items for the three and nine months ended September 30, ~~2022~~2023 and ~~2021~~2022 as follows (see Note 19 – Restructuring Initiatives for further details):

Three Months Ended
September 30, Nine Months Ended
September 30,
2022 2021 2022 2021
Restructuring Initiatives by Segment
Pharma $ — $ 13 $ — $ 86
Beauty + Home 2,344 5,442 3,022 7,995
Food + Beverage (74) 131 (33) 169
Corporate & Other — 4,637 — 10,521
Total Restructuring Initiatives $ 2,270 $ 10,223 $ 2,989 $ 18,771


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Restructuring Initiatives by Plan:
Optimization initiative	$	6,586	$	2,254	$	20,069	$	2,254
Prior year initiatives	(425)		16		(441)		735
Total Restructuring Initiatives	$	6,161	$	2,270	$	19,628	$	2,989

Restructuring Initiatives by Segment:
Aptar Pharma	$	92	$	—	$	1,657	$	—
Aptar Beauty	2,880		2,240		12,650		2,774
Aptar Closures	3,098		30		4,060		215
Corporate & Other	91		—		1,261		—
Total Restructuring Initiatives	$	6,161	$	2,270	$	19,628	$	2,989

(4)Net unrealized investment gain (loss) represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).

~~Table of Contents~~

NOTE 17 – ACQUISITIONS

Business Combinations

On August 1, 2023, we paid the remaining $5.2 million purchase price in relation to the 2021 Hengyu acquisition. No further liability remains outstanding for this acquisition.

On March 1, 2023, we completed the acquisition of all the outstanding capital stock of iD SCENT. Located in Lyon, France, iD SCENT is an expert producer of paper fragrance sampling solutions that present multiple sustainability features. The purchase price was approximately $9.4 million (net of $1.4 million cash acquired) and was funded with cash on hand. The results of iD SCENT have been included in the consolidated financial statements within our Aptar Beauty segment since the date of acquisition.

Also on March 1, 2023, we completed the acquisition of 80% of the equity interest of Gulf Closures W.L.L. ( "Gulf Closures"). Gulf Closures, located in Bahrain, is a closure manufacturer for beverage products. The purchase price for 80% ownership was approximately $1.5 million (net of $1.2 million cash acquired) and was funded with cash on hand. This values the full company equity at approximately $3.3 million and implies a non-controlling interest valued at approximately $0.7 million as of the acquisition date. The results of Gulf Closures have been included in the consolidated financial statements within our Aptar Closures segment since the date of acquisition.

On August 31, 2022, we completed the acquisition of all the outstanding capital stock of Metaphase Design Group Inc. ("Metaphase"). Metaphase, located in St. Louis, Missouri, is a leading expert in ergonomic and industrial design of handheld devices including medical devices. The purchase price was approximately $5.1 million (net of $0.1 million cash acquired) and was funded with cash on hand. As of the acquisition date, $1.0 million was held in restricted cash for an indemnity escrow. The results of Metaphase have been included in the consolidated financial statements within our Aptar Pharma segment since the date of acquisition.

On September 2, 2021, following the signature of a share purchase agreement on July 22, 2021 and the approval of the French Ministry of Economy under the foreign investment clearance regulations, we completed the acquisition of 64.3% of the share capital of Voluntis S.A. (“Voluntis”). Voluntis, based in Paris, France and Boston, MA, is a pioneer in digital therapeutics. We acquired from certain members of the management and certain shareholders the entirety of their shares representing approximately 64.3% of the share capital of Voluntis (on a non-diluted basis) at a price of €8.70 per share for €50.8 million (approximately $60.4 million) funded with available cash on hand. This values the full company equity (on a fully diluted basis) at €79.1 million (approximately $93.9 million). Aptar launched a mandatory cash simplified tender offer to acquire Voluntis's remaining shares for the same price of €8.70 per share. During September 2021, Aptar acquired €8.4 million (approximately $9.9 million) of additional shares from the tender offer, bringing the total investment as of September 30, 2021 to €59.2 million (approximately $70.3 million) representing 74.9% of the total share capital, which implied a non-controlling interest valued at €19.9 million (approximately $23.6 million). Following completion of the tender offer, Aptar implemented a mandatory squeeze-out on the remaining outstanding shares of Voluntis on the same financial terms as those of the tender offer. During the fourth quarter of 2021, the tender offer and squeeze-out were completed and funded with available cash on hand and we acquired the remaining 25.1% of the share capital for €19.5 million (approximately $22.6 million), resulting in Aptar owning 100.0% of the share capital of Voluntis.

The fair value of the Voluntis assets acquired include a technology intangible asset of $27.9 million and other intangible assets of $8.4 million. The technology intangible asset was valued using the Multi-Period Excess Earnings Method ("MPEEM") valuation approach. Judgment was applied with respect to determining the fair value of the acquired technology, which involved the use of significant estimates and assumptions with respect to the revenue growth rate, technology obsolescence rate and discount rate.

On August 17, 2021, we completed the acquisition of 80% of the equity interests of Weihai Hengyu Medical Products Co., Ltd. ("Hengyu"). Hengyu, a leading Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery, is based in Weihai, China. Under the terms of the agreement, 90% of the estimated purchase price for 80% ownership, RMB 347.7 million (approximately $53.6 million), was paid to the sellers in August 2021 with available cash on hand. A final purchase price adjustment of RMB 1.5 million (approximately $0.2 million) was recorded to Accounts payable, accrued and other liabilities and was paid in the fourth quarter of 2021. The remaining 10% of the acquisition price for 80% ownership, RMB 38.7 million (approximately $6.0 million), is payable to the sellers eighteen months after closing plus simple interest of 4% and is expected to be funded with available cash on hand. This values the full company equity (on a fully diluted basis) at RMB 484.9 million (approximately $74.8 million) and implies a non-controlling interest valued at RMB 97.0 million (approximately $15.0 million) as of the acquisition date. Pursuant to the agreement, we have the option to acquire the remaining 20% of the equity of Hengyu upon the fifth anniversary of the closing date.

The fair value of the Hengyu assets acquired include a customer relationship intangible asset of $24.1 million and other intangible assets of $5.6 million. The customer relationship intangible asset was valued using the MPEEM valuation approach. Judgment was applied with respect to determining the fair value of the customer relationships, which involved the use of significant estimates and assumptions with respect to the revenue growth rates, customer attrition rates, Adjusted EBIT margins and discount rate.

~~Table of Contents~~

~~The following table summarizes the assets acquired and liabilities assumed for the Voluntis and Hengyu acquisitions as of the acquisition dates at estimated fair value.~~



	~~2021~~
~~Assets~~
~~Cash and equivalents~~	$	~~3,852~~
~~Accounts receivable~~	~~5,208~~
~~Inventories~~	~~606~~
~~Other Receivable~~	~~286~~
~~Prepaid and other~~	~~1,863~~
~~Property, plant and equipment~~	~~14,081~~
~~Goodwill~~	~~104,433~~
~~Intangible assets~~	~~65,981~~
~~Operating lease right-of-use assets~~	~~2,309~~
~~Other miscellaneous assets~~	78
~~Liabilities~~
~~Current maturities of long-term obligations, net of unamortized debt issuance costs~~	~~1,410~~
~~Accounts payable, accrued and other liabilities~~	~~9,663~~
~~Deferred income taxes~~	~~16,792~~
~~Operating lease liabilities~~	~~2,306~~
~~Deferred and other non-current liabilities~~	~~5,770~~
~~Net assets acquired~~	$	~~162,756~~

The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives for the Voluntis and Hengyu acquisitions as of the acquisition dates:

2021
Weighted-Average Useful Life (in Years) Estimated Fair Value of Assets
Acquired technology 10 $ 34,322
Customer relationships 11.6 30,258
License agreements and other 0.25 1,401
Total $ 65,981

Goodwill in the amount of $104.4 million was recorded related to the Voluntis and Hengyu acquisitions, which is included in the Pharma segment. Goodwill is calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill acquired in the Voluntis and Hengyu acquisitions largely consists of expansion into the digital health solutions market, by adding digital therapeutic solutions and broadening our digital health services provided to customers; as well as strengthening our capabilities in high-growth economies by enhancing the ability to respond to changing local market needs in the injectables market. Goodwill will not be amortized, but will be tested for impairment at least annually. For the Voluntis and Hengyu acquisitions, no goodwill will be deductible for tax purposes.

Table of Contents

NOTE 18 – INVESTMENT IN EQUITY SECURITIES

Our investment in equity securities consisted of the following:


		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
Equity Method Investments:	Equity Method Investments:					Equity Method Investments:
BTY	BTY	$	29,877	$	33,199	BTY	$	31,665	$	31,490
Sonmol	Sonmol	4,876		5,904		Sonmol	4,621		4,997

Desotec GmbH	Desotec GmbH	791		919		Desotec GmbH	859		863

Other Investments:	Other Investments:					Other Investments:
PureCycle	PureCycle	6,323		9,006		PureCycle	1,532		5,297
YAT	YAT	5,340		5,978		YAT	5,204		5,508
Loop	Loop	2,894		2,894		Loop	2,894		2,894
Others	Others	1,390		1,585		Others	1,247		1,259
		$	51,491	$	59,485		$	48,022	$	52,308

Equity ~~method investments~~Method Investments

BTY

On January 1, 2020, we acquired 49% of the equity interests in 3 related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32.0 million. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years after the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. For the nine months ended September 30, 2023 and September 30, 2022, Aptar had purchases of $10.7 million and $7.2 million, respectively, from BTY. As of September 30, 2023 and December 31, 2022, approximately $2.1 million and $1.5 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Condensed Consolidated Balance Sheets.

Sonmol

On April 1, 2020, we invested $5.0 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”),. Sonmol is a ~~pharmaceutical and~~ leading Chinese pharmaceutical company that provides consumer electric devices and connected devices for asthma control.

Desotec GmbH

During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of special assembly machines for bulk processing for the pharmaceutical, beauty and ~~home and food and beverages~~closures markets.

Other ~~investments~~Investments

~~During August 2019,~~In prior years, we invested, through a series of transactions, an aggregate amount of ~~$3.5~~$2.9 million in ~~two~~ preferred equity investments in Loop, a sustainability ~~companies Loop and PureCycle that were accounted for at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly~~company.

In prior years, we also invested, through a series of transactions, ~~for identical or similar investments of the same issuer. During 2020, we invested an additional $1.4~~$3.0 million in ~~these two equity investments~~PureCycle and ~~also~~ received ~~$333 thousand~~$0.7 million of equity ~~in PureCycle~~ in exchange for our resource dedication for technological partnership and support. In November 2020, we increased the value of the PureCycle investment by $3.1 million based on observable price changes.

In March 2021, PureCycle was purchased by a special purpose acquisition company and was subsequently listed on Nasdaq under the ticker PCT. At that time, our investment in PureCycle was converted into shares of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income. ~~In September 2021, we received $333 thousand~~

Table of shares of PCT in exchange for our resource dedication for technological partnership and support and exercised an option to purchase $1.0 million of additional shares in connection with an FDA milestone.Contents

We have sold the following PCT shares related to the PureCycle investment:

~~Table of Contents~~


		Shares Sold	Proceeds		Realized Gain			Shares Sold	Proceeds		Realized Gain
October 2021		191,349	$	2,439	$	2,000
March 2022	March 2022	107,600	$	1,088	$	841	March 2022	107,600	$	1,088	$	841
August 2022	August 2022	50,000	$	511	$	372	August 2022	50,000	$	511	$	372
July 2023							July 2023	248,859	$	2,659	$	1,968
August 2023							August 2023	261,590	$	2,945	$	2,220

For the three and nine months ended September 30, ~~2022~~2023 and ~~2021,~~2022, we recorded the following net investment ~~gain/(loss)~~gain or loss on our investment in PureCycle:

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Net investment gain (loss) $ 649 $ (9,021) $ (1,084) $ 6,177


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Net investment (loss) gain	$	(1,240)	$	649	$	1,839	$	(1,084)

On July 7, 2021, we invested approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company.

~~Other than the expected credit loss reserve against the outstanding Kali Care note receivable, there~~There were no indications of impairment noted in the nine months ended September 30, ~~2022~~2023 related to these investments. In March 2022, we recorded a $1.5 million expected credit loss reserve against the outstanding note receivable from one of our venture investments (Kali Care) as a result of a proposed sale of such business.

NOTE 19 – RESTRUCTURING INITIATIVES

In late 2017, we began a business transformation to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness. The primary focus of the plan was the Beauty + Home segment; however, certain global general and administrative functions were also addressed. As of the end of 2021, we had successfully completed the vast majority of our planned initiatives related to our transformation plan and do not expect significant additional restructuring expenses related to this plan going forward. For the three and nine months ended September 30, 2022, we recognized $16 thousand and $0.7 million of restructuring costs related to this plan, respectively. For the three and nine months ended September 30, 2021, we recognized $10.2 million and $18.8 million of restructuring costs related to this plan, respectively. The cumulative expense incurred as of September 30, 2022 was $137.0 million.

~~As of September 30, 2022 we have recorded the following activity associated with the business transformation:~~

Beginning Reserve at 12/31/2021 Net Charges for the Nine Months Ended 9/30/2022 Cash Paid Interest and
FX Impact Ending Reserve at 9/30/2022
Employee severance $ 3,535 $ 660 $ (2,747) $ (152) $ 1,296
Professional fees and other costs 260 75 (314) (10) 11
Totals $ 3,795 $ 735 $ (3,061) $ (162) $ 1,307

During the third quarter of 2022, we began an initiative to ~~optimize~~better leverage our ~~operations~~fixed cost base through growth and ~~SG&A expenses.~~cost reduction measures. For the three and nine months ended September 30, 2023, we recognized $6.6 million and $20.1 million of restructuring costs related to this initiative, respectively. For the three months ended September 30, 2022, we recognized $2.3 million of restructuring costs related to this ~~plan.~~initiative. The cumulative expense incurred as of September 30, 2023 was $26.3 million.

As of September 30, ~~2022,~~2023, we have recorded the following activity associated with our optimization ~~plan:~~initiative:


		Beginning Reserve at 12/31/2021		Net Charges for the Nine Months Ended 9/30/2022		Cash Paid		Interest and FX Impact		Ending Reserve at 9/30/2022			Beginning Reserve at 12/31/2022		Net Charges for the Nine Months Ended 9/30/2023		Cash Paid		Interest and FX Impact		Ending Reserve at 9/30/2023
Employee severance	Employee severance	$	—	$	2,052	$	—	$	(6)	$	2,046	Employee severance	$	4,993	$	15,833	$	(8,605)	$	(105)	$	12,116
Professional fees and other costs	Professional fees and other costs	—		202		(202)		—		—		Professional fees and other costs	—		4,236		(3,991)		8		253
Totals	Totals	$	—	$	2,254	$	(202)	$	(6)	$	2,046	Totals	$	4,993	$	20,069	$	(12,596)	$	(97)	$	12,369

3130

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS, OR AS OTHERWISE INDICATED)

RESULTS OF OPERATIONS


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2022		2021		2022		2021			2023		2022		2023		2022
Net sales	Net sales	100.0	%	100.0	%	100.0	%	100.0	%	Net sales	100.0	%	100.0	%	100.0	%	100.0	%
Cost of sales (exclusive of depreciation and amortization shown below)	Cost of sales (exclusive of depreciation and amortization shown below)	65.3		65.1		64.9		64.2		Cost of sales (exclusive of depreciation and amortization shown below)	63.5		65.3		64.1		64.9
Selling, research & development and administrative	Selling, research & development and administrative	16.2		16.5		16.5		17.0		Selling, research & development and administrative	15.5		16.2		16.1		16.5
Depreciation and amortization	Depreciation and amortization	6.9		7.2		6.9		7.2		Depreciation and amortization	7.0		6.9		7.0		6.9
Restructuring initiatives	Restructuring initiatives	0.2		1.2		0.1		0.8		Restructuring initiatives	0.7		0.2		0.7		0.1
Operating income	Operating income	11.4		10.0		11.6		10.8		Operating income	13.3		11.4		12.1		11.6
Other income (expense)		(1.2)		(2.0)		(1.3)		(0.8)
Interest expense										Interest expense	(1.1)		(1.2)		(1.1)		(1.2)
Other expense										Other expense	0.1		(0.1)		0.1		(0.1)
Income before income taxes	Income before income taxes	10.2		8.0		10.3		10.0		Income before income taxes	12.3		10.1		11.1		10.3
Net Income	Net Income	6.5		5.7		7.1		7.7		Net Income	9.4		6.5		8.4		7.1
Effective tax rate	Effective tax rate	36.2	%	29.2	%	31.0	%	22.9	%	Effective tax rate	23.4	%	36.2	%	24.6	%	31.0	%
Adjusted EBITDA margin (1)	Adjusted EBITDA margin (1)	18.4	%	18.7	%	18.6	%	18.8	%	Adjusted EBITDA margin (1)	21.7	%	18.4	%	19.9	%	18.6	%

(1)Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under "Non-U.S. GAAP ~~Measures".~~Measures."

~~SIGNIFICANT DEVELOPMENTS~~

~~The COVID-19 pandemic resulted in disruptions~~During the year ended December 31, 2022, our organizational structure consisted of three market-focused business segments: Pharma, Beauty + Home and Food + Beverage. Effective January 1, 2023, we realigned two of our segments, allowing us to better serve our customers and positioning us for long-term profitable growth. We continue to have three reporting segments; Aptar Pharma and Aptar Beauty are named for the markets they serve with multiple product platforms, while Aptar Closures is primarily named for a single product platform that serves all available markets. Previously reported amounts have been reclassified to conform to the global economy and supply chains. As the rates of transmission have slowed in many regions during 2022, we have seen several of our impacted applications return to more normal volume levels. We have seen improvement in sales of our products to our prescription, beauty, hair care and sun care customers as people return to more active lifestyles. However, we have also seen more normal volumes in some of the applications which benefited from the pandemic, such as our personal cleansing and surface cleaner products, food applications, active material science solutions and injectables components. While some countries continue to experience disruptions due to efforts to eliminate the virus, we do not believe these impacts will be material to our business based on the current ~~environment.~~

As of September 30, 2022, the war in Ukraine has not had a significant direct impact on our business though the near-term visibility for this situation is expected to remain fluid and uncertain for the next several quarters. However, we have experienced some indirect impacts on our business, including higher energy and other input costs as well as certain supply chain disruptions.period presentation.

NET SALES

We reported net sales of ~~$836.9~~$893.0 million for the quarter ended September 30, ~~2022,~~2023, which represents a 1%7% increase compared to ~~$825.4~~$836.9 million reported during the third quarter of ~~2021.~~2022. The U.S. dollar ~~strengthened~~weakened compared to the euro and other major currencies in which we operate, resulting in a ~~negative~~positive currency translation impact of 8%4%. ~~There was no significant impact from our~~Our acquisitions of ~~Voluntis S.A. ("Voluntis"), Weihai Hengyu Medical Products Co., Ltd. ("Hengyu")~~Metaphase, iD SCENT, and ~~Metaphase Design Group Inc. ("Metaphase")~~Gulf Closures also had a 1% positive impact on our consolidated ~~net sales~~results during the third quarter of ~~2022.~~2023. Therefore, core sales, which excludes acquisitions and changes in foreign currency rates, increased by 9%2% in the third quarter of ~~2022~~2023 compared to the same period in ~~2021.~~2022. Of our 9%2% core sales increase, ~~approximately 5% is related~~half was due to ~~improved volumes with~~strong volume growth, especially for products in our ~~Pharma segment driving~~prescription, consumer healthcare and beauty applications, while inflationary price adjustments represented the ~~majority of this increase. Price adjustments related to the passing through of higher resin and~~ other ~~input costs accounted for the remaining 4% of the core sales increase.~~half.

Third Quarter 2022
Net Sales Change over Prior Year Pharma Beauty
+ Home Food +
Beverage Total
Core Sales Growth 20 % 4 % — % 9 %
Acquisitions 1 % — % — % — %
Currency Effects (1) (11) % (8) % (3) % (8) %
Total Reported Net Sales Growth 10 % (4) % (3) % 1 %

~~Table of Contents~~


Third Quarter 2023 Net Sales Change over Prior Year	Aptar Pharma		Aptar Beauty		Aptar Closures		Total
Reported Net Sales Growth	13	%	7	%	(6)	%	7	%
Currency Effects (1)	(5)	%	(5)	%	(2)	%	(4)	%
Acquisitions	—	%	—	%	(1)	%	(1)	%
Core Sales Growth	8	%	2	%	(9)	%	2	%

Reported net sales for the first nine months of ~~2022~~2023 increased 5% to ~~$2.53~~$2.65 billion compared to ~~$2.41~~$2.53 billion for the first nine months of ~~2021.~~2022. The average U.S. dollar exchange rate ~~strengthened~~weakened compared to the euro and other major currencies in which we operate, resulting in a ~~negative~~positive currency translation impact of 6%1%. ~~There was no significant impact from our~~Our acquisitions of ~~Voluntis, Hengyu~~Metaphase, iD SCENT, and ~~Metaphase~~Gulf Closures had a 1% positive impact on our consolidated results during the first nine months of ~~2022.~~2023. Therefore, core sales, which excludes acquisitions and changes in foreign currency rates, increased by ~~11%~~3% in the first nine months of ~~2022~~2023 compared to the same period in ~~2021. Price~~2022. The combination of strong volume growth, especially for products in our prescription, consumer healthcare and beauty applications as discussed above, along with price increases to recover inflationary cost increases ~~continue to have~~had a ~~strong~~positive impact on our core sales. Of our ~~11%~~3% core sales increase, approximately ~~5% is~~2% was due to ~~price adjustments related to the passing through of higher resin and other input costs while~~ improved volumes and product mix while inflationary price adjustments represented the remaining 6%1% of the increase.

Nine Months Ended September 30, 2022
Net Sales Change over Prior Year Pharma Beauty
+ Home Food +
Beverage Total
Core Sales Growth 15 % 8 % 8 % 11 %
Acquisitions 1 % — % — % — %
Currency Effects (1) (8) % (6) % (2) % (6) %
Total Reported Net Sales Growth 8 % 2 % 6 % 5 %

Table of Contents


Nine Months Ended September 30, 2023 Net Sales Change over Prior Year	Aptar Pharma		Aptar Beauty		Aptar Closures		Total
Reported Net Sales Growth	11	%	5	%	(7)	%	5	%
Currency Effects (1)	(1)	%	(1)	%	—	%	(1)	%
Acquisitions	(1)	%	—	%	(1)	%	(1)	%
Core Sales Growth	9	%	4	%	(8)	%	3	%

(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

The following table sets forth, for the periods indicated, net sales ~~sourced~~ by geographic location:


		Three Months Ended September 30,								Nine Months Ended September 30,									Three Months Ended September 30,								Nine Months Ended September 30,
		2022		% of Total		2021		% of Total		2022		% of Total		2021		% of Total			2023		% of Total		2022		% of Total		2023		% of Total		2022		% of Total

Domestic	Domestic	$	279,810	33	%	$	280,237	34	%	$	848,617	34	%	$	804,582	33	%	Domestic	$	254,780	29	%	$	279,810	33	%	$	747,791	28	%	$	848,617	34	%
Europe	Europe	436,833		52	%	433,489		53	%	1,336,929		53	%	1,296,171		54	%	Europe	509,204		57	%	436,833		52	%	1,530,753		58	%	1,336,929		53	%
Latin America	Latin America	63,281		8	%	57,750		7	%	180,167		7	%	162,776		7	%	Latin America	73,037		8	%	63,281		8	%	207,109		8	%	180,167		7	%
Asia	Asia	56,936		7	%	53,966		6	%	160,622		6	%	149,699		6	%	Asia	55,976		6	%	56,936		7	%	163,317		6	%	160,622		6	%

For further discussion on net sales by reporting segment, please refer to the analysis of segment net sales and segment Adjusted EBITDA on the following pages.

COST OF SALES (EXCLUSIVE OF DEPRECIATION AND AMORTIZATION SHOWN BELOW)

Cost of sales (“COS”) as a percent of net sales ~~increased~~decreased to 63.5% in the third quarter of 2023 compared to 65.3% in the third quarter of ~~2022 compared to 65.1% in the third quarter of 2021. While our~~2022. Our COS percentage was positively impacted by an improved mix of our higher-margin Pharma product sales compared to the same period in ~~2021, this positive impact was more than offset by~~2022. We also benefited from the moderation of inflationary cost increases, ~~higher tooling sales~~ which typically carry lower margins than our normal product sales, and under-absorption at certain Beauty + Home and Food + Beverage sites due to lower production volumes. During the third quarter, we experienced increases in several input costs including utilities, metals, freight and labor, including a $4.5 million one-time payment to certain European employees to mitigate higher inflationary costs.negatively impacted prior year results. While we ~~maintain~~maintained our normal pass-through of resin cost increases and ~~have~~ implemented general price increases to offset other cost increases during the third quarter of 2022, there is no margin on resin pass-through costs, which ~~increases~~increased our COS as a percentage of sales. During the third quarter of 2023, lower input costs had the opposite impact, which lowered our COS as a percentage of sales.

For the first nine months of ~~2022,~~2023, COS as a percent of net sales ~~increased~~decreased to ~~64.9%~~64.1% compared to ~~64.2%~~64.9% in the same period in ~~2021~~2022, in spite of approximately $16 million of additional costs related to the validation of the new injectables expansion capacity as well as inefficiencies in the first part of the year due to the ~~same~~Enterprise Resource Planning ("ERP") system implementation. As discussed above, this decrease is mainly due to an improved mix of our higher-margin Pharma products and the moderation of inflationary cost ~~increases discussed above.~~increases.

SELLING, RESEARCH & DEVELOPMENT AND ADMINISTRATIVE

Selling, research & development and administrative expenses (“SG&A”) ~~decreased~~increased by approximately ~~$0.5~~$2.7 million to ~~$135.4~~$138.1 million in the third quarter of ~~2022~~2023 compared to ~~$135.9~~$135.4 million during the same period in ~~2021.~~2022. Excluding changes in foreign currency rates, SG&A decreased by approximately $2.7 million in the quarter. Incremental costs related to our acquisitions of Metaphase, iD SCENT, and Gulf Closures were $0.4 million. The current quarter decrease in SG&A is related to lower headcount and other overhead costsas part of our ongoing focus on fixed cost management. SG&A as a percentage of net sales decreased to 15.5% in the third quarter of 2023 compared to 16.2% in the same period in 2022.

SG&A increased by $11.1 million to $427.5 million in the first nine months of 2023 compared to $416.4 million during the same period in 2022. Excluding changes in foreign currency rates, SG&A increased by approximately ~~$9.3~~$7.9 million in the ~~quarter. This increase is mainly due~~first nine months of 2023 compared to the first nine months of 2022. Incremental costs related to our acquisitions of Metaphase, iD SCENT, and Gulf Closures were $1.1 million. Improvements from our overhead cost management initiatives for the first nine months of 2023 were more than offset by higher compensation costs, including accruals related to our current short-term and long-term incentive compensation programs, along with ~~higher professional fees for internal projects and~~ higher travel costs compared to ~~2021.~~2022. SG&A as a percentage of net sales decreased to ~~16.2%~~16.1% in the ~~third quarter~~first nine months of ~~2022~~2023 compared to 16.5% in the same period in ~~2021.~~2022.

3332

Table of Contents

SG&A increased by $5.2 million to $416.4 million in the first nine months of 2022 compared to $411.2 million during the same period in 2021. Excluding changes in foreign currency rates, SG&A increased by approximately $27.0 million in the first nine months of 2022 compared to the first nine months of 2021. Of this increase, $3.0 million relates to incremental SG&A costs in 2022 due to our acquisitions of Hengyu and Voluntis which were completed during the third quarter of 2021. The remaining increase is partially related to higher compensation costs, including accruals related to our current short-term incentive compensation programs and the timing of certain equity compensation arrangement expense recognition. We also experienced an increase in information systems costs due to an upgrade of our enterprise reporting system along with higher professional fees for internal projects and higher travel costs compared to 2021. Also, in March 2022 we recorded a $1.4 million expected net credit loss reserve against the outstanding note receivable from one of our venture investments (Kali Care). SG&A as a percentage of net sales decreased to 16.5% in the first nine months of 2022 compared to 17.0% during the same period in 2021.

DEPRECIATION AND AMORTIZATION

Reported depreciation and amortization expenses ~~decreased~~increased by approximately ~~$1.7~~$5.1 million to ~~$57.6~~$62.7 million in the third quarter of ~~2022~~2023 compared to ~~$59.3~~$57.6 million during the same period in ~~2021.~~2022. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately ~~$3.1~~$2.6 million in the third quarter compared to the third quarter of ~~2021. Approximately $1.1 million~~2022. Incremental depreciation and amortization costs related to our acquisitions of Metaphase, iD SCENT, and Gulf Closures were $0.4 million. The majority of this increase ~~is due~~relates to ~~incremental depreciation and amortization associated with our acquisitions of Voluntis and Hengyu, each of which closed during the third quarter of 2021. We also increased our~~higher capital spending during the current and prior ~~year~~years to support our growth ~~strategy.~~strategy, including several new manufacturing facilities commencing production during 2023. Depreciation and amortization as a percentage of net sales ~~decreased~~increased to ~~6.9%~~7.0% in the third quarter of ~~2022~~2023 compared to ~~7.2%~~6.9% in the same period of the prior year.

Reported depreciation and amortization expenses increased by approximately ~~$0.3~~$9.4 million to ~~$174.8~~$184.2 million in the first nine months of ~~2022~~2023 compared to ~~$174.5~~$174.8 million during the same period a year ago. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately ~~$10.7~~$7.8 million in the first nine months of ~~2022~~2023 compared to the same period a year ago. Incremental depreciation and amortization costs related to our acquisitions of Metaphase, iD SCENT, and Gulf Closures were $0.6 million. As ~~mentioned~~discussed above, ~~approximately $4.1 million of~~ this increase is due to ~~our acquisitions of Voluntis and Hengyu completed during the third quarter of 2021 and the remaining increase relates to~~ higher internal capital ~~spending~~investments during the current and prior ~~year to support our growth strategy.~~years. Depreciation and amortization as a percentage of net sales ~~decreased~~increased to ~~6.9%~~7.0% in the first nine months of ~~2022~~2023 compared to ~~7.2%~~6.9% in the same period of the prior year.

RESTRUCTURING INITIATIVES

~~In late 2017,~~During the third quarter of 2022, we began ~~a business transformation plan~~an initiative to ~~drive profitable sales~~better leverage our fixed cost base through growth ~~increase operational excellence, enhance our approach to innovation~~ and ~~improve organizational effectiveness. The primary focus~~cost reduction measures. For the three and nine months ended September 30, 2023, we recognized $6.6 million and $20.1 million of the plan was the Beauty + Home segment; however, certain global general and administrative functions were also addressed. As of the end of 2021, we had successfully completed the vast majority of our planned initiativesrestructuring costs related to ~~our transformation plan, including implementing new commercial strategies, reducing~~this initiative, respectively. For the three months ended September 30, 2022, we recognized $2.3 million of restructuring costs ~~and adding capabilities in Asia and in fast growing application fields that we believe will position the segment for future growth and profitability.~~related to this initiative. The cumulative expense incurred ~~for this transformation plan~~ as of September 30, ~~2022~~2023 was ~~$137.0 million, of which $0.7 million was recognized in the first nine months of 2022.~~

We continue to look at our operating structure and are continuing to identify actions to further reduce cost and improve our competitiveness. During the third quarter, we recognized $2.3 million in charges.$26.3 million.

Restructuring costs for the three and nine months ended September 30, 2023 and 2022 ~~and 2021 are~~were as follows:

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Restructuring Initiatives by Segment
Pharma $ — $ 13 $ — $ 86
Beauty + Home 2,344 5,442 3,022 7,995
Food + Beverage (74) 131 (33) 169
Corporate & Other — 4,637 — 10,521
Total Restructuring Initiatives $ 2,270 $ 10,223 $ 2,989 $ 18,771


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Restructuring Initiatives by Plan:
Optimization initiative	$	6,586	$	2,254	$	20,069	$	2,254
Prior year initiatives	(425)		16		(441)		735
Total Restructuring Initiatives	$	6,161	$	2,270	$	19,628	$	2,989

Restructuring Initiatives by Segment:
Aptar Pharma	$	92	$	—	$	1,657	$	—
Aptar Beauty	2,880		2,240		12,650		2,774
Aptar Closures	3,098		30		4,060		215
Corporate & Other	91		—		1,261		—
Total Restructuring Initiatives	$	6,161	$	2,270	$	19,628	$	2,989

OPERATING INCOME

Operating income increased approximately ~~$12.3~~$24.1 million to ~~$95.2~~$119.3 million in the third quarter of ~~2022~~2023 compared to ~~$82.9~~$95.2 million in the same period a year ago. Excluding changes in foreign currency rates, operating income increased by approximately ~~$22.2~~$17.6 million in the quarter compared to the same period a year ~~ago. Strong~~ago mainly due to the strong sales growth ~~along with lower restructuring costs, during~~in our Pharma segment and the ~~current quarter drove this improvement.~~SG&A leverage mentioned above. Operating income as a percentage of net sales increased to ~~11.4%~~13.3% in the third quarter of ~~2022~~2023 compared to ~~10.0%~~11.4% in the prior year period.

~~Table of Contents~~

For the first nine months of ~~2022,~~2023, operating income increased approximately ~~$34.1~~$25.8 million to ~~$294.1~~$319.8 million compared to ~~$259.9~~$294.1 million in the same period of the prior year. Excluding changes in foreign currency rates, operating income increased by approximately ~~$56.3~~$19.9 million in the first nine months of ~~2022~~2023 compared to the same period a year ~~ago. As~~ago as our strong Pharma segment growth and SG&A leverage mentioned above ~~the combination of strong sales and lower~~was partially offset by higher restructuring ~~costs led to this improvement.~~costs. Operating income as a percentage of net sales increased to ~~11.6%~~12.1% in the first nine months of ~~2022~~2023 compared to ~~10.8%~~11.6% for the same period in the prior year.

~~TOTAL~~INTEREST EXPENSE

Interest expense increased approximately $0.2 million to $10.0 million in the third quarter of 2023 compared to $9.8 million for the same period of the prior year. This slight increase is due to the maturity of the €100 million 0.98% Senior Notes due July 2023 which was repaid using our variable interest rate revolving credit facility.

Table of Contents

Interest expense decreased by $0.8 million to $29.9 million in the first nine months of 2023 compared to $30.7 million during the first nine months of 2022. This reduction is mainly due to the repayment of part of our private placement debt, which also included a $0.4 million make-whole payment for the early redemption during the second quarter of 2022 which did not repeat during 2023. See Note 6 - Debt of the Condensed Consolidated Financial Statements for further details.

NET OTHER INCOME (EXPENSE)

Net other ~~expense~~income increased $1.2 million to $0.7 million of income in the third quarter of ~~2022 decreased $6.4~~2023 from $0.5 million ~~to $10.3 million from $16.7 million~~of expense in the same period of the prior year. This ~~reduction~~increase is mainly due to $0.8 million of improvements in our equity investments along with $0.6 million in lower pension costs during the third quarter of 2023 compared to the third quarter of 2022.

Net other income increased $6.7 million to $4.3 million of income for the nine months ended September 30, 2023 from $2.4 million of expense in the same period of the prior year. $2.9 million of this increase is due to the change in the fair value of our PureCycle investment. As discussed in Note 18 - Investment in Equity Securities of the Condensed Consolidated Financial Statements, our investment in PureCycle was converted into shares of PCT, a publicly traded entity, during the first quarter of 2021. This investment is recorded at fair value based on observable market prices for identical assets with the change in fair value being recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income. During the third quarter, we recognized a $0.6 million gain on this investment while we reported a $9.0 million loss during the third quarter of 2021. Interest expense increased by $1.7 million in the third quarter of 2022, primarily as a result of our $400 million 3.60% Senior Notes due March 2032, which were issued on March 7, 2022. See Note 6 - Debt of the Condensed Consolidated Financial Statements for further details. During the prior year, we also recognized a $1.4 million foreign currency gain on an Argentina Blue Chip Swap agreement, which negatively impacts the current year comparison.

~~Net other expense increased $14.6 million to $33.1 million of expense for the nine months ended September 30, 2022 from $18.5 million of expense in the same period of the prior year. Of this~~The remaining increase ~~$7.3 million~~ is due to ~~the change~~improvements in ~~fair value of~~ our investment in PureCycle as discussed above. Interest expense also increased by $8.1 million in the first nine months of 2022 as a result of approximately seven months of interest expense on our $400 million 3.60% Senior Notesother equity investments along with lower pension costs as discussed above.

PROVISION FOR INCOME TAXES

The effective tax rate for the three months ended September 30, ~~2022~~2023 and ~~2021,~~2022, respectively, was ~~36.2%~~23.4% and ~~29.2%~~36.2%. The effective tax rate for the nine months ended September 30, ~~2022~~2023 and ~~2021,~~2022, respectively, was ~~31.0%~~24.6% and ~~22.9%~~31.0%.The effective tax rate for the three months ended September 30, 2023 reflects additional tax benefits from employee stock-based compensation and a benefit related to a change in the U.S. tax regulations issued during the quarter related to foreign tax credits. The effective tax rate for the three months ended September 30, 2022 reflects an out-of-period charge of $7.2 million for taxes related to a legal entity reorganization to enhance ~~the Company's~~our dividend and cash management capabilities. The tax charge ~~contributed~~had an 8.5% ~~to the~~ impact on the effective tax rate for the three months ended September 30, 2022. The ~~tax charge should have been recognized in the three months ended March 31, 2022. The~~ lower reported effective tax rate for the nine months ended September 30, ~~2021~~2023 reflects additional tax benefits from employee stock-based ~~compensation. The impacts~~compensation, the refining of certain U.S. tax filing positions and a change in the ~~error on~~U.S. tax regulations pertaining to foreign tax credits. As mentioned above, the ~~three months ended March 31, 2022 and~~tax rate for the ~~three~~nine months ended September 30, 2022, ~~are not considered material to either period.~~reflects an out-of-period charge for $7.2 million and had a 2.8% impact on the effective tax rate.

NET INCOME ATTRIBUTABLE TO APTARGROUP, INC.

We reported net income attributable to AptarGroup, Inc. of ~~$54.2~~$84.3 million and ~~$180.3~~$222.1 million in the three and nine months ended September 30, ~~2022,~~2023, respectively, compared to ~~$47.3~~$54.2 million and ~~$186.5~~$180.3 million for the same periods in the prior year.

APTAR PHARMA SEGMENT

Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form our Aptar Pharma segment.


		Three Months Ended September 30,						Nine Months Ended September 30,							Three Months Ended September 30,						Nine Months Ended September 30,
		2022			2021			2022			2021				2023			2022			2023			2022

Net Sales	Net Sales	$	343,397		$	313,225		$	1,026,090		$	952,400		Net Sales	$	389,188		$	343,397		$	1,135,934		$	1,026,090
Adjusted EBITDA (1)	Adjusted EBITDA (1)	107,235			100,738			333,793			315,201			Adjusted EBITDA (1)	136,344			107,235			371,508			333,793
Adjusted EBITDA margin (1)	Adjusted EBITDA margin (1)	31.2		%	32.2		%	32.5		%	33.1		%	Adjusted EBITDA margin (1)	35.0		%	31.2		%	32.7		%	32.5		%

(1)Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under "Non-U.S. GAAP Measures."

Table of Contents

Net sales for the Aptar Pharma segment increased 13% in the third quarter of 2023 to $389.2 million compared to $343.4 million in the third quarter of 2022. Changes in currencies positively affected net sales by 5%, while the acquisition of Metaphase did not have a significant impact during the third quarter of 2023. Therefore, core sales increased by 8% in the third quarter of 2023 compared to the third quarter of 2022. The majority of the sales growth is due to higher volumes in our prescription drug and consumer health care divisions. Core sales of our products to the prescription drug market increased 20% on strong demand for our products used on emergency medicines as customers prepare for opioid overdose reversal medications going over the counter in North America. We also continue to see strong growth in our allergic rhinitis, asthma, COPD therapies and central nervous system product sales. The 14% core sales growth in the consumer health care market was driven by higher demand for our eye care, cough and cold and nasal saline rinse solutions. Sales of our products to the injectables market increased 6% as new capacity continues to come online. Active material science solutions decreased 23% due to lower tooling sales along with a decrease in active vials used in diabetes care products and lower sales of our products used for probiotics after a period of rapid growth. Digital Health currently does not represent a significant percentage of the total Pharma sales.


Third Quarter 2023 Net Sales Change over Prior Year	Prescription Drug		Consumer Health Care		Injectables		Active Material Science Solutions		Digital Health		Total
Reported Net Sales Growth	25	%	21	%	13	%	(21)	%	(76)	%	13	%
Currency Effects (1)	(5)	%	(7)	%	(6)	%	(2)	%	(1)	%	(5)	%
Acquisitions	—	%	—	%	(1)	%	—	%	—	%	—	%
Core Sales Growth	20	%	14	%	6	%	(23)	%	(77)	%	8	%

Net sales for the first nine months of 2023 increased by 11% to $1.14 billion compared to $1.03 billion in the first nine months of 2022. Changes in currency rates positively impacted net sales by 1%, and the acquisition of Metaphase also had a positive 1% impact during the first nine months of 2023. Therefore, core sales increased by 9% in the first nine months of 2023 compared to the same period in the prior year. Strong core sales growth for our products to the prescription and consumer health care markets more than compensated for lower sales to the injectables and active material science solutions markets. Core sales to the prescription drug market increased 26% on continued strong demand for our allergic rhinitis, asthma and emergency medicines and central nervous system devices. The 19% core sales growth in the consumer health care market was driven by higher demand for our nasal decongestant, saline rinses, eye care and cough and cold solutions. Core sales of our products to the injectables market declined 9% primarily due to the shutdown of operations for the implementation of our new ERP system in the first quarter. In addition, we were up against strong prior year comparisons as we experienced strong sales of our elastomeric components for COVID-19 and other vaccines during the prior year period which did not repeat in the first nine months of 2023. Similarly, core sales of our active material science solutions decreased 23% mainly on strong prior year period demand for our active film products used with at-home COVID-19 antigen test kits and tooling sales that did not repeat during the first nine months of 2023. Digital Health currently does not represent a significant percentage of the total Pharma sales.


Nine Months Ended September 30, 2023 Net Sales Change over Prior Year	Prescription Drug		Consumer Health Care		Injectables		Active Material Science Solutions		Digital Health		Total
Reported Net Sales Growth	27	%	21	%	(6)	%	(23)	%	(18)	%	11	%
Currency Effects (1)	(1)	%	(2)	%	(1)	%	—	%	(4)	%	(1)	%
Acquisitions	—	%	—	%	(2)	%	—	%	—	%	(1)	%
Core Sales Growth	26	%	19	%	(9)	%	(23)	%	(22)	%	9	%

(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

Adjusted EBITDA in the third quarter of 2023 increased 27% to $136.3 million compared to $107.2 million in the same period of the prior year. Earnings derived from the increase in prescription and consumer health care product sales growth, along with lower overhead costs, more than compensated for the softness in active material science solutions. Our Adjusted EBITDA margin improved to 35.0% in the third quarter of 2023 from 31.2% in the third quarter of 2022 mainly on the strength of our proprietary dispensing device sales.

Adjusted EBITDA in the first nine months of 2023 increased 11% to $371.5 million compared to $333.8 million in the same period of the prior year. The positive impact of our strong core sales growth in the prescription drug and consumer healthcare divisions was partially offset by the additional expenses related to our injectables ERP system implementation early in the year and the impact of lower COVID-19 related sales in our injectables and active material science solutions divisions, as discussed above. Overall, our Adjusted EBITDA margin improved slightly to 32.7% in the first nine months of 2023 compared to 32.5% in the first nine months of 2022.

Table of Contents

APTAR BEAUTY SEGMENT

Operations that sell dispensing systems and sealing solutions to the beauty, personal care and home care markets form our Aptar Beauty segment.


	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022

Net Sales	$	323,980		$	303,046		$	979,956		$	929,793
Adjusted EBITDA (1)	41,070			36,563			121,375			112,343
Adjusted EBITDA margin (1)	12.7		%	12.1		%	12.4		%	12.1		%

Reported net sales for the quarter ended September 30, 2023 increased 7% to $324.0 million compared to $303.0 million in the third quarter of the prior year. Changes in currency rates positively impacted net sales by 5% in the third quarter of 2023 while our acquisition of iD SCENT did not have a material impact on the sales in the quarter. Therefore, core sales increased 2% in the third quarter of 2023 compared to the same quarter of the prior year. Regionally, Europe delivered solid quarterly sales growth which more than compensated for the ongoing softness in demand in North America. Latin America also had good growth and Asia continued to gradually improve. Core sales of our products to the beauty market increased 14% as consumer demand for prestige and mass fragrance applications remained strong. Personal care and home care core sales decreased 15% and 24%, respectively, due to ongoing softness in demand, mainly in North America.


Third Quarter 2023 Net Sales Change over Prior Year	Personal Care		Beauty		Home Care		Total
Reported Net Sales Growth	(11)	%	21	%	(21)	%	7	%
Currency Effects (1)	(4)	%	(6)	%	(3)	%	(5)	%
Acquisitions	—	%	(1)	%	—	%	—	%
Core Sales Growth	(15)	%	14	%	(24)	%	2	%

For the first nine months of 2023, reported net sales increased 5% to $980.0 million compared to $929.8 million in the first nine months of the prior year. Changes in currency rates positively impacted net sales by approximately 1% while our acquisition of iD SCENT did not have an impact on segment sales. Therefore, core sales increased by 4% in the first nine months of 2023 compared to the same period in the prior year. Consistent with the quarterly results, strong regional sales growth in Europe and Latin America more than offset lower North American demand. Core sales of our products to the beauty market increased 14% during the first nine months of 2023 on higher sales in both prestige and mass fragrance, along with continued growth for our facial skin care and color cosmetic solutions. Personal care core sales decreased 7% as higher demand for our sun care applications was offset by softness in baby and hair care product sales mainly due to customer destocking in North America. Core sales of our home care market products declined 23% mainly due to lower demand from our hair care and surface cleaner customers.


Nine Months Ended September 30, 2023 Net Sales Change over Prior Year	Personal Care		Beauty		Home Care		Total
Reported Net Sales Growth	(6)	%	15	%	(22)	%	5	%
Currency Effects (1)	(1)	%	(1)	%	(1)	%	(1)	%
Acquisitions	—	%	—	%	—	%	—	%
Core Sales Growth	(7)	%	14	%	(23)	%	4	%

(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

Adjusted EBITDA in the third quarter of 2023 increased 12% to $41.1 million compared to $36.6 million in the same period in the prior year. This is primarily attributable to higher tooling sales, lower input costs and operational improvements, which more than compensated for lower profitability on product sales. Our Adjusted EBITDA margin improved from 12.1% in the third quarter of 2022 to 12.7% during the third quarter of 2023.

Adjusted EBITDA in the first nine months of 2023 increased 8% to $121.4 million compared to $112.3 million reported in the same period in the prior year mainly due to higher profitability on product sales, along with lower input costs and operational improvements as discussed above. Therefore, our Adjusted EBITDA margin improved from 12.1% in the first nine months of 2022 to 12.4% during the first nine months of 2023.

Table of Contents

APTAR CLOSURES SEGMENT

Operations that sell dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets form our Aptar Closures segment. Aptar's food protection business and elastomeric flow-control technology business continue to report through the Aptar Closures segment.


	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022

Net Sales	$	179,829		$	190,417		$	533,080		$	570,452
Adjusted EBITDA (1)	27,607			23,483			81,387			69,020
Adjusted EBITDA margin (1)	15.4		%	12.3		%	15.3		%	12.1		%

~~Table of Contents~~

~~Net~~Reported sales for the ~~Pharma segment increased 10% in the third~~ quarter ~~of 2022~~ended September 30, 2023 decreased approximately 6% to ~~$343.4~~$179.8 million compared to ~~$313.2~~$190.4 million in the third quarter of ~~2021.~~the prior year. Changes in ~~currencies negatively affected~~currency rates positively impacted net sales by ~~11%~~2%, while ~~the acquisitions~~our acquisition of ~~Voluntis, Hengyu and Metaphase had a positive impact of~~Gulf Closures positively impacted net sales by 1% ~~during~~. Therefore, core sales for the third quarter of ~~2022. Therefore, core sales increased~~2023 decreased by ~~20% in the third quarter of 2022~~9% compared to the ~~third~~same quarter of ~~2021. The majority~~the prior year. Approximately 3% of the ~~sale growth~~decrease for the current quarter is due to ~~higher volumes~~the pass-through of lower input costs while the remaining 6% is due to lower product and tooling sales. ~~Core sales of our products~~Sales to the ~~prescription drug~~food market ~~increased 17%~~decreased 11% primarily on ~~strong~~softer demand for our ~~allergic rhinitis~~dairy and ~~asthma devices as many regions continue~~dry spice applications. The 3% increase in beverage market sales is mostly related to experience post-pandemic re-openings. We also realized strong sales of our products on emergency medical applications for existing and new solutions in the prescription drug market. The 26% core sales growth in the consumer health care market was driven by higher customer demand for our ~~nasal decongestant and saline rinse solutions. Core~~concentrate applications. Personal care sales ~~of our elastomeric components to the injectables market increased 5%~~declined 24% due to ~~continued strong~~lower demand for our ~~vaccine~~body and biologic components, even as demand for COVID-19 vaccines began to decline. Core sales of our active material science solutions increased 33% on higher tooling sales and demand for our oral dose and other diagnostic products.hair care closures.


Third Quarter 2022 Net Sales Change over Prior Year		Prescription Drug		Consumer Health Care		Injectables		Active Material Science Solutions		Digital Health (2)		Total
Third Quarter 2023 Net Sales Change over Prior Year														Third Quarter 2023 Net Sales Change over Prior Year	Food		Beverage		Personal Care		Other (2)		Total
Reported Net Sales Growth														Reported Net Sales Growth	(10)	%	17	%	(22)	%	25	%	(6)	%
Currency Effects (1)														Currency Effects (1)	(1)	%	(5)	%	(2)	%	(1)	%	(2)	%
Acquisitions														Acquisitions	—	%	(9)	%	—	%	—	%	(1)	%
Core Sales Growth	Core Sales Growth	17	%	26	%	5	%	33	%	—	%	20	%	Core Sales Growth	(11)	%	3	%	(24)	%	24	%	(9)	%
Acquisitions		—	%	—	%	2	%	—	%	100	%	1	%
Currency Effects (1)		(11)	%	(13)	%	(12)	%	(6)	%	—	%	(11)	%
Total Reported Net Sales Growth		6	%	13	%	(5)	%	27	%	100	%	10	%

Net sales for the first nine months of ~~2022 increased~~2023 decreased by 8%7% to ~~$1.03 billion~~$533.1 million compared to ~~$952.4~~$570.5 million in the first nine months of ~~2021.~~2022. Changes in currency rates ~~negatively~~had no impact on net sales while our acquisition of Gulf Closures positively impacted net sales by ~~8%, while the acquisitions of Voluntis, Hengyu and Metaphase had a positive impact of~~ 1% ~~during the first nine months of 2022.~~. Therefore, core sales ~~increased~~decreased by ~~15%~~8% in the first nine months of ~~2022~~2023 compared to the same period in the prior year. ~~All legacy markets showed~~Approximately half of the 8% core sales ~~growth during~~decrease is due to passing through lower input costs. Tooling sales and volumes were also lower as customers continued to work through their inventory levels, primarily in North America. Core sales to the food and personal care markets decreased 8% and 20%, respectively, while core sales to the beverage market increased 2% in the first nine months of ~~2022. Core sales~~2023 compared to the ~~prescription drug~~same period of the prior year. For the food market, ~~increased 12% on solid demand~~we were up against strong prior year period comparisons, mainly for sauces and condiment applications and our ~~allergic rhinitis, asthma and emergency medical devices due to post-pandemic re-openings and product launches as discussed above.~~food service packaging products. The ~~17% core sales growth in the consumer health~~personal care market was ~~driven by~~also negatively impacted with lower sales of our body and hair care applications. The beverage market reported growth mainly from higher demand for our nasal decongestant, saline rinses and cough and cold solutions. Core sales of our elastomeric components for COVID-19 and other vaccines drove the 7% core sales growth in our injectables market. Similarly, core sales of our active material science solutions increased 31% mainly on strong demand for our oral solid dose solutions and Activ-Film products used with at-home COVID-19 test kits.juice applications.


Nine Months Ended September 30, 2022 Net Sales Change over Prior Year		Prescription Drug		Consumer Health Care		Injectables		Active Material Science Solutions		Digital Health (2)		Total
Nine Months Ended September 30, 2023 Net Sales Change over Prior Year														Nine Months Ended September 30, 2023 Net Sales Change over Prior Year	Food		Beverage		Personal Care		Other (2)		Total
Reported Net Sales Growth														Reported Net Sales Growth	(8)	%	10	%	(19)	%	3	%	(7)	%
Currency Effects (1)														Currency Effects (1)	—	%	(2)	%	(1)	%	—	%	—	%
Acquisitions														Acquisitions	—	%	(6)	%	—	%	—	%	(1)	%
Core Sales Growth	Core Sales Growth	12	%	17	%	7	%	31	%	—	%	15	%	Core Sales Growth	(8)	%	2	%	(20)	%	3	%	(8)	%
Acquisitions		—	%	—	%	3	%	—	%	100	%	1	%
Currency Effects (1)		(8)	%	(8)	%	(9)	%	(5)	%	—	%	(8)	%
Total Reported Net Sales Growth		4	%	9	%	1	%	26	%	100	%	8	%

(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

(2)~~Core sales for the comparable period not deemed significant.~~Other includes beauty, home care and healthcare markets.

Adjusted EBITDA in the third quarter of ~~2022~~2023 increased 6%18% to ~~$107.2~~$27.6 million compared to $100.7 million in the same period of the prior year. Strong product sales growth more than compensated for a $10.6 million negative impact from the translation of our foreign currency results into U.S. dollars and a $2.2 million one-time inflation payment made to certain European employees. Our Adjusted EBITDA margin declined to 31.2% in the third quarter of 2022 from 32.2% in the third quarter of 2021 due to the lack of margin on the pass-through of higher input costs, along with higher SG&A costs and the one-time inflation payment made to certain European employees.

Adjusted EBITDA in the first nine months of 2022 increased 6% to $333.8 million compared to $315.2 million in the same period of the prior year. This increase is mainly driven by our strong core sales growth which was able to compensate for a negative $24.2 million impact from the translation of our foreign currency results into U.S. dollars and the $2.2 million one-time inflation payment mentioned above. However, the lack of margin on the pass-through of higher input costs and incremental startup costs for our digital health investments and elastomeric component capacity expansion led to a lower Adjusted EBITDA margin of 32.5% in the first nine months of 2022 compared to 33.1% in the first nine months of 2021.

~~Table of Contents~~

~~BEAUTY + HOME SEGMENT~~

~~Operations that sell dispensing systems and sealing solutions to the beauty, personal care and home care markets form our Beauty + Home segment.~~

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Net Sales $ 359,823 $ 374,088 $ 1,099,368 $ 1,081,280
Adjusted EBITDA (1) 41,230 43,789 125,607 117,055
Adjusted EBITDA margin (1) 11.5 % 11.7 % 11.4 % 10.8 %

~~(1)~~Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under "Non-U.S. GAAP Measures".

Reported net sales for the quarter ended September 30, 2022 decreased 4% to $359.8 million compared to $374.1 million in the third quarter of the prior year. Changes in currency rates negatively impacted net sales by 8% in the third quarter of 2022. Therefore, core sales increased 4% in the third quarter of 2022 compared to the same quarter of the prior year. The current quarter core sales growth was driven by our price pass-through initiatives. Core sales of our products to the beauty market increased 6% as consumer demand for fragrance and color cosmetic applications increased. Personal care core sales increased 5% due to higher sales to the hair care and sun care markets. Core sales to the home care markets decreased 6% on strong prior year comparisons for household cleaner and laundry care products.

Third Quarter 2022
Net Sales Change over Prior Year Personal
Care Beauty Home
Care Total
Core Sales Growth 5 % 6 % (6) % 4 %
Currency Effects (1) (7) % (10) % (5) % (8) %
Total Reported Net Sales Growth (2) % (4) % (11) % (4) %

For the first nine months of 2022, net sales increased 2% to $1.10 billion compared to $1.08 billion in the first nine months of the prior year. Changes in currency rates negatively impacted net sales by approximately 6%. Therefore, core sales increased by 8% in the first nine months of 2022 compared to the same period in the prior year. Approximately 7% of this growth came from the pass-through of higher input costs while the remaining increase is due to higher product volumes and mix. Core sales of our products to the beauty market increased 13% during the first nine months of 2022 as we experienced growth across the majority of our applications. Personal care core sales increased 6% on higher sales of our hair care and sun care applications. Core sales of our home care market products declined 12% mainly due to lower tooling sales and normalizing demand for our dish care, industrial and household cleaner applications as rates of COVID-19 transmission have slowed in certain regions.

Nine Months Ended September 30, 2022
Net Sales Change over Prior Year Personal
Care Beauty Home
Care Total
Core Sales Growth 6 % 13 % (12) % 8 %
Currency Effects (1) (5) % (8) % (3) % (6) %
Total Reported Net Sales Growth 1 % 5 % (15) % 2 %

~~(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.~~

Adjusted EBITDA in the third quarter of 2022 decreased 6% to $41.2 million compared to $43.8 million in the same period in the prior year. The decrease is mainly due to a negative $3.7 million impact from the translation of our foreign currency results into U.S. dollars and a $1.9 million one-time inflation payment made to certain European employees. During the prior year, we reported a $2.7 million favorable value added tax ruling in Brazil, which also negatively impacts the current year comparison.

Adjusted EBITDA in the first nine months of 2022 increased 7% to $125.6 million compared to $117.1 million reported in the same period in the prior year on product sales growth and operational improvements, mainly during the first half of 2022. These improvements were more than able to compensate for a negative $8.1 million impact from the translation of our foreign currency results and the one-time inflation payment made to certain European employees mentioned above. During the prior year, we reported a $2.7 million favorable value added tax ruling in Brazil, which negatively impacts the current year comparison.

~~Table of Contents~~

~~FOOD + BEVERAGE SEGMENT~~

~~Operations that sell dispensing systems, sealing solutions and food service trays to the food and beverage markets form our Food + Beverage segment.~~

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Net Sales $ 133,640 $ 138,129 $ 400,877 $ 379,548
Adjusted EBITDA (1) 18,816 22,379 55,756 61,995
Adjusted EBITDA margin (1) 14.1 % 16.2 % 13.9 % 16.3 %

~~(1)Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization,unallocated corporate expenses,~~restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under "Non-U.S. GAAP Measures".

Reported sales for the quarter ended September 30, 2022 decreased approximately 3% to $133.6 million compared to $138.1 million in the third quarter of the prior year. Changes in currency rates negatively impacted net sales by 3%. Therefore, core sales for the third quarter of 2022 were flat compared to the same quarter of the prior year. Higher tooling sales and an increase in the passing through of higher input costs offset slightly lower product sales volumes during the third quarter of 2022. Our food market volumes increased mainly on higher tooling sales along with strong growth in our food service packaging applications. The decrease in beverage market sales is mostly related to lower tooling sales leaving product sales relatively flat compared with prior year levels.

Third Quarter 2022
Net Sales Change over Prior Year Food Beverage Total
Core Sales Growth 7 % (16) % — %
Currency Effects (1) (3) % (4) % (3) %
Total Reported Net Sales Growth 4 % (20) % (3) %

Net sales for the first nine months of 2022 increased by 6% to $400.9 million compared to $379.5 million in the first nine months of 2021. Changes in currency rates negatively impacted net sales by 2%. Therefore, core sales increased by 8% in the first nine months of 2022 compared to the same period in the prior year. Increased product and tooling sales, along with the pass-through of higher material costs, positively impacted the first nine months of 2022. Approximately 6% of the 8% core sales increase is due to passing through higher resin and other input costs. Core sales to the food market increased 10%, while core sales to the beverage market increased 2% in the first nine months of 2022 compared to the same period of the prior year. For the food market, we realized growth in sauces and condiments and our food service packaging products. The beverage market also reported growth due to pricing pass-throughs and improving sales of our premium bottled water products as the market continues to recover from the lower COVID-19 pandemic levels last year.

Nine Months Ended September 30, 2022
Net Sales Change over Prior Year Food Beverage Total
Core Sales Growth 10 % 2 % 8 %
Currency Effects (1) (2) % (3) % (2) %
Total Reported Net Sales Growth 8 % (1) % 6 %

~~(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.~~

~~Adjusted EBITDA in the third quarter of 2022 decreased 16% to $18.8 million compared to $22.4~~$23.5 million reported in the same period of the prior year. ~~Lower product sales~~Operational improvements, along with ~~some operational inefficiencies, specifically under-absorption in certain North American sites, negatively impacted results. We also reported a negative $0.5 million impact from~~lower SG&A costs were able to compensate for the ~~translation of our foreign currency results into U.S. dollars and a $0.3 million one-time inflation payment made to certain European employees. As mentioned above,~~ lower product sales ~~were mostly offset by higher tooling sales. Historically,~~noted above. Approximately one third of our ~~tooling~~ sales decrease was due to passing through lower input costs. These pass-throughs typically do not carry any margin, but the lower ~~margins than~~sales favorably impact our ~~product sales. This change in sales mix also negatively impacted our current quarter adjusted~~Adjusted EBITDA margin. Therefore, our Adjusted EBITDA margin improved from 12.3% in the third quarter of 2022 to 15.4% during the third quarter of 2023.

3837

Table of Contents

Adjusted EBITDA in the first nine months of ~~2022 decreased 10%~~2023 increased 18% to ~~$55.8~~$81.4 million compared to ~~$62.0~~$69.0 million reported in the same period of the prior year. Our profitability was positively impacted by a focus on operational improvements and containing costs within our new segment structure. As discussed above, ~~we experienced increased product and tooling~~approximately half of our sales ~~growth~~decrease was due to passing through lower input costs. As these pass-throughs typically do not carry any margin, the lower sales favorably impact our Adjusted EBITDA margin. This led to our Adjusted EBITDA margin improving from 12.1% in the first nine months of 2022 to 15.3% during the first nine months of 2022. However, our profitability was negatively impacted by unfavorable product mix and some operational inefficiencies in North America. We also reported a negative $0.8 million impact from the translation of our foreign currency results into U.S. dollars and a $0.3 million one-time inflation payment made to certain European employees. These issues, along with the lack of margin on the pass-through of higher input costs, had a negative impact on our Adjusted EBITDA margin during the first nine months of 2022.2023.

CORPORATE & OTHER

In addition to our three reporting segments, we assign certain costs to “Corporate & Other,” which is presented separately in Note 16 – Segment Information of the Notes to the Condensed Consolidated Financial Statements. For Corporate & Other, Adjusted EBITDA (which excludes net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items) primarily includes certain professional fees, compensation and information system costs which are not allocated directly to our reporting segments.

For the quarter ended September 30, ~~2022,~~2023, Corporate & Other Adjusted EBITDA ~~increased~~decreased to $11.7 million of expense from $13.5 million ~~from $12.7 million~~of expense in the third quarter of ~~2021.~~2022. This ~~increase~~expense decrease is ~~partially~~due to approximately $4.2 million of realized gains on the sale of PCT shares related to the PureCycle investment partially offset by higher professional fees for corporate projects and higher incentive compensation costs, including accruals related to our current short-term and ~~travel costs compared to 2021. We also wrote off $0.5 million of assets associated with an office space lease which was not renewed.~~equity compensation programs.

Corporate & Other Adjusted EBITDA in the first nine months of ~~2022~~2023 increased to $46.0 million of expense compared to $45.2 million ~~compared to $40.3 million~~of expense reported in the same period of the prior year. ~~This~~As mentioned above, this increase is ~~partially~~mainly related to higher incentive compensation costs including accruals related to our current short-term incentive compensation programs and the timing of equity compensation expense recognition including substantive vesting conditions for retirement eligible employees. We also reportedalong with higher professional fees ~~and travel costs as restrictions on travel eased as compared to the prior year.~~for corporate projects.

NON-U.S. GAAP MEASURES

In addition to the information presented herein that conforms to accounting principles generally accepted in the United States of America ("U.S. GAAP"), we also present financial information that does not conform to U.S. GAAP, which are referred to as non-U.S. GAAP financial measures. Management may assess our financial results both on a U.S. GAAP basis and on a non-U.S. GAAP basis. We believe it is useful to present these non-U.S. GAAP financial measures because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect our core operating performance. These non-U.S. GAAP financial measures should not be considered in isolation or as a substitute for U.S. GAAP financial results, but should be read in conjunction with the unaudited Condensed Consolidated Statements of Income and other information presented herein. Investors are cautioned against placing undue reliance on these non-U.S. GAAP measures. Further, investors are urged to review and consider carefully the adjustments made by management to the most directly comparable U.S. GAAP financial measure to arrive at these non-U.S. GAAP financial measures.

In our Management’s Discussion and Analysis, we exclude the impact of foreign currency translation when presenting net sales and other information, which we define as “constant currency.” Changes in net sales excluding the impact of foreign currency translation is a non-U.S. GAAP financial measure. As a worldwide business, it is important that we take into account the effects of foreign currency translation when we view our results and plan our strategies. Consequently, when our management looks at our financial results to measure the core performance of our business, we may exclude the impact of foreign currency translation by translating our prior period results at current period foreign currency exchange rates. As a result, our management believes that these presentations are useful internally and may be useful to investors. We also exclude the impact of material acquisitions when comparing results to prior periods. Changes in operating results excluding the impact of acquisitions are non-U.S. GAAP financial measures. We believe it is important to exclude the impact of acquisitions on period over period results in order to evaluate performance on a more comparable basis.

We present earnings before net interest and taxes (“EBIT”) and earnings before net interest, taxes, depreciation and amortization (“EBITDA”). We also present our adjusted earnings before net interest and taxes (“Adjusted EBIT”) and adjusted earnings before net interest, taxes, depreciation and amortization (“Adjusted EBITDA”), both of which exclude restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Our Outlook is also provided on a non-U.S. GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring and acquisition costs.

We provide a reconciliation of Net Debt to Net Capital as a non-U.S. GAAP measure. “Net Debt” is calculated as ~~interest bearing~~interest-bearing debt less cash and equivalents and short-term investments while “Net Capital” is calculated as stockholders’ equity plus Net Debt. Net Debt to Net Capital measures a company’s financial leverage, which gives users an idea of a company's financial structure, or how it is financing its operations, along with insight into its financial strength. We believe that it is meaningful to take into consideration the balance of our cash, cash equivalents and short-term investments when evaluating our leverage. If needed, such assets could be used to reduce our gross debt position.

3938

Table of Contents

Finally, we provide a reconciliation of free cash flow as a non-U.S. GAAP measure. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives.


		Three Months Ended																	Three Months Ended
		September 30, 2022																	September 30, 2023

		Consolidated			Pharma			Beauty + Home			Food + Beverage			Corporate & Other		Net Interest			Consolidated			Aptar Pharma			Aptar Beauty			Aptar Closures			Corporate & Other		Net Interest
Net Sales	Net Sales	$	836,860		$	343,397		$	359,823		$	133,640		$	—	$	—	Net Sales	$	892,997		$	389,188		$	323,980		$	179,829		$	—	$	—

Reported net income	Reported net income	$	54,177															Reported net income	$	84,298
Reported income taxes	Reported income taxes	30,738																Reported income taxes	25,751
Reported income before income taxes	Reported income before income taxes	84,915			83,571			16,184			9,005			(14,841)		(9,004)		Reported income before income taxes	110,049			108,113			17,415			11,647			(18,088)		(9,038)
Adjustments:	Adjustments:																	Adjustments:
Restructuring initiatives	Restructuring initiatives	2,270			—			2,344			(74)			—				Restructuring initiatives	6,161			92			2,880			3,098			91
Net unrealized investment gain		(277)												(277)
Transaction costs related to acquisitions		231			231			—			—			—
Net investment loss																		Net investment loss	1,240												1,240
Realized gain on investments included in net investment loss above																		Realized gain on investments included in net investment loss above	4,188												4,188

Adjusted earnings before income taxes	Adjusted earnings before income taxes	87,139			83,802			18,528			8,931			(15,118)		(9,004)		Adjusted earnings before income taxes	121,638			108,205			20,295			14,745			(12,569)		(9,038)
Interest expense	Interest expense	9,756														9,756		Interest expense	9,984														9,984
Interest income	Interest income	(752)														(752)		Interest income	(946)														(946)
Adjusted earnings before net interest and taxes (Adjusted EBIT)	Adjusted earnings before net interest and taxes (Adjusted EBIT)	96,143			83,802			18,528			8,931			(15,118)		—		Adjusted earnings before net interest and taxes (Adjusted EBIT)	130,676			108,205			20,295			14,745			(12,569)		—
Depreciation and amortization	Depreciation and amortization	57,601			23,433			22,702			9,885			1,581				Depreciation and amortization	62,686			28,139			20,775			12,862			910

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	153,744		$	107,235		$	41,230		$	18,816		$	(13,537)	$	—	Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	193,362		$	136,344		$	41,070		$	27,607		$	(11,659)	$	—

Reported net income margin (Reported net income / Reported Net Sales)																		Reported net income margin (Reported net income / Reported Net Sales)	9.4		%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)	Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)	18.4		%	31.2		%	11.5		%	14.1		%					Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)	21.7		%	35.0		%	12.7		%	15.4		%

Table of Contents


	Three Months Ended
	September 30, 2022

	Consolidated			Aptar Pharma			Aptar Beauty			Aptar Closures			Corporate & Other		Net Interest
Net Sales	$	836,860		$	343,397		$	303,046		$	190,417		$	—	$	—

Reported net income	$	54,177
Reported income taxes	30,738
Reported income before income taxes	84,915			83,571			14,729			10,460			(14,841)		(9,004)
Adjustments:
Restructuring initiatives	2,270			—			2,240			30			—
Net investment gain	(649)												(649)
Realized gain on investments included in net investment gain above	372												372
Transaction costs related to acquisitions	231			231			—			—			—

Adjusted earnings before income taxes	87,139			83,802			16,969			10,490			(15,118)		(9,004)
Interest expense	9,756														9,756
Interest income	(752)														(752)
Adjusted earnings before net interest and taxes (Adjusted EBIT)	96,143			83,802			16,969			10,490			(15,118)		—
Depreciation and amortization	57,601			23,433			19,594			12,993			1,581

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	153,744		$	107,235		$	36,563		$	23,483		$	(13,537)	$	—

Reported net income margin (Reported net income / Reported Net Sales)	6.5		%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)	18.4		%	31.2		%	12.1		%	12.3		%

Table of Contents


		Three Months Ended																	Nine Months Ended
		September 30, 2021																	September 30, 2023

		Consolidated			Pharma			Beauty + Home			Food + Beverage			Corporate & Other		Net Interest			Consolidated			Aptar Pharma			Aptar Beauty			Aptar Closures			Corporate & Other		Net Interest
Net Sales	Net Sales	$	825,442		$	313,225		$	374,088		$	138,129		$	—	$	—	Net Sales	$	2,648,970		$	1,135,934		$	979,956		$	533,080		$	—	$	—

Reported net income	Reported net income	$	46,894															Reported net income	$	221,931
Reported income taxes	Reported income taxes	19,340																Reported income taxes	72,265
Reported income before income taxes	Reported income before income taxes	66,234			75,611			14,443			12,027			(28,237)		(7,610)		Reported income before income taxes	294,196			288,603			46,643			39,174			(52,590)		(27,634)
Adjustments:	Adjustments:																	Adjustments:
Restructuring initiatives	Restructuring initiatives	10,223			13			5,442			131			4,637				Restructuring initiatives	19,628			1,657			12,650			4,060			1,261
Net unrealized investment loss		9,021												9,021
Net investment gain																		Net investment gain	(1,839)												(1,839)
Realized gain on investments included in net investment gain above																		Realized gain on investments included in net investment gain above	4,188												4,188
Transaction costs related to acquisitions	Transaction costs related to acquisitions	1,793			1,793			—			—			—				Transaction costs related to acquisitions	255			—			199			56			—

Adjusted earnings before income taxes	Adjusted earnings before income taxes	87,271			77,417			19,885			12,158			(14,579)		(7,610)		Adjusted earnings before income taxes	316,428			290,260			59,492			43,290			(48,980)		(27,634)
Interest expense	Interest expense	8,011														8,011		Interest expense	29,900														29,900
Interest income	Interest income	(401)														(401)		Interest income	(2,266)														(2,266)
Adjusted earnings before net interest and taxes (Adjusted EBIT)	Adjusted earnings before net interest and taxes (Adjusted EBIT)	94,881			77,417			19,885			12,158			(14,579)		—		Adjusted earnings before net interest and taxes (Adjusted EBIT)	344,062			290,260			59,492			43,290			(48,980)		—
Depreciation and amortization	Depreciation and amortization	59,280			23,321			23,904			10,221			1,834				Depreciation and amortization	184,212			81,248			61,883			38,097			2,984

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	154,161		$	100,738		$	43,789		$	22,379		$	(12,745)	$	—	Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	528,274		$	371,508		$	121,375		$	81,387		$	(45,996)	$	—

Reported net income margin (Reported net income / Reported Net Sales)																		Reported net income margin (Reported net income / Reported Net Sales)	8.4		%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)	Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)	18.7		%	32.2		%	11.7		%	16.2		%					Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)	19.9		%	32.7		%	12.4		%	15.3		%

Table of Contents


		Nine Months Ended																	Nine Months Ended
		September 30, 2022																	September 30, 2022

		Consolidated			Pharma			Beauty + Home			Food + Beverage			Corporate & Other		Net Interest			Consolidated			Aptar Pharma			Aptar Beauty			Aptar Closures			Corporate & Other		Net Interest
Net Sales	Net Sales	$	2,526,335		$	1,026,090		$	1,099,368		$	400,877		$	—	$	—	Net Sales	$	2,526,335		$	1,026,090		$	929,793		$	570,452		$	—	$	—

Reported net income	Reported net income	$	180,161															Reported net income	$	180,161
Reported income taxes	Reported income taxes	80,851																Reported income taxes	80,851
Reported income before income taxes	Reported income before income taxes	261,012			263,222			52,918			25,572			(52,061)		(28,639)		Reported income before income taxes	261,012			263,222			49,196			29,294			(52,061)		(28,639)
Adjustments:	Adjustments:																	Adjustments:
Restructuring initiatives	Restructuring initiatives	2,989			—			3,022			(33)			—				Restructuring initiatives	2,989			—			2,774			215			—
Net unrealized investment loss		2,297												2,297
Net investment loss																		Net investment loss	1,084												1,084
Realized gain on investments included in net investment loss above																		Realized gain on investments included in net investment loss above	1,213												1,213
Transaction costs related to acquisitions	Transaction costs related to acquisitions	231			231			—			—			—				Transaction costs related to acquisitions	231			231			—			—			—

Adjusted earnings before income taxes	Adjusted earnings before income taxes	266,529			263,453			55,940			25,539			(49,764)		(28,639)		Adjusted earnings before income taxes	266,529			263,453			51,970			29,509			(49,764)		(28,639)
Interest expense	Interest expense	30,668														30,668		Interest expense	30,668														30,668
Interest income	Interest income	(2,029)														(2,029)		Interest income	(2,029)														(2,029)
Adjusted earnings before net interest and taxes (Adjusted EBIT)	Adjusted earnings before net interest and taxes (Adjusted EBIT)	295,168			263,453			55,940			25,539			(49,764)		—		Adjusted earnings before net interest and taxes (Adjusted EBIT)	295,168			263,453			51,970			29,509			(49,764)		—
Depreciation and amortization	Depreciation and amortization	174,818			70,340			69,667			30,217			4,594				Depreciation and amortization	174,818			70,340			60,373			39,511			4,594

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	469,986		$	333,793		$	125,607		$	55,756		$	(45,170)	$	—	Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	469,986		$	333,793		$	112,343		$	69,020		$	(45,170)	$	—

Reported net income margin (Reported net income / Reported Net Sales)																		Reported net income margin (Reported net income / Reported Net Sales)	7.1		%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)	Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)	18.6		%	32.5		%	11.4		%	13.9		%					Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)	18.6		%	32.5		%	12.1		%	12.1		%


Net Debt to Net Capital Reconciliation	September 30,			December 31,
	2023			2022

Notes payable, revolving credit facility and overdrafts	$	124,503		$	3,810
Current maturities of long-term obligations, net of unamortized debt issuance costs	366,378			118,981
Long-Term Obligations, net of unamortized debt issuance costs	680,065			1,052,597
Total Debt	1,170,946			1,175,388
Less:
Cash and equivalents	151,573			141,732

Net Debt	$	1,019,373		$	1,033,656

Total Stockholders' Equity	$	2,213,689		$	2,068,204
Net Debt	1,019,373			1,033,656
Net Capital	$	3,233,062		$	3,101,860

Net Debt to Net Capital	31.5		%	33.3		%

Table of Contents

Nine Months Ended
September 30, 2021
Consolidated Pharma Beauty + Home Food + Beverage Corporate & Other Net Interest
Net Sales $ 2,413,228 $ 952,400 $ 1,081,280 $ 379,548 $ — $ —
Reported net income $ 186,107
Reported income taxes 55,309
Reported income before income taxes 241,416 245,087 36,253 31,728 (50,457) (21,195)
Adjustments:
Restructuring initiatives 18,771 86 7,995 169 10,521
Net unrealized investment gain (6,177) (6,177)
Transaction costs related to acquisitions 4,227 4,227 — — —
Adjusted earnings before income taxes 258,237 249,400 44,248 31,897 (46,113) (21,195)
Interest expense 22,601 22,601
Interest income (1,406) (1,406)
Adjusted earnings before net interest and taxes (Adjusted EBIT) 279,432 249,400 44,248 31,897 (46,113) —
Depreciation and amortization 174,508 65,801 72,807 30,098 5,802
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 453,940 $ 315,201 $ 117,055 $ 61,995 $ (40,311) $ —
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 18.8 % 33.1 % 10.8 % 16.3 %

Net Debt to Net Capital Reconciliation September 30, December 31,
2022 2021
Notes payable, revolving credit facility and overdrafts $ 53,209 $ 147,276
Current maturities of long-term obligations, net of unamortized debt issuance costs 111,034 142,351
Long-Term Obligations, net of unamortized debt issuance costs 1,028,048 907,024
Total Debt 1,192,291 1,196,651
Less:
Cash and equivalents 124,812 122,925
Short-term investments — 740
Net Debt $ 1,067,479 $ 1,072,986
Total Stockholders' Equity $ 1,888,125 $ 1,984,600
Net Debt 1,067,479 1,072,986
Net Capital $ 2,955,604 $ 3,057,586
Net Debt to Net Capital 36.1 % 35.1 %

~~Table of Contents~~


Free Cash Flow Reconciliation	Free Cash Flow Reconciliation	September 30,		September 30,		Free Cash Flow Reconciliation	September 30,		September 30,
		2022		2021			2023		2022

Net Cash Provided by Operations	Net Cash Provided by Operations	$	306,349	$	259,373	Net Cash Provided by Operations	$	355,602	$	306,349
Capital Expenditures	Capital Expenditures	(226,131)		(216,689)		Capital Expenditures	(231,199)		(226,131)
Proceeds from Government Grants	Proceeds from Government Grants	17,058		—		Proceeds from Government Grants	—		17,058
Free Cash Flow	Free Cash Flow	$	97,276	$	42,684	Free Cash Flow	$	124,403	$	97,276

FOREIGN CURRENCY

Because of our international presence, movements in exchange rates may have a significant impact on the translation of the financial statements of our foreign subsidiaries. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso, Swiss franc and other Asian, European and South American currencies. A ~~strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Conversely, a~~ weakening U.S. dollar has an additive effect. In some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Conversely, a strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Any changes in exchange rates on such inter-country sales could materially impact our results of operations. During the third quarter and for the ~~first~~ nine months ~~of 2022,~~ended September 30, 2023, the U.S. dollar ~~strengthened~~weakened compared to all European currencies except the ~~major European~~Russian ruble and most Asian currencies. This resulted in ~~a dilutive~~an additive impact on our translated results during the third quarter and year-to-date period of ~~2022~~2023 when compared to the third quarter and year-to-date period of ~~2021.~~2022.

QUARTERLY TRENDS

Our results of operations in the last quarter of the year typically are negatively impacted by customer plant shutdowns in December. Several of the markets we serve are impacted by the seasonality of underlying consumer products. This, in turn, may have an impact on our net sales and results of operations for those markets. The diversification of our product portfolio minimizes fluctuations in our overall quarterly financial statements and results in an immaterial seasonality impact on our Condensed Consolidated Financial Statements when viewed quarter over quarter.

Generally, we have incurred higher stock-based compensation expense in the first quarter compared with the rest of the fiscal year due to the timing and recognition of stock-based expense from substantive vesting for retirement eligible employees. As of September 30, 2023, our estimated stock option expense on a pre-tax basis for the year 2023 compared to 2022 is as follows:


	2023		2022
First Quarter	$	15,042	$	13,362
Second Quarter	10,391		8,774
Third Quarter	10,051		9,805
Fourth Quarter (estimated for 2023)	9,689		8,996
	$	45,173	$	40,937

LIQUIDITY AND CAPITAL RESOURCES

Given our current low level of leverage relative to others in our industry and our ability to generate strong levels of cash flow from operations, we believe we are in a strong financial position ~~and have the financial resources~~ to meet our business requirements in the foreseeable future. We have historically used cash flow from operations, our revolving and other credit facilities, proceeds from stock options and debt, as needed, as our primary sources of liquidity. Our primary uses of cash are to invest in equipment and facilities that are necessary to support our growth, pay quarterly dividends to stockholders, to make acquisitions and repurchase shares of our common stock ~~and to make acquisitions~~ that will contribute to the achievement of our strategic objectives. Due to ~~uncertainties amid the war in Ukraine, potential new COVID-19 variants across the globe~~uncertain macroeconomic conditions, including rising interest rates and the inflationary environment, in the event that customer demand decreases significantly for a prolonged period of time and adversely impacts our cash flows from operations, we would have the ability to restrict and significantly reduce capital expenditure levels and share repurchases, as well as ~~evaluate~~reevaluate our acquisition strategy. A prolonged and significant reduction in capital expenditure levels could increase future repairs and maintenance costs as well as have a negative impact on operating margins if we were unable to invest in new innovative products.

Cash and equivalents and restricted cash increased to ~~$125.8~~$152.1 million at September 30, ~~2022~~2023 from ~~$122.9~~$142.7 million at December 31, ~~2021.~~2022. Total short and long-term ~~interest bearing~~interest-bearing debt of $1.2 billion at September 30, ~~2022~~2023 was consistent with the $1.2 billion at December 31, ~~2021.~~2022. The ratio of our Net Debt ~~(interest bearing~~(interest-bearing debt less cash and equivalents) to Net Capital (stockholders’ equity plus Net Debt) ~~increased~~decreased to ~~36.1%~~31.5% at September 30, ~~2022 compared to 35.1%~~2023 from 33.3% at December 31, ~~2021 primarily driven by the lower stockholders equity driven by currency translation adjustments.~~2022. See the reconciliation under "Non-U.S. GAAP ~~Measures".~~Measures."

In the first nine months of ~~2022,~~2023, our operations provided approximately ~~$306.3~~$355.6 million in net cash flow compared to ~~$259.4~~$306.3 million for the same period a year ago. In both periods, cash flow from operations was primarily derived from earnings before depreciation and amortization. ~~The increase in cash provided by operating activities during the first nine months~~

Table of 2022 is primarily attributable to improved working capital management and lower restructuring costs. Partially offsetting other increases in cash provided by operations was a $16.3 million contribution to our domestic and foreign benefit plans during the first nine months of 2022.Contents

We used ~~$222.4~~$239.3 million in cash for investing activities during the first nine months of ~~2022~~2023 compared to ~~$343.4~~$222.4 million during the same period a year ago. During 2023, approximately $9.4 million was utilized to fund the iD SCENT acquisition, $5.2 million was utilized to fund the remaining payment on the Hengyu acquisition and $1.5 million was utilized to fund the Gulf Closures acquisition. Our investment in capital projects net of government grant proceeds increased ~~$9.4~~$22.1 million during the first nine months of ~~2022~~2023 compared to the first nine months of ~~2021, which is~~2022 primarily ~~related~~due to ~~additional investments in capacity for our injectables division, offset by~~the $17.1 million ~~received by government~~in grant proceeds ~~primarily for~~received in 2022 offsetting a portion of our ~~active material science solution division.~~capital expenditures. Our ~~2022~~2023 estimated cash outlays for capital expenditures net of government grant proceeds are expected to be ~~in the range of~~ approximately $300 ~~million to $320~~ million.

~~Table of Contents~~

Financing activities used ~~$80.1~~$94.0 million in cash during the first nine months of ~~2022~~2023 compared to ~~$98.9~~$80.1 million in cash used by financing activities during the same period a year ago. During the first nine months of 2023, we paid $76.7 million of dividends, received $39.7 million from stock option exercises and purchased $37.3 million of treasury stock. Additionally, we paid our outstanding contingent consideration obligation for Fusion of $25.3 million of which $22.8 million was treated as a financing outflow and repaid $117.3 million of long-term debt. During the first nine months of 2022, we received proceeds from long-term obligations of $406.6 million primarily from the issuance of $400 million of our 3.60% Senior Notes due March 2032 ~~during the first quarter of 2022. As part of our bond offering, we paid $4.0 million in debt issuance costs. Additionally,~~and we repaid $93.5 million related to our revolving credit facility, ~~paid $56 million related to our term loan that matured in July 2022, paid $74.7 million of dividends and purchased $72.3 million of treasury stock. We~~ redeemed all $75.0 million of our 3.25% senior unsecured notes ~~during the second quarter of 2022 at a price equal to the principal amount plus accrued interest~~ and ~~a $0.4 million make-whole premium. Additionally, we redeemed all~~repaid $125.0 million of our 3.49% senior unsecured ~~notes during~~notes.

In October 2020, we entered into an unsecured money market borrowing arrangement to provide short term financing of up to $30 million that is available in the ~~third~~U.S. No borrowing on this facility is permitted over a quarter ~~at a price equal to the principal amount plus accrued interest.~~end date. As such, no balance was utilized under this arrangement as of September 30, 2023.

On June 30, 2021, we entered into an amended and restated multi-currency revolving credit facility (the "revolving credit facility") with a syndicate of banks to replace the ~~then existing~~then-existing facility maturing July 2022 (the "prior credit facility") and to amend and restate the unsecured term loan facility extended to our wholly-owned UK subsidiary under the prior credit facility (as amended, the "amended term facility"). The revolving credit facility matures in June 2026, subject to a maximum of two one-year extensions in certain circumstances, and provides for unsecured financing of up to $600 million available in the U.S. and to our wholly-owned UK subsidiary. The amended term facility matured in July 2022 and was ~~paid~~repaid in full. The revolving credit facility can be drawn in various currencies including USD, EUR, GBP, and CHF to the equivalent of $600 million, which may be increased by up to $300 million subject to the satisfaction of certain conditions. As of September 30, 2023, $44.5 million and €75.0 million ($79.3 million) was utilized under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. As of December 31, 2022, no balance was utilized under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary.

There are no compensating balance requirements associated with our revolving credit facility. Each borrowing under the revolving credit facility will bear interest at rates based on ~~LIBOR~~SOFR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. In May 2023 the revolving credit facility was amended to make SOFR the default borrowing rate for USD. The revolving credit facility also provides mechanics relating to a transition away from ~~LIBOR (in the case of USD) and the~~ designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. As of September 30, 2022, no balance was utilized under the revolving credit facility in the U.S. and €50.0 million (approximately $49.0 million) was utilized by our wholly-owned UK subsidiary. As of December 31, 2021, $133 million was utilized under the revolving credit facility in the U.S., €10 million (approximately $11.4 million) was utilized by our wholly-owned UK subsidiary and $56 million remained outstanding under the amended term facility. Credit facility balances are included in notes payable, revolving credit facility and overdrafts on the Condensed Consolidated Balance Sheets.

Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:


	Requirement	Level at September 30, ~~2022~~2023
Consolidated Leverage Ratio (1)	Maximum of 3.50 to 1.00	~~1.76~~1.61 to 1.00
Consolidated Interest Coverage Ratio (1)	Minimum of 3.00 to 1.00	~~16.02~~16.19 to 1.00

(1)Definitions of ratios are included as part of the revolving credit facility agreement and ~~note purchase~~private placement agreements.

Based upon the above consolidated leverage ratio covenant, we would have the ability to borrow approximately an additional ~~$1.1~~$1.2 billion before the 3.50 to 1.00 maximum ratio requirement iswould be exceeded.

~~In October 2020,~~On July 6, 2022, we entered into an ~~unsecured money market borrowing arrangement~~agreement to ~~provide short term financing~~swap approximately $200 million of upour fixed USD debt to ~~$30~~fixed EUR debt which would generate interest savings of approximately $0.5 million ~~that is available in the U.S. No borrowing on this facility is permitted over a~~per quarter ~~end date. As such, no balance was utilized under this arrangement~~based upon exchange rates as of ~~September 30, 2022.~~the transaction date.

On October 12, 2023, the Board of Directors declared a quarterly cash dividend of $0.41 per share payable on November 16, 2023 to stockholders of record as of October 26, 2023.

Table of Contents

Our foreign operations have historically met cash requirements with the use of internally generated cash or uncommitted short-term borrowings. We also have committed financing arrangements in both the U.S. and the UK as detailed above. We manage our global cash requirements considering (i) available funds among the many subsidiaries through which we conduct business, (ii) the geographic location of our liquidity needs, and (iii) the cost to access international cash balances.

All outstanding amounts related to suppliers participating in the SCF are recorded within Accounts payable, accrued and other liabilities in our Condensed Consolidated Balance Sheets, and associated payments are included in operating activities within our Condensed Consolidated Statements of Cash Flows. As of September 30, 2022 and December 31, 2021, the amounts payable related to the SCF program were approximately $35 million and $30 million, respectively.

~~Table of Contents~~

Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. We have also seen an increasing trend in pressure from certain customers to lengthen their payment terms. As the majority of our products are made to order, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements. However, some of our contracts specify an amount of finished goods safety stock we are required to maintain.

To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. We are also lengthening the payment terms with our suppliers to be in line with customer trends. While we have offered third party alternatives for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.

On July 6, 2022, we entered into an agreement to swap approximately $200 million of our fixed USD debt to fixed EUR debt which should generate interest savings of approximately $0.5 million per quarter based upon current exchange rates.

~~On October 13, 2022, the Board of Directors declared a quarterly cash dividend of $0.38 per share payable on November 16, 2022 to stockholders of record as of October 26, 2022.~~

CONTINGENCIES

The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature. Please refer to Note 12 - Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements for a discussion of contingencies affecting our business.

RECENTLY ISSUED ACCOUNTING STANDARDS

We have reviewed the recently issued ~~accounting standards updates~~ASUs to the FASB’s Accounting Standards Codification that have future effective dates. Standards that have been adopted during ~~2022~~2023 are discussed in Note 1 – Summary of Significant Accounting Policies of the Notes to Condensed Consolidated Financial Statements.

In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and can be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. During 2021, we amended the revolving credit facility to provide mechanics relating to a transition away from LIBOR (in the case of USD) and the designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. We are evaluating any further impact this standard may have on our Condensed Consolidated Financial Statements and anticipate no further significant impacts.

Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our Condensed Consolidated Financial Statements upon adoption.

OUTLOOK

~~Looking forward to~~In the fourth quarter, we expect continued growth in our ~~Pharma segment is expected~~proprietary pharma drug delivery systems and continued improvement in our injectables division’s performance as new capacity continues to ~~continue~~come online. Our fragrance dispensing solutions experienced strong growth in the first nine months of the year and we anticipate sales for these dispensing solutions to ~~grow at more normalized levels, however,~~finish strong in 2023. Our Beauty and Closures segments will be aided by the improving environment in North America as we ~~do not expect~~start to ~~repeat last year’s strong sales of active material solutions for at-home COVID-19 test kits. We anticipate~~move past the softening in demand in markets such as personal care, food and beverage to continue. We remain focused on managing the inflationary environment through price initiatives and energy surcharges, as well as controlling expenses. We will continue to allocate capital selectively while maintaining our strong balance sheet.destocking caused by elevated inventory levels.

We expect earnings per share for the fourth quarter of ~~2022,~~2023, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of ~~$0.73~~$1.06 to ~~$0.83~~$1.14 and this guidance is based on an effective tax rate range of ~~28%~~24% to ~~30%~~26%.

~~Table of Contents~~

FORWARD-LOOKING STATEMENTS

Certain statements in Management’s Discussion and Analysis and other sections of this Form 10-Q are forward-looking and involve a number of risks and uncertainties, including certain statements set forth in the Significant Developments, Restructuring Initiatives, Quarterly Trends, Liquidity and Capital Resources, Contingencies and Outlook sections of this Form 10-Q. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential”, "are optimistic" and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to:

•geopolitical conflicts worldwide including the invasion of Ukraine by the Russian military and the recent events in the Middle East and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions;

•lower demand and asset utilization due to an economic recession either globally or in key markets we operate within;

•the impact of COVID-19 and its variants on our global supply chain and our global customers, employees and operations, which has elevated and will continue to elevate many of the risks and uncertainties discussed below;

•economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth;

•the ~~availability~~execution of ~~direct labor workers and the increase in direct labor costs, especially in North America;~~

•our ~~ability to preserve organizational culture and maintain employee productivity in the work-from-home environment caused by the current pandemic;~~fixed cost initiatives, including our optimization initiative;

•the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers;

•fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs (particularly resin, metal, anodization costs and energy costs);

•significant fluctuations in foreign currency exchange rates or our effective tax rate;

•the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate;

•financial conditions of customers and suppliers;

•consolidations within our customer or supplier bases;

•changes in customer and/or consumer spending levels;

•loss of one or more key accounts;

•our ability to successfully implement facility expansions and new facility projects;

•our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases;

•changes in capital availability or cost, including rising interest rates;

Table of Contents

•volatility of global credit markets;

•our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired, including contingent consideration valuation;

•our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio;

•direct or indirect consequences of acts of war, terrorism or social unrest;

•cybersecurity threats that could impact our networks and reporting systems;

•the impact of natural disasters and other weather-related occurrences;

•fiscal and monetary policies and other regulations;

•changes or difficulties in complying with government regulation;

•changing regulations or market conditions regarding environmental sustainability;

•work stoppages due to labor disputes;

•competition, including technological advances;

•our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights;

•the outcome of any legal proceeding that has been or may be instituted against us and others;

•our ability to meet future cash flow estimates to support our goodwill impairment testing;

•the demand for existing and new products;

•the success of our customers’ products, particularly in the pharmaceutical industry;

•our ability to manage worldwide customer launches of complex technical products, particularly in developing markets;

•difficulties in product development and uncertainties related to the timing or outcome of product development;

•significant product liability claims; and

•other risks associated with our operations.

~~Table of Contents~~

Although we believe that our forward-looking statements are based on reasonable assumptions, there can be no assurance that actual results, performance or achievements will not differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Please refer to Item 1A (Risk Factors) of Part I included in our Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 for additional risks and uncertainties that may cause our actual results or other events to differ materially from those expressed or implied in such forward-looking statements.

4846

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our subsidiaries. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso, Swiss franc and other Asian, European and South American currencies. A ~~strengthening~~weakening U.S. dollar relative to foreign currencies has ~~a dilutive~~an additive translation effect on our financial condition and results of operations. Conversely, a ~~weakening~~strengthening U.S. dollar relative to foreign currencies has ~~an additive~~a dilutive translation effect on our financial condition and results of operations. Additionally, in some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Any changes in exchange rates on such inter-country sales may impact our results of operations.

The table below provides information as of September 30, ~~2022~~2023 about our forward currency exchange contracts. The majority of the contracts expire before the end of the fourth quarter of ~~2022.~~2023.


Buy/Sell	Buy/Sell	Contract Amount (in thousands)		Average Contractual Exchange Rate	Min / Max Notional Volumes	Buy/Sell	Contract Amount (in thousands)		Average Contractual Exchange Rate	Min / Max Notional Volumes

EUR / USD	EUR / USD	$	15,109	1.0170	9,784 - 21,523	EUR / USD	$	13,536	1.0879	13,535 - 30,321
EUR / BRL	EUR / BRL	10,437		5.5793	10,437 - 11,011	EUR / BRL	11,314		5.3288	11,314 - 12,050
EUR / CNY		1,666		7.1966	1,666 - 2,750
CZK / EUR	CZK / EUR	1,666		0.0401	1,666 - 7,092	CZK / EUR	5,829		0.0414	2,148 - 7,194
EUR / THB	EUR / THB	4,486		37.5751	4,486 - 4,663	EUR / THB	4,652		36.8238	4,652 - 4,964
MXN / USD						MXN / USD	4,000		0.0576	4,000 - 5,300
USD / EUR						USD / EUR	3,714		0.9157	1,837 - 3,714
USD / CNY						USD / CNY	2,100		7.0552	2,100 - 2100
CHF / EUR	CHF / EUR	5,503		1.0317	0 - 5,503	CHF / EUR	1,889		1.0427	478 - 1,889
MXN / USD		3,700		0.0485	2,400 - 3,700
USD / CNY		1,000		6.6671	1,000 - 1,400
EUR / CNY						EUR / CNY	1,585		7.5409	1,585 - 6,504
GBP / EUR						GBP / EUR	959		1.1605	476 - 959
EUR / MXN	EUR / MXN	3,626		21.0721	2,037 - 3,626	EUR / MXN	845		18.5248	0 - 845
GBP / EUR		363		1.1687	363 - 1,170
EUR / CHF						EUR / CHF	212		0.9642	0 - 212
USD / GBP						USD / GBP	183		0.7756	76 - 183
CHF / USD						CHF / USD	163		1.1366	161 - 273
USD / CHF						USD / CHF	93		0.8904	0 - 93
EUR / GBP	EUR / GBP	722		0.8701	0 - 722	EUR / GBP	53		0.8625	0 - 53
USD / EUR		8,476		0.9999	708 - 11,116
CHF / USD		153		1.0437	153 - 156
Total	Total	$	56,907			Total	$	51,127

As of September 30, ~~2022,~~2023, we have recorded the fair value of foreign currency forward exchange contracts of ~~$0.2~~$0.4 million in prepaid and other and ~~$0.9~~$0.3 million in accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets. On July 6, 2022, we entered into a seven year USD/EUR fixed-to-fixed cross currency interest rate swap to effectively hedge the interest rate exposure relating to $203 million of the $400 million 3.60% Senior Notes due March 2032 which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged ~~USD~~ $203 million of fixed-rate 3.60% USD debt to €200 million of fixed-rate 2.5224% ~~euro~~EUR debt. The fair value of this net investment hedge is ~~$4.8~~$12.0 million reported in ~~prepaid~~accounts payable, accrued and other ~~assets~~liabilities on the Condensed Consolidated Balance Sheets.

ITEM 4. CONTROLS AND PROCEDURES

DISCLOSURE CONTROLS AND PROCEDURES

Management has evaluated, with the participation of the chief executive officer and chief financial officer of the Company, the effectiveness of our disclosure controls and procedures (as that term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of September 30, ~~2022.~~2023. Based on that evaluation, the chief executive officer and chief financial officer have concluded that these controls and procedures were effective as of such date.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

During the fiscal quarter ended September 30, ~~2022,~~2023, we implemented ~~enterprise resource planning ("ERP")~~ERP systems at ~~one~~three operating ~~facility.~~units. Consequently, the control environments have been modified at ~~this location~~these locations to incorporate the controls contained within the new ERP systems. Except for the foregoing, no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) occurred during our fiscal quarter ended September 30, ~~2022~~2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

4947

Table of Contents

PART II - OTHER INFORMATION

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

RECENT SALES OF UNREGISTERED SECURITIES

Certain French employees are eligible to participate in the FCP Aptar Savings Plan (the “Plan”). An independent agent purchases shares of common stock available under the Plan for cash on the open market and we do not issue shares. We do not receive any proceeds from the purchase of common stock under the Plan. The agent under the Plan is BNP Paribas Fund Services. No underwriters are used under the Plan. All shares are sold in reliance upon the exemption from registration under the Securities Act of 1933 provided by Regulation S promulgated under that Act. During the quarter ended September 30, ~~2022,~~2023, the Plan purchased ~~4,447~~no shares of our common stock on behalf of the participants, and sold 11,324 shares of our common stock on behalf of the participants at an average price of ~~$98.09,~~$105.73, for an aggregate amount of ~~$0.4 million, and sold 6,569 shares of our common stock on behalf of the participants at an average price of $165.43, for an aggregate amount of $1.1~~$1.2 million. At September 30, ~~2022,~~2023, the Plan owned ~~123,253~~120,479 shares of our common stock.

ISSUER PURCHASES OF EQUITY SECURITIES

On April 18, 2019, we announced a share purchase authorization of up to $350 million of common stock. This authorization replaced previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

During the three and nine months ended September 30, ~~2022,~~2023, we repurchased approximately ~~181~~66 thousand shares for ~~$19.2~~$8.3 million and ~~669~~318 thousand shares for ~~$72.3~~$37.3 million, respectively. As of September 30, ~~2022,~~2023, there was ~~$128.1~~$70.9 million of authorized share repurchases remaining under the existing authorization.

The following table summarizes our purchases of our securities for the quarter ended September 30, ~~2022:~~2023:

Period Total Number Of Shares Purchased Average Price Paid Per Share Total Number Of Shares Purchased As Part Of Publicly Announced Plans Or Programs Dollar Value Of Shares That May Yet Be Purchased Under The Plans Or Programs
(in millions)
7/1 - 7/31/22 — $ — — $ 147.3
8/1 - 8/31/22 111,000 107.82 111,000 135.3
9/1 - 9/30/22 70,000 103.90 70,000 128.1
Total 181,000 $ 106.31 181,000 $ 128.1



Period	Total Number Of Shares Purchased	Average Price Paid Per Share		Total Number Of Shares Purchased As Part Of Publicly Announced Plans Or Programs	Dollar Value Of Shares That May Yet Be Purchased Under The Plans Or Programs (in millions)

7/1 - 7/31/23	—	$	—	—	$	79.2
8/1 - 8/31/23	33,525	125.02		33,525	75.0
9/1 - 9/30/23	32,000	127.23		32,000	70.9
Total	65,525	$	126.10	65,525	$	70.9

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Plan Elections

During the three months ended September 30, 2023, no director or officer of the Company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.

5048

Table of Contents

ITEM 6. EXHIBITS


Exhibit 3.1						A mended and Restated Bylaws of AptarGroup, Inc. adopted on October 11, 2023, filed as Exhibit 3.1 to the Company's current report on Form 8-K filed on October 13, 2023, is hereby incorporated by reference.

Exhibit 31.1						Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 31.2						Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.1						Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.2						Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 101						The following information from our Quarterly Report on Form 10-Q for the third quarter of fiscal ~~2022,~~2023, filed with the SEC on October ~~28, 2022,~~26, 2023, formatted in Inline Extensible Business Reporting Language (XBRL): (i) the Cover Page, (ii) the Condensed Consolidated Statements of Income – Three and Nine Months Ended September 30, ~~2022~~2023 and ~~2021,~~2022, (iii) the Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, ~~2022~~2023 and ~~2021,~~2022, (iv) the Condensed Consolidated Balance Sheets – September 30, ~~2022~~2023 and December 31, ~~2021,~~2022, (v) the Condensed Consolidated Statements of Changes in Equity – Three and Nine Months Ended September 30, ~~2022~~2023 and ~~2021,~~2022, (vi) the Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, ~~2022~~2023 and ~~2021~~2022 and (vii) the Notes to Condensed Consolidated Financial Statements.
Exhibit 104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

5149

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


						AptarGroup, Inc.
						(Registrant)

			By			/s/ ROBERT W. KUHN
						Robert W. Kuhn
						Executive Vice President and Chief Financial Officer
						(Duly Authorized Officer and
						Principal Accounting and Financial Officer)


						Date: October ~~28, 2022~~26, 2023

5250



	Pharma		Beauty + Home		Food + Beverage		Total
Balance as of December 31, 2021	$	520,197	$	325,719	$	128,241	$	974,157
Acquisition	3,029		—		—		3,029
Foreign currency exchange effects	(51,844)		(14,462)		(839)		(67,145)
Balance as of September 30, 2022	$	471,382	$	311,257	$	127,402	$	910,041


	September 30, 2022		December 31, 2021
Revolving credit facility 1.68%	$	49,005	$	144,383
Overdrafts 1.46% to 15.37%	4,204		2,893
	$	53,209	$	147,276



	2021
		Weighted-Average Useful Life (in Years)	Estimated Fair Value of Assets
Acquired technology		10	$	34,322
Customer relationships		11.6	30,258

License agreements and other		0.25	1,401
Total			$	65,981


Third Quarter 2022 Net Sales Change over Prior Year	Pharma		Beauty + Home		Food + Beverage		Total
Core Sales Growth	20	%	4	%	—	%	9	%
Acquisitions	1	%	—	%	—	%	—	%
Currency Effects (1)	(11)	%	(8)	%	(3)	%	(8)	%
Total Reported Net Sales Growth	10	%	(4)	%	(3)	%	1	%